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A whole-genome approach to identify microRNA “modifiers” of breast cancer 
stem cell self-renewal 
An emerging notion in the breast cancer field is that a rare subpopulation of cells 
within the tumor bearing stem cell (SC)-like properties, cancer stem cells (CSCs), are 
responsible for the degree of aggressiveness of the tumor, as well as the emergence of 
therapeutic resistance and disease relapse. Therefore, the development of novel 
therapeutic strategies that specifically target the CSCs population within a tumor 
could be the key to achieve an effective cure for breast cancer.  
One strategy for targeting CSCs could be to inhibit their altered self-renewal 
mechanism and induce a quasi-normal differentiation process in tumor cells. 
However, the mechanisms that control the replicative mode of SC division and the 
degree of “stemness” of tumours are poorly characterized.  
Recent research has highlighted the role of microRNAs (miRNAs), a class of small 
non-coding RNAs, as key regulators of gene expression in a variety of cellular 
processes, including SC self-renewal and differentiation. miRNAs negatively regulate 
gene expression at a post-transcriptional level and their expression is often 
deregulated in disease, making them ideal candidates as tumour biomarkers.  
Despite recent studies uncovered new microRNA molecules linked to stem cell 
biology, we definitively miss a defined picture of which microRNAs are involved in 
the regulation of breast cancer stem cell self-renewal and their contribution to 
tumorigenesis.  
The overall goal of this project was to identify key miRNA “modifiers” of breast 
cancer SC self-renewal that could either inhibit or enhance the self-renewal potential 
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acquisition/regulation of stem-cell traits and bona fide novel therapeutic targets.  
We used a lentiviral microRNA library, composed of approximately 650 precursor 
microRNAs, to perform a functional whole-genome screening based on phenotypic 
competition assays on a very aggressive breast cancer cell line with stem-like 
properties (SUM159). Infected cells were challenged in an in-vitro 3D competition 
assay based on self-renewal ability of CSCs. In the competition assay, miRNAs that 
supported stem cells expansion were positively selected during passages, while 
microRNAs that inhibited self-renewal were depleted overtime. In parallel we also 
performed a 2D assay based on cell proliferation to gain insights into the ability of 
miRNAs to alter the proliferation of SUM159 cancer cells in adherent conditions. For 
each screening the positive and the negative selected miRNAs were identified by 
means of Next Generation Sequencing analysis.  
The screening yielded to 20 candidate microRNAs selected as potential modifiers of 
self-renewal: 18 presumably acting by decreasing self-renewal (and hypothetically 
with tumor suppressing functions) and 2 by increasing self-renewal (and potentially 
with oncogenic functions). A proof-of-principle validation revealed that 6 out of 10 
tested clones, confirmed their effects even when analyzed as single clones, 
underlining the potentiality of the whole-genome phenotype screening. 
We focused our attention on the most promising candidates, namely miR-124 (which 
inhibited self-renewal) and miR-657 (which increased self-renewal) and, in order to 
search for the mechanism through which these microRNAs exert their function, we 
performed an RNA-seq analysis of transcriptional changes induced upon the 
overexpression of miR-124 and miR-657. We revealed that miR-124 in particular was 
able to regulate hundreds of genes and control independently different pathway 
related to self-renewal, migration and proliferation, suggesting that this miRNA could 
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effectively act at multiple levels to silence the self-renewal potential of cancer stem 
cells and, likely, inhibit the proliferation and migratory ability of the tumor, too.  
As further experiments, we will definitively need to completely understand the role of 
miR-124 with the potential of being effective even on the most aggressive breast 
cancer disease. 




1.1 Normal mammary stem cells and breast cancer stem cells  
1.1.1 Mammary gland development and mammary stem cells  
The mammary gland is a glandular epithelium composed mainly of ducts that 
terminate in lobular structures, termed terminal lobular-ductal units (TLDUs). TLDUs 
are generally composed of two cell types: secretory or inner luminal cells and basal 
myoepithelial cells (Watson and Khaled, 2008). 
As the names suggest, luminal cells are positioned around the central lumen, whereas 
basal myoepithelial cells are positioned in direct contact with the basement membrane 
(Figure 1). Immunohistochemically, these cells can be distinguished by the expression 
of different cytokeratin proteins: cytokeratins 8 and 18 (CK8 and CK18) identify 
luminal cells, cytokeratins 5 and 14 (CK5 and CK14) instead are typically expressed 
by basal-myoepithelial cells. Besides, the mammary epithelium is surrounded by a 
stroma, which is composed of adipose tissue, fibroblasts, blood vessels and nerve 
terminals. Stroma is also commonly referred to as the “mammary fat pat” (Figure 1). 
The capability of the mammary gland to undergo different cycles of remodeling 
throughout the life of the organism renders this gland a unique organ. Indeed, it is 
possible to distinguish different stages in the maturation of the human mammary 
gland (schematized in Figure 2). The first stage is in the embryo, when the human fetal 
breast is formed from an epithelial structure called the “primordium”, which, at 21 
weeks, starts migrating towards the mesenchyme (Jolicoeur, 2005). In the neonatal 
stage, the terminal lobular units and the end buds appear and remain unchanged until 
puberty, when sex hormone signaling leads to duct elongation, side-branching and 
maturation of the breast. During pregnancy, other modifications occur. In particular, 
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luminal cells are stimulated to proliferate and differentiate into the milk-producing 
cells, called “acini” or “alveoli”. Simultaneously, basal myoepithelial cells, which 
surround the milk-producing cells, assist and favor the ejection of milk by contracting 
(lactation stage) (Gjorevski and Nelson, 2011).  
 
 
Figure 1 – Representation of the mammary gland and its components. The figure shows a terminal 
lobular-ductal unit composed of luminal epithelial cells and myoepithelial cells. Adipocytes, 
fibroblasts, and all the stroma components, which surround the duct, are also shown. Figure taken from 








Figure 2 – Schematic representation of the phases of mammary gland development. 6 stage of 
mammary gland development are shown: embryonic, prepuberty, puberty, virgin, pregnancy, lactation. 
Critical molelcular regulators of the different stages are also indicated. Figure taken from (Manavathi 
et al., 2014). 
 
Notably, at the end of lactation the mammary gland returns almost, but not 
completely, to its state before pregnancy (involution). Overall, the mammary gland is 
able to support multiple cycles of remodeling (pregnancy, lactation, involution) for 
several cycles. This observation suggests the existence of a pool of cells, termed 
“mammary stem cells” (MaSCs), which can i) generate all the cellular lineages of the 
mammary gland and ii) sustain the plasticity that is required whenever lactation is 
needed. The evidence that such a cell population is, indeed, likely to exist came 
definitively from Stingl’s lab in 2006 (Stingl et al., 2006). 
They exploited in vivo transplantation analysis and injected single rare epithelial 
FACS-sorted adult mouse mammary cells into cleared mammary fat pads of mice. 
Under these conditions, they were able to regenerate an entire mammary gland within 
6 weeks upon injection, thus demonstrating that a multipotent population of rare cells, 
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MaSCs, exists (Stingl et al., 2006). 
MaSCs share the typical characteristics of adult tissue stem cells, including the ability 
to self-renew and support multilineage differentiation (Van Keymeulen et al., 2011). 
Under physiological conditions, self-renewal is achieved by a unique pattern of 
asymmetric cell division (ACD): each ACD generates a daughter stem cell that retains 
stem identity and properties, and a daughter progenitor cell, which is committed to 
differentiation. This type of cell division preserves the stem cell pool over time, while 
allowing the generation of differentiating progenitors. Under particular conditions, for 
example, when tissue regeneration is required (such as upon injuries), a stem cell 
could divide symmetrically (SCD), generating two daughter cells with stem cell 
features. The daughter SCs would then undergo asymmetric cell division (ACD) to 
generate the differentiating progenitors and promote rapid regeneration of the tissue. 
Another stem cell peculiarity is its quiescent or slowly dividing state. Conversely, 
progenitor cells (such as those of the transit-amplifying compartment) sustain tissue 
proliferation during mammary gland formation or pregnancy. Lastly, stem cells are 
able to withstand anoikis, surviving in anchorage-independent growth. This 
characteristic allowed the development of a typical MaSC assay by Dontu and co-
workers, called the “mammosphere assay” (Dontu et al., 2003). This assay consists of 
growing epithelial cells in vitro under anchorage-independent conditions (by the use 
of tissue culture plates that impair the adhesion of cells) in a growing medium, which 
is depleted of serum components to preserve the undifferentiated state of cells. Under 
these conditions, only MaSCs are able to survive and grow as clonal spheroids, called 
mammospheres, composed of quiescent stem cells and differentiating progenitor cells. 
Thus, the number of clonal spheroids formed is a proportional to the number of stem 
cells in the initial population. Mammospheres can be dissociated into single cell 
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suspensions, in which only stem cells can support a new round of mammosphere 
formation and create the second generation of spheres by self-renewing. Hence, serial 
propagation of mammospheres is considered as an in vitro assay to measure self-
renewal of MaSCs (Dontu et al., 2003). Importantly, under mammosphere culture 
MaSCs retain also their ability to differentiate, and when grown under differentiating 
conditions can form both luminal-like and myoepithelial-like colonies (Dontu, 2003). 
Additionally, they can generate β-casein+ acini structures in the presence of prolactin 
(Dontu et al., 2003). 
After the discovery of a rare population of adult stem cells residing within the 
mammary gland, scientists have exploited multiple approaches to specifically isolate 
these MaSCs. The typical approach relies on the use of cell surface markers that are 
associated with MaSCs. Stingl’s lab, for example, demonstrated that MaSCs express 
low levels of Sca-1, medium levels of CD24 (heat-stable antigen) and high levels of 
CD49f (α6 integrin) or CD29 (β1 integrin) (Sca-1neg/CD24med/+CD49fhi/CD29hi) 
(Stingl et al., 2006). These murine MaSCs are capable of serial transplantion in vivo 
and, thus, were defined as mammary repopulating units (MRUs). Similarly, Eirew’s 
lab showed that MaSCs could be isolated as CD49fhi/ Epcamlow/neg basal cells (Eirew 
et al., 2008). 
Our laboratory recently developed another approach for MaSC isolation from 
mammosphere cultures that does not rely on surface markers. This approach exploits 
the ability of MaSCs to slowly and asymmetrically divide in mammosphere cultures 
and, hence, asymmetrically dilute the lipophilic fluorescent dye known as PKH26. 
The dye is retained by the stem cells (which are PKH26 positive – PKHpos), and is, 
instead, diluted in the progenitors and differentiated cells (PKH26 negative– PKHneg). 
Using this approach, it is possible to isolate a quasi-pure population of MaSCs by 
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FACS-sorting the PKHpos cells from dissociated mammospheres. Notably, the PKHpos 
cells are fully functional, able to form mammospheres in-vitro and regenerate the 
entire mammary gland upon fat pad transplantation experiments in-vivo (Pece et al., 
2010) (Cicalese et al., 2009). 
 
1.1.2 Breast cancer and breast cancer stem cells 
Human breast tumors are considered a heterogeneous disease, mainly classified 
histologically on the basis of their hormonal receptor status. In particular, pathologists 
look mainly at 1) the immunoreactivity for the estrogen receptor (ER) and the 
progesterone receptor (PR), 2) overexpression of the human epidermal growth factor 
receptor 2 (HER2), and 3) the proliferative index (Ki67), to stratify breast cancers. 
Tumors that express the ER are named luminal ER+ breast cancers and are associated 
with a better prognosis. In contrast, tumors that lack expression of the 3 receptors 
(i.e., ER-, PR-, HER2-) are named “triple negative”, and are associated with a more 
aggressive phenotype and a worse prognosis.  
Recently, a new type of classification of breast cancers has been developed, the so-
called “molecular classification”, which takes into account the molecular 
characteristics of tumors to distinguish five major subtypes: Luminal A, luminal B, 
HER2 amplified, Basal and Claudin-low (Prat et al., 2010). Of note, the different 
molecular subtypes better define breast tumor heterogeneity, patient outcome and 
therapeutic responses (Hu et al., 2006) (Sabatier et al., 2014). The subtype 
classification can be derived using an entire transcriptome analysis or by a simple 50-
gene set (PAM50), extensively validated on formalin-fixed, paraffin-embedded 
tissues and acting as independent predictor of survival in breast cancer (Guiu et al., 
2012). The molecular classification suggests also that the different tumor subtypes 
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resemble different gene expression profiles of the breast hierarchy. For example, the 
transcriptome of Luminal A and B breast cancers is similar to that of mature luminal 
cells, whereas the expression profile of the basal-like subtype (and claudin-low 
subtype in particular) is similar to the profile of MaSCs (Liu et al., 2014) (Figure 3).  
The parallelism between physiological development of a normal mammary gland and 
the aberrant development of breast cancer also extends to the apex of the cellular 
hierarchy, the stem cells. Hence, the development and maintenance of the breast 
cancer appears to be fueled by certain cells, known as tumor-initiating cells (TICs) or 
cancer stem cells (CSCs), which are able to form tumors when transplanted in mice 
(Visvader and Stingl, 2014). Breast cancer was one of the first malignancies for which 
a CSC hypothesis was postulated (breast cancer stem cells or BCSCs). Although this 
hypothesis struggled initially to gain acceptance, the experimental proof that CSCs 
reside within the tumor mass came from the seminal work by Al Hajj and colleagues, 
who isolated, using two surface markers CD44 and CD24, a population of cells 
enriched for SC traits from the tumor mass (Al-Hajj, 2003). CSCs defined as Lin-
/CD44+/CD24- cells were able to generate tumors when transplanted in 
immunocompromised mice, even when as few as 100 cells were injected. Conversely, 
no tumor formation was detected when thousands of non-tumorigenic CD44-/CD24+ 
counterpart (NTG) cells were injected (Al-Hajj, 2003). Importantly, the same 
heterogeneity of the initial tumors could be reproduced upon TICs/CSCs 
transplantation, and the process could be repeated serially (serial transplantation), 
concluding that the CD44+/CD24- population shares many features with normal SCs, 
including self-renewal and differentiation.  
CSCs are now believed to be responsible for the most dangerous features of cancer, 
such as recurrence, therapeutic resistance and metastasis (Visvader and Lindeman, 
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2008). In particular, the self-renewal ability of CSCs appears to be more pronounced 
than that of normal MaSCs and aberrant outgrowth of cancer cells with SC traits is 
frequently observed (Liu and Wicha, 2010; Visvader and Lindeman, 2012) Recent 
observations suggest that BCSCs undergo SCD (rather than ACD) more frequently 
than their normal counterparts, thereby ensuring that the CSC pool never extinguishes 
and acquires unlimited self-renewal potential (Stingl, 2007) (Cicalese et al., 2009). 
Despite many efforts to reveal how MaSCs control their mode of division, the 
mechanisms that mediate the acquisition of stem cell traits, as well as the control 
ACD or SCD are mostly unknown. 
 
Figure 3 – Possible relationships between cell of origin and breast cancer subtypes. The figure 
shows a self-renewing mammary stem cell (MaSC) that gives rise to different progenitors 
(myoepithelial and luminal), which in turn differentiate into ductal, alveolar or myooepithelial cells. 
Different molecular subtypes of breast cancer are shown along the top, originating from different cells 
in the mammary gland cellular hierarchy. The critical molecular players involved in cancer 
development such as PTEN, TP53, BRCA1, RB, are indicated– Figure taken from (Visvader and 
Stingl, 2014). 
 




microRNAs (miRNAs) have recently emerged as appealing molecules able to control 
several important cellular processes, including stem cell biology. 
miRNAs are small RNA molecules, typically 20-22 nucleotides in length, which act 
by negatively regulating messenger RNAs (mRNAs). Their ability to affect gene 
expression is accomplished through base pairing of the miRNA to the 3’ untranslated 
region (UTR) of a target mRNA (Bartel, 2009).  
The discovery of the first miRNA molecule goes back to 1993, when Lee’s laboratory 
identified Lin-4 (Lee et al., 1993), a small RNA molecule fundamental in the control 
of the timing of C. elegans larval development. A few years later, in 2000, another 
small RNA molecule, named let-7, was discovered with a similar function in an 
advanced stage of C. elegans development (Reinhart et al., 2000). Of note, let-7 was 
also found to exist in other species, including human and mouse, suggesting that 
miRNAs existed in higher eukaryotes too. Since then, a great number of miRNAs 
have been identified in different organisms, such us plants, animals, flies and viruses 
(Lagos-Quintana et al., 2001). A recent analysis in humans revealed that 2588 unique 
sequences of mature miRNAs have now been identified (according to last miRbase 
database, release 21) (Kozomara and Griffiths-Jones, 2014). 
miRNAs are able to regulate many genes at the same time and, conversely, the 
expression of one gene might be controlled by different miRNAs. Bioinformatics 
analyses predict that miRNAs might control the activity of at least 30% of all the 
protein-coding genes. This feature, together with the fact that many miRNAs are 
conserved among different species, confers to these molecules the unique ability to be 
involved in the regulation of many cellular processes. Indeed, functional studies 
indicate that miRNAs participate in the control of almost all the physiological 
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processes within the cell, such as development, cell cycle, differentiation, and 
apoptosis (Filipowicz et al., 2008) (Bushati and Cohen, 2007) (Chekulaeva and 
Filipowicz, 2009). Moreover, a role for miRNAs as regulators of pathological 
processes has been pointed out, with particular emphasis on cancer disease, where 
miRNA deregulation is a frequent hallmark (Calin et al., 2004) (Ventura and Jacks, 
2009) (Esquela-Kerscher and Slack, 2006).  
With these observations in mind, it is not surprising that there has been great interest 
in the study of mechanisms controlling miRNA biogenesis and of their mechanisms 
of action.  
 
1.2.1 miRNA nomenomenclature and occupancy in the genome 
The nomenclature of miRNAs is based on their order of discovery, meaning that they 
are progressively numbered. A “letter suffix” is added when two or more miRNAs 
show a very high sequence homology. Conversely, a “number suffix” identifies 
miRNAs that have the same mature sequence, but derive from different transcripts. 
Lastly, the suffix 5p or 3p is added when mature miRNAs are derived from the 5’-3’ 
or 3’-5’ arm of the precursor miRNA, respectively.  
miRNA genes occupy different genomic regions. About half of them are located 
within protein coding genes, such as in exons or introns, and are therefore known as 
“intragenic” miRNAs (Hinske et al., 2010). These intragenic miRNA genes usually 
have the same orientation as their “host” gene, signifying that they can be co-
transcribed with the host. Alternatively, miRNA genes are located in regions of the 
genome quite distant from any protein-coding gene (gene deserts), thus, they are 
transcribed as independent transcriptional units by their own promoters. Such 
miRNAs are called “intergenic” miRNAs (Bartel, 2004) (Lee and Ambros, 2001) 
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(Garzon et al., 2009). 
Sometimes, multiple miRNA genes are located in the genome in close proximity to 
each other (< 10 kb). These miRNA clusters are typically transcribed as a unique 
multi-cistronic primary transcript (Lagos-Quintana et al., 2001) (Lau, 2001). A well-
known cluster-miRNA is the 17-92, which is composed of 6 different miRNA genes 
(miR-17, 18a, 19a, 20a, 19b-1 and 92a-1), which share a common promoter and 
processing mechanism (Olive et al., 2010). 
 
1.2.2 miRNA biogenesis 
The main steps of miRNA biogenesis are illustrated in Figure 4. miRNA biogenesis 
begins in the nucleus, where these molecules are transcribed by RNA polymerase II 
(Pol II) to generate a primary miRNA (pri-miRNA) with a characteristic stem loop 
structure (Lee et al., 2002). Pri-miRNAs can be quite long, from hundreds of 
nucleotides to tens of kb and are often capped and polyadenylated. In some cases, 
miRNA transcription can be mediated by RNA polymerase III (Pol III), in particular, 
for miRNAs located in genomic regions with a high content of Alu repeats (Borchert 
et al., 2006). For most intragenic miRNAs, transcription occurs by exploiting thei 
same regulatory machinery of the “host” gene and miRNA maturation is associated 
with mRNA splicing (Bartel, 2004). 
Hereafter, the biogenesis of miRNAs requires two maturation steps. During the first 
step, the primary miRNA is cleaved in the nucleus to create a ≈ 70-100 nucleotide 
stem loop intermediate, known as the precursor miRNA (pre-miRNA). This process is 
executed by Drosha, a ribonuclease (RNase) III enzyme, that cuts both strands of the 
pri-miRNA, leaving a phosphate at its 5’ end and an ≈ 2 nucleotide overhang at its 3’ 
end (Basyuk et al., 2003). Drosha forms part of a multi-complex nuclear protein, 
  Introduction 
 
 12 
together with DGCR8 (DiGeorge syndrome critical region gene 8), known as the 
Microprocessor complex. DGCR8 protein has two ds-RNA-binding domains (ds-
RBDs) and functions as a Drosha partner, since it guides the latter in the pri-miRNA 
cleavage by recognizing the ssRNA-dsRNA junction at the base of the hairpin (Han et 
al., 2006). Of note, some miRNA molecules, called “mirtrons”, can bypass this 
cleavage step and originate the pre-miRNAs from intron splicing events (Filipowicz 
et al., 2008). The pre-miRNA is, then, exported from the nucleus to the cytoplasm by 
the Exportin-5 enzyme, which recognizes its peculiar arm (≈ 2-nucleotide 3’ 
overhang), and together with RAN-GTPase directs the export event (Lund et al., 
2004).  
In the cytoplasm, the second maturation step takes place through another RNase III 
enzyme, similar to Drosha, known as Dicer. Dicer acts by cutting both strands of the 
duplex at about two helical turns away from the base of the stem loop, generating 
another 5’ phosphate end and a 2-nucleotide 3’ overhang, thus defining the second 
arm of the mature miRNA molecule (Bartel, 2004). Dicer functions with its partner 
molecule TRBP (TAR RNA Binding Protein), which binds to the N-terminal part of 
Dicer and facilitates the recruitment of one of the Argonaute proteins (Ago). In higher 
eukaryotes, four different isoforms of Ago exist (Ago1 – Ago4). Once the mature 
miRNA is loaded onto the Ago, the RNA-induced silencing complex (RISC) is 
formed, which executes silencing functions. The loading of the miRNA onto the Ago 
requires Ago-mediated unwinding of the ds mature miRNA and the selection of just 
one of the two strands, which is retained in the RISC complex. Ideally, both of the 
strands could be loaded into the complex, however, it has been observed that the 
strand that has the less stable 5’ end is preferentially incorporated. This strand is 
called the “guide strand” as it guides the silencing function. Conversely, the discarded 
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Figure 4 - miRNA biogenesis. The figure illustrates all the steps involved in miRNA biogenesis, 
including transcription, nuclear cleavage and export, cytoplasmic cleavage and the final loading of the 
mature miRNA onto the RISC complex [taken from (Winter et al., 2009)].  
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1.2.3 miRNA target recognition 
The critical region involved in miRNA target recognition lies at the 5’ end of the 
miRNA, positioned between the 2nd and 8th nucleotide and called the “seed sequence”. 
This region is able to base pair, with a certain degree of complementarity, to the 
miRNA responsive element (MRE) usually located in the 3’ untranslated region 
(UTR) of the target mRNA. The number of complementary bases between the 
miRNA and its target mRNA determines the strength of interaction and is used to 
classify the MREs as an 8-mer, 7-mer or 6-mer (Fang and Rajewsky, 2011) (Figure 5). 
In the case of a perfect match, the miRNA guides the RISC complex to cleave the 
mRNA through the AGO2 protein. The latter represents the only human AGO protein 
having an intrinsic and specific “slicing” activity (Bartel, 2004). However, in the 
majority of the cases a perfect complementarity does not occur, and target 
downregulation occurs through mRNA destabilization or translational repression by 
multiple mechanisms, briefly described here and summarized in Figure 6. For example, 
miRNAs may induce target destabilization by mRNA deadenylation, followed by de-
capping and degradation. Alternatively, miRNAs may induce translational repression 
by interfering with protein synthesis at different levels. miRNAs can interfere with the 
initiation phase of translation by competing with eIF4E (eukaryotic translation 
initiation factor 4E), an initiation factor that mediates mRNA circularization for the 
binding of the polyA-tail to the cap-5’ terminus of the mRNA. Alternatively, miRNAs 
may prevent the access or the formation of the 60S ribosomal subunit though a 
mechanism that is not yet completely understood. Translational repression can also 
occur after the initiation phase (mainly during elongation), either by decreasing the 
elongation rate or by inducing ribosome drop-off, which renders ribosomes prone to 
terminate their job prematurely. Finally, an extreme and not totally accepted 
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possibility, is that miRNAs may somehow impair the maturation of the nascent 
peptide by inducing proteolysis. 
 
 
Figure 5 – Representation of the miRNA – mRNA binding site. The miRNA “seed sequence” and 
mRNA “MRE” are represented in red and green, respectevely. Different MREs are possible: i) a 6-mer 
site lacks the match in the 8th position (complementary at positions 2-7); ii) a 7-mer is complementary 
at positions 2-8, as represented in green; iii) an 8-mer site includes a further base pair in the 9th position 
plus an A residue in the first position. Generally, an A residue at position 1 of the mRNA and an A/U 
residue at position 9 (shown in yellow) improve the site efficiency even without base pairing. Good 
base pairing at positions 13-16 is important when the complementarity of the seed region is suboptimal 
[taken from (Filipowicz et al., 2008). 
 
 





Figure 6  - Possible mechanisms of target repression. miRNAs repress mRNA targets by: 1) 
destabilizing the mRNA by polyadenylation; 2) inhibiting the initiation phase of translation; 3) 
inhibiting the elongation phase of translation; 4) possibly degrading nascent polypeptides miRNAs 
(Filipowicz et al., 2008). 
 
1.2.4 miRNA: mode of action 
The result of mRNA repression by miRNAs might be the reduction in the amount of 
the target protein to a level that is below that required for a protein to function 
(meaningless biological activity). This mode of regulation is called “binary off-
switch” and is mainly observed for genes that should not be expressed in a particular 
cell type or stage (Bartel, 2009). In this case, the miRNA:mRNA interaction is 
fundamental in the regulation of a binary decision that is critical for cell fate 
establishment. One relevant example is the interaction between ZEB1 and miR-200s. 
ZEB1 is a transcriptional factor gene involved in the “epithelial-to-mesenchymal 
transition (EMT)” program, physiologically active during embryonic development 
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(Kalluri and Weinberg, 2009). It has been demonstrated that this gene is able to 
suppress the miRNAs of the miR-200 family by inhibiting the transcription of the two 
miR-200 genomic clusters (Bracken et al., 2008). In turn, miRNAs can extensively 
target ZEB1 to suppress its function (more than 6 different MREs are located in the 3’ 
UTR of ZEB1 transcripts), thus generating a negative feedback loop (Park et al., 
2008). The epithelial and mesenchymal states are regulated simply by the equilibrium 
between ZEB1 and miR-200s. The double negative feedback loop ensures that, once 
the fate is established, it is maintained over time unless a shift in the abundance of one 
of the two players (ZEB1 and miR-200s) is induced (Wellner et al., 2009). 
Alternatively, miRNAs can function by refining protein levels to one that is optimal 
for the functional role exerted in the cells. In this case, miRNAs function by “tuning” 
one or multiple targets, in order to achieve smooth fluctuations in protein expression 
and ensure a more robust biological effect (Nazarov et al., 2013). 
 
1.2.5 miRNA targets: computational predictions and tools to study miRNA-
mRNA interactions  
The need for scientists to know, with a certain degree of reliability, the identity of 
target genes regulated by the miRNA under investigation has become more and more 
imperative. Indeed, the discovery of target mRNAs can lead to the discovery of new 
pathways regulating critical biological processes under physiological and pathological 
conditions. Since miRNAs are capable of base pairing with target mRNAs displaying 
limited complementarity, they can potentially downregulate several mRNA targets, 
simultaneously. For this reason, many genome-wide approaches have been developed 
with the aim of identifying miRNA targets. These include: i) computational tools and 
ii) gene/protein expression profiling upon miRNA modulation. A schematic 
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representation of these methods is depicted in Figure 7. 
Computational tools are based on prediction algorithms. Five major algorithms are 
available: miRanda, Targetscan, Pictar, DIANA-microT and RNAhybrid. All of them 
share common rules, such as the presence of seed-matched elements, the degree of 
MRE conservation among different species, and the stability of miRNA:target 
interaction (Maziere and Enright, 2007). The main two algorithms used are miRanda 
and Targetscan. miRanda identifies regions of complementarity in the 3’UTR of the 
target gene without requiring an absolute perfect complementarity. It keeps into 
account the free energy binding contribution and the number of seed-matched sites in 
the mRNAs. All these parameters contribute to the strengh of the miRNA:mRNA 
predicted interaction measured as a score (miRsvr score). The lower the score, the 
stronger the predicted interaction. Typically, miRanda yields more predicted targets 
than other algorithms, however, it has a high rate of false positives (30 – 40%). 
Targetscan predictions are instead more stringent since it searches for biological 
targets keeping into account 8-mer and 7-mer sites, conserved across species, that 
bind with perfect complementarity to the MRE in the 3’UTR of mRNAs (Creighton et 
al., 2008).This process aims to filter out false positives as much as possible during the 
prediction process, thus reducing the estimated false positive rate range to between 
20% and 30%. Targetscan calculates a “context score” as measurement of the 
likelihood of a mRNA to be repressed by a selected miRNA. Unfortunately, many 
true targets are discarded by the stringent criteria of this algorithm  
An alternative or complementary strategy to identifying miRNA targets is to perturb 
the expression of a particular miRNA and identify any genes or proteins that change 
expression as a consequence. A seminal study applying this strategy came from Lim 
and colleagues, who transiently transfected the muscle specific miR-1 and miR-124 
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into HeLa cells and exploited microarray analysis to determine transcriptional 
changes (Lee P. Lim, 2005). This studied revealed that miRNA effects could be 
scored by transcriptome analysis. Indeed, they found that ~100 mRNA were 
downregulated upon miR-1 and miR-124 overexpression and that the vast majority of 
these (>75%) contained an MRE in their 3’ UTR corresponding to the overexpressed 
miRNAs (Lee P. Lim, 2005). An alternative strategy is to determine the consequences 
of knockdown or deletion of endogenous miRNAs; however, changes in mRNA 
levels after knockdown were not as pronounced as those after overexpression (Lee 
and Shin, 2012). 
A more recently established approach to miRNA target identification involves the use 
of high-throughput RNA sequencing (RNA-seq) to detect transcriptional changes 
(Wang et al., 2009). Compared with microarray technology, RNA-seq possesses a 
higher sensitivity together with a broader dynamic range and does not require 
sequence information. With this approach, Burow et al. evaluated the global effects of 
a well-studied oncogenic miRNA, miR-155, on the transcriptome of an estrogen 
receptor-positive (ER
+
), luminal, breast cancer cell line, MCF7. By performing RNA-
seq analysis, the authors studied changes in the transcriptome mediated by miR-155 
modulation in MCF7, and demonstrated that this miRNA is able to alter many 
pathways, with the MAPK signaling cascade being the main one (Martin et al., 2014). 
Another strategy to decipher miRNA targets is to use proteomic approaches to 
observe protein changes in response to miRNA overexpression or downregulation (Li 
et al., 2012). In this case, the stable isotope labeling by amino acids in cell culture 
(SILAC) technique, or its variants, have been exploited to analyze protein abundance 
by mass spectrometry (Li et al., 2012). 
Lastly, biochemical approaches to study miRNA-mRNA interactions have been used. 
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These methods rely on the physical interaction between the miRISC (miRNA loaded 
RISC complex) and the target mRNAs, and are considered as the most accurate way 
to define the miRNA targetome, although technically very challenging. Briefly, these 
methods require the immunopurification of the miRISC complex, through one of its 
subunits (such as Ago2), together with associated mRNAs (Ago-RNA 
immunoprecipitation or Ago-RIP). Ago-associated mRNAs are revealed through 
Affymetrix (Ago-RIP-Chip) or via deep sequencing (Ago-RIP-seq) (Karginov et al., 
2007). Crosslinking treatments are usually employed to avoid contaminants and to 
precisely map MREs. Two main techiniques are used: High-throughput Sequencing of 
RNA isolated by crosslinking immunoprecipitation and Photoactivatable-
Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation (HITS-CLIP and 
PAR-CLIP). 
 
Figure 7  - Summary of genome-wide approaches for miRNA target identification. Computational 
methods and experimental approaches, including expression profiling and biochemical methods, have 
been applied to miRNA target identification. Figure taken from (Lee and Shin, 2012). 
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1.3 miRNAs and stemness 
Given the central role of miRNAs in controlling gene expression programs that 
regulate cell identity and behavior, it is not surprising that miRNAs have been linked 
to stem cells (both embryonic and adult) and to the control of their peculiar 
characteristics, such as self-renewal and differentiation (Guo et al., 2011). Indeed, the 
stem cell and miRNA fields of research have converged following the identification 
of stem cell-specific miRNAs. These miRNAs target genes required for stem cell 
function, thereby, critically affecting stem cell fate and behavior. 
 
1.3.1 miRNAs and embryonic stem cell differentiation  
The first evidence that miRNAs can control mammalian stem cells came from 
experiments on embryonic stem cells (ESCs). These cells can be cultured in vitro as 
pluripotent stem cells and pushed to differentiate into different cell lineages by 
specific differentiation media. Analysis of miRNA expression profiles in 
undifferentiated ESCs revealed that these cells possess a unique pattern of miRNAs, 
with the miR-290 species alone comprising more than 60% of all miRNA molecules 
(Tiscornia and Izpisua Belmonte, 2010). By analyzing the expression profiles of 
mouse embryonic fibroblasts (MEFs) and neuronal precursors (NPC), it was 
immediately clear that the miRNAs of this family (plus those of the miR-302 family) 
are uniquely expressed in ESCs (ESC-specific miRNAs) (Marson et al., 2008). 
Of note, genetic depletion of Dicer, one of the key enzymes involved in miRNA 
biogenesis, in mice caused severe impairment of expression of most, if not all, the 
miRNAs, defects in differentiation, and embryonic lethality (Bernstein et al., 2003). 
This strong phenotype was immediately associated with a possible role for miRNAs 
in promoting differentiation (Bernstein et al., 2003). Similarly, DGCR8-deficient 
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ESCs displayed impairment of the differentiation process (Wang et al., 2007). Both 
Dicer-null and DGCR8-deficient ESCs also exhibited a cell cycle delay together with 
a failure to shut down some of the transcription factors (OCT4, Nanog, Sox2) 
associated with self-renewal (Wu et al., 2014). These defects could be rescued by the 
expression of the ESC-specific miRNAs (miR-290s and miR-302s) suggesting that 
they are, indeed, necessary for self-renewal of this cell type (Wang et al., 2008). 
Furthermore, the expression of ESC-specific miRNAs enhanced the production of 
murine induced pluripotent stem (iPS) cells, indicating a role of these miRNAs in 
specifying ESC identity (Judson et al., 2009). 
Conversely, other miRNAs, such as miR-145, let-7 and miR-21, are downregulated in 
self-renewing ESCs, but become upregulated during differentiation (Niu et al., 2011).  
These miRNAs act by silencing pluripotency genes, such as OCT4, Nanog, Sox2 and 
Klf4. Thus, they suppress the self-renewal program and promote the differentiation of 
ESCs towards a specific cell lineage (Xu et al., 2009) (Fre et al., 2005). 
These findings unequivocally established a pivotal role of miRNAs in dictating the 
transition from an embryonic state to a more differentiated one by promoting cell 
cycle progression or silencing of self-renewal genes. 
 
1.3.2 miRNAs and adult stem cell differentiation  
In addition to studies in ESCs, the function of miRNAs has also been explored in 
adult stem cells by many research groups. The number of miRNAs that were found to 
participate in the control of adult stem cells is quite high. Here, I will briefly discuss 
some of these miRNAs to illustrate how they were identified and their modes of 
action.  
One of the first adult stem cell models to be investigated was that of the 
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hematopoietic system, for which it is possible to isolate stem cells and progenitors, 
and to follow their differentiation processes. In this system, several miRNAs were 
found to be involved in the regulation of specific steps of hematopoiesis. For 
example, miR-181, miR-223 and miR-142 are all upregulated when bone marrow 
progenitor cells begin to differentiate towards the lymphoid or the myeloid lineages 
(Chen et al., 2004). Importantly, miR-155, expressed both in mature myeloid and 
lymphoid cells and upregulated in several types of lymphoma, is a required for the 
correct differentiation process and affects immune response in vivo. Indeed, 
transcriptome analysis in miR-155-deficient T lymphocytes revealed that cytokines 
and chemokines are among the key target genes regulated by this miRNA (Rodriguez 
et al., 2007). 
In non-hematopoietic tissue, miR-203, one of the most abundant miRNA in 
mammalian skin, was among the first miRNAs to be shown to control cell fate 
decision. In a seminal study by Yi and co-workers, miR-203 was described to have a 
well-defined spatio-temporal expression regulation, through in-situ hybridization 
analysis of skin primary mouse keratinocytes. In particular, this miRNA was poorly 
expressed in epidermal stem cells and its expression started to increase as soon as 
these cells differentiated. Moreover, the authors showed that activation of miR-203 
depletes the stem cell pool, while the inhibition of endogenous miR-203 resulted in 
the normal pattern of differentiation of epidermal stem cells. Mechanistically, miR-
203 targets ΔNp63α, a transcription factor essential for maintenance of epidermal 
stem cells (Yi et al., 2008). 
In another study by Green et al., a role for miR-205 in the control of differentiation of 
mammary epithelial cell progenitors has been described (Greene et al., 2010). The 
authors initially isolated a subpopulation of cells, enriched in progenitors, from a 
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mouse mammary epithelial cell line (COMMA-DbetaGeo) by FACS-sorting for stem 
cell antigen 1 expression (Sca-1+). The authors then compared the expression profiles 
of this Sca-1+ subpopulation with the Sca-1– counterpart. By microarray analysis, they 
found that miR-205 was highly expressed in the Sca-1+ subpopulation. Moreover, 
overexpression of this miRNA in-vitro (COMMA-DbetaGeo) caused an expansion of 
the progenitor cell population and increased cell proliferation. They also identified the 
tumor suppressor gene PTEN as miR-205 target. Taken together, these results indicate 
that miR-205 is involved in the maintenance of self-renewal, at least in mammary 
epithelial stem cells (Greene et al., 2010).  
 
1.3.3 miRNAs and self-renewal maintenance  
A role for miRNAs in the maintenance of stem cell traits has also emerged. For 
example, it has been shown that the miR-290-295 cluster is ESC-specific and is 
directly involved in maintaining pluripotency; indeed, its levels decrease as the ESC 
differentiates. This miRNA family exerts its role by targeting the repressor of DNA 
methyl transferase (DMNTs), called RBL2, which in turn is no longer able to 
inactivate OCT4, maintaining active a critical effector of self-renewal (Houbaviy, 
2003). 
 
1.4 miRNAs and cancer biology 
The role for miRNAs in controlling cell transformation and tumor progression has 
been also explored. Although this field has only recently emerged, several miRNAs 
have been implicated in human cancer and shown to influence key cancer-relevant 
pathways and cancer genes (Jansson and Lund, 2012). One of the initial observations 
made by Carlo Croce and co-workers was that miRNA loci frequently map to 
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genomic regions commonly amplified or deleted in various human cancers (fragile 
sites), suggesting a possible link between tumors and miRNAs (Calin et al., 2004). 
This hypothesis was corroborated when expression profile analysis revealed that 
tumors presented a widespread deregulation of miRNA expression (Volinia et al., 
2006). Notably, miRNAs may not act only on master cancer regulatory genes, but 
may influence the properties of the network to which these gene belong, thereby 
stabilizing or de-stabilizing the whole network (Kwak et al., 2010). 
microRNAs may act as either oncogenic or tumor suppressor molecules. Hence, in 
tumor formation we assist to a strongly reduction or even to a complete depletion of 
tumor suppressor microRNAs (Figure 8B) or to an amplification⁄overexpression of the 
oncogenic ones (Figure 8C). 
A miRNA functioning as a tumor suppressor might inhibit the expression of an 
oncogene under normal conditions; when expression of this miRNA is lost, oncogene 
expression increases thus promoting tumor formation (Figure 8B). In contrast, a 
miRNA functioning as an oncogene might promote tumor formation by inhibiting the 
expression of a tumor suppressor gene (Figure 8C). For example, the miR-17-92 cluster 
acts primarily as an oncogene and cooperates with c-Myc to accelerate tumorigenesis 
in a mouse model of B cell lymphoma (He et al., 2005). Indeed, it maps to a 
chromosomal region that is frequently amplified in a subset of human B cell 
lymphomas (Ota et al., 2004). Similarly, miR-155 has been found to be upregulated in 
several hematopoietic malignancies and tumors of the breast, lung and pancreas 
(Kluiver et al., 2006). Experiments performed on genetically engineered mice with 
gain- and loss-of-function alleles of miR-155 demonstrated that this miRNA is able to 
generate tumors. Indeed, ectopic expression of miR-155 in B cells of transgenic mice 
is sufficient to induce proliferation of pre-B cells and consequently leukemia 
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(Costinean et al., 2006).  
Conversely, miR-15 and miR-16 are located in a genomic region that is deleted in the 
majority of chronic lymphocyte leukemias (CLLs) and in prostate cancer, suggesting 
that these miRNAs may act as tumor suppressors (Calin et al., 2002). Importantly, a 
significant regression of prostate tumor xenografts was observed upon intratumoral 
delivery of miR-15a and miR-16-1 (Bonci et al., 2008). Another well-studied tumor 
suppressor miRNA is let-7. In humans, let-7 refers to a family of miRNAs composed 
of a dozen members organized in eight different genomic loci. Some of these loci are 
deleted in a variety of human cancers and overexpression of multiple let-7 miRNAs 
can suppress tumor development in vivo, in xenograft or mouse models of lung cancer 
(Esquela-Kerscher et al., 2008). Besides let-7, many other miRNAs were found to 
have a tumor suppressor function. Many miRNAs are associated with cell 
differentiation, which is by definition a tumor suppressive mechanism. Indeed, a 
global decrease in miRNA expression has been observed in tumors as a consequence 
of genetic (deletion or mutations in miRNA genes), epigenetic (methylation-induced 
silencing of miRNA promoters), or molecular events (regulation of transcription 
factors that control miRNA expression)(Chang et al., 2007) (Iorio et al., 2005) (Ozen 
et al., 2007). Accordingly, mutations or alterations of the genes involved in the 
miRNA biogenesis pathway (such as Dicer or Drosha) are associated with increased 
tumor malignancy and poor prognosis (Lin et al., 2010; Merritt et al., 2008). Indeed, 
Tyler Jack’s lab demonstrated that silencing of three different components of the 
miRNA processing machinery (Dicer, Drosha and DGCR8) resulted in enhanced 
oncogene-induced transformation and accelerated tumor formation in-vivo. These 
findings suggest that global loss of miRNAs favors tumorigenesis (Kumar et al., 
2007). 
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Finally, miR-22 has been identified as a potent oncogene in leukemia. Transgenic 
mice conditionally expressing miR-22 showed an increase in hematopoietic stem cell 
self-renewal and defects in differentiation. Moreover, miR-22 inhibition was able to 
block proliferation of leukemic cells. In the same study, they demonstrated that miR-
22 exerts its role by targeting the tumor suppressor protein TET2 (Song et al., 2013). 
 
 
Figure 8   – Possible roles of miRNAs acting as tumor suppressor or oncogenic molecules. A) In 
normal tissues, miRNA molecules are regularly processed and cells proliferate and differentiate 
normally. B) miRNAs acting as tumor suppressor molecules are often lost in cancer and might promote 
the over-expression of oncogenes. C) miRNAs functioning as oncogenes are often overexpressed in 
cancer and might promote tumor formation by inhibiting the expression of a tumor suppressor gene. 
Figure taken from (Esquela-Kerscher and Slack, 2006). 
 
 
  Introduction 
 
 28 
1.4.1 miRNAs and breast cancer stem cells 
In 2007, Yu et al. first linked the let-7 miRNA family to BCSCs. In their work, they 
compared the expression of selected miRNAs in lin-/CD44+/CD24- tumor initiating 
cells (TICs) to that in the CD44-/CD24+ non-tumorigenic counterpart (NTG) and 
found that levels of the let-7 family were strongly reduced in TICs (Yu et al., 2007). 
As chemotherapy increases the proportion of CSCs within breast tumors, they used as 
a model system a derivative of the SK-BR-3 breast cancer cells, called SK-3rd, 
generated by serial passaging in NOD/SCID mice treated with chemotherapy. They 
demonstrated that let-7 levels were decreased in SK-3rd cells, compared to the 
parental clone; however, upon SK-3rd cell differentiation in vitro, let-7 levels 
increased (Yu et al., 2007). Overexpressing let-7 in TICs decreased mammosphere-
forming ability, and tumor formation and metastasis in-vivo. The authors dissected the 
mechanism of action of let-7 in SK-BR-3 and SK-3rd cells and found that this 
miRNA directly targets H-Ras and HMGA2, which control self-renewal and 
differentiation (Yu et al., 2007). 
A few years later, Shimono et al. used a similar approach and compared the miRNA 
expression profiles of 460 miRNAs, by RT-qPCR, in human breast cancer cells 
(isolated by surface markers lin-/CD44+/CD24-) and in their non-tumorigenic 
counterparts. Using this approach, the authors were able to derive a signature of 37 
miRNAs differentially expressed in BCSCs compared to their non-tumorigenic 
counterparts (Shimono et al., 2009). Multiple members of miR-200 were 
downregulated in the stem cell compartment and were also found to be downregulated 
in MaSCs isolated from normal human and murine mammary gland tissue. High-
resolution experiments on the miR-200 family, revealed that ectopic expression of 
miR-200c suppressed the ability of normal MaSCs to form mammary outgrowths in-
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vivo and, more importantly, inhibited in vivo tumor formation by human BCSCs. At 
the molecular level, miR-200c inhibited repression of BMI, a member of the 
Polycomb repressing complex 1 (PRC1) and a regulator of self-renewal and 
differentiation of adult stem cells (Shimono et al., 2009). 
In a recent study, a role for miR-205 in the regulation of MaSC fate and 
tumorigenesis was elucidated. In particular, the repression of miR-205 by the Notch 
ligand Jagged 1 (JAG1) in breast epithelial cells, promoted EMT and loss of epithelial 
polarization (Chao et al., 2014). These effects were accompanied by an expansion of 
the stem cell population by SCD and the formation of spontaneous mammary lesions 
in vivo. Mechanistically, miR-205 targets both ZEB1/2 (similarly to the miR-200s) 
and Notch2, generating another feedback mechanism involved in the control of 
epithelial vs. mesenchymal states (Chao et al., 2014). 
Thus, mounting evidence indicates that miRNAs are key regulators of SC (including 
MASCs), self-renewal and that their deregulation can lead to aberrant regulation of 
the SC compartment and tumor formation. 
 
1.5 Genome-wide screenings 
Genetic screenings represent a reverse-genetic approach, in which multiple genomic 
elements (i.e. genes) are analyzed at the same time to search for those that are relevant 
to the phenotype of interest, by a totally unbiased approach. When applied at the 
genome-wide level, all (or most of) the genes in the genome are analyzed at the same 
time, to systematically explore their contribution to a certain biological process. The 
advantage of using such an approach is that it allows new functions to be associated 
with specific genes, and explores interactions between genes and their biological 
pathways. The main problem with genome-wide screenings is that they are extremely 
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technologically challenging due to the high number of genes being screened at the 
same time, and the necessity to keep confounding variables under control, which 
could influence the phenotype and thus alter the screening results.  
Biologists generally exploit RNA interference (RNAi) methods to perturb the 
function of genes of interest in cells using short-interfering RNA (siRNA) molecules 
or short hairpin RNA (shRNA) molecules to exert the silencing (loss-of-function 
studies). Once the phenotype of interest has been observed, the sequence responsible 
for that phenotype is tracked back and, hence, genes capable of influencing the 
phenotype are identified. 
Transfection using oligonucleotide siRNAs has greatly facilitated functional analysis 
of the human transcriptome, however one of the main downsides of such an approach 
is the need of delivering siRNAs into recipient cells by transfection, which makes it 
hardly feasible in non-dividing and/or primary cells. Moreover, siRNAs have 
transient effects and, thus, are not suitable to perform long-term assay or in-vivo 
experiments. 
To overcome these limitations, shRNA vectors are frequently used. In this case a 
retroviral or lentiviral vector can be stably integrated into a target cell genome 
ensuing into the stable expression of a specific shRNA, resulting in the permanent 
reduction of the target gene product. Viral integration ensures a broader range of 
infectable target cells, including non-dividing and primary cells. However, to achieve 
robust biological effects, several conditions have to be satisfied, such as: i) efficient 
delivery of DNA-based plasmid into the host cell; ii) stable genomic integration; iii) 
transcription of the pri-shRNA hairpin; and iv)precise processing of pre-shRNA 
hairpin to yield a functional silencing duplex. 
In large-scale applications, shRNA vector libraries directed toward entire genomes 
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could be used. In this case, silecing is accomplished by individual transfection of cells 
with a single shRNA from the library. This approach is very time-consuming, 
expensive and suffers of many sources of variability, for instance due to different 
reagent batches, , different confluence of plated cells. Alternatively, pooled shRNA 
library screenings could be exploited.  Briefly, from hundreds to thousands of hairpins 
are combined (pooled) together and used to interrogate simultaneously a large 
population of cells, thus minimizing the experimental variability. In this case, cells are 
infected in a way that allows just a single shRNA expression vector to be integrated in 
the genome. Hence, different cells in the population have different silenced genes and 
could behave differently according to the effect of the silencing. Transduced cells 
could be screened for a phenotype of interest, to select those shRNAs that confer a 
specific phenotypic advantage/disadvantage. In particular, those shRNAs that inhibit 
the functions under the selection process are depleted from the initial pool (negative-
selected/ drop-out screen), whereas constructs that enhance the functions will be 
enriched, as cells harboring these shRNAs will survive/expand in the selection 
process (positive-selected/ drop-in screen). 
The main advantage of pooled shRNA libraries is that all the cells are cultivated 
under the same conditions, minimizing variability, and simplifying the experiments. 
Furthermore, the stronger is the phenotypic effect of the shRNA, the stronger and the 
quicker is the depletion/enrichment from the initial pool. However, clone 
devonvolution is not trivial and usually requires the exploitation of ad-hoc high-
throughput approaches such as microarrays or next generation sequencing. One of the 
main drawbacks is, for instance, that RNAi-based-loss-of-function studies require that 
a strong shRNA expression should be maintained throughout the experiment. Indeed, 
if the shRNA expression is prevented because of unfavorable integration sites or other 
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inhibitory effects, than the effect of the shRNA is hidden. To overcome this problem, 
Scott Lowe developed a tool to track and isolate cells with strong target knockdown. 
The tool consists of an inducible shRNA expression system, the TRMPV vector, 
containing two fluorescent reporters: 1) the constitutive active yellow-green protein 
Venus and 2) the inducible dsRed fluorescent protein, whose expression is coupled to 
that of the shRNA of interest.  
To test this vector, they transduced an established mouse lymphoma cell line (Eu-
myc; Trp53 -/-) and performed a proof-of-principle experiment. By doxycycline 
treatment, they obtained a strong induction of dsRed expression and demonstrated 
that the double positive cells (VENUS+, dsRred+) provided a more sensitive 
assessment of deleterious shRNA effects than Venus alone. To this end, they propose 
the use of the TRMPV vector to facilitate the selection by FACS analysis of pure 
clonal populations capable of strong shRNA induction (Zuber et al., 2010). 
Genome-wide shRNA libraries are extremely powerful and could be employed to get 
insights into many biological processes, including the study of genes related to 
cancer, stem cell biology or both (cancer stem cells). 
For instance, in the work by Luo et al, an shRNA library was exploited to uncover 
putative therapeutic targets by identifying genes that were selectively required for the 
proliferation or survival of cancer cells with certain mutations. They developed a 
library containing 74,905 retroviral shRNAs targeting 32,293 unique human 
transcripts and applied it (6 pools of ∼ 13,000 shRNAs per pool) to the colorectal 
cancer cell line DLD-1, carrying a K-Ras active point mutation that ensures a 
malignant phenotype (Luo et al., 2009). With such a loss-of-function experiment, they 
were able to detect shRNAs that displayed an anti-proliferative effect and were, thus, 
depleted from the population, by calculating the change in relative abundance of each 
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shRNA over time using microarray hybridization (Luo et al., 2009). Among the 
negatively selected genes, they discovered strong enrichment in genes regulating 
mitotic functions, meaning that the depletion of such genes impaired the viability of 
Ras mutant cells. They were able to describe a pathway involving the mitotic kinase 
PLK1, the anaphase-promoting complex/cyclosome (APC/C), and the proteasome 
that is essential for Ras mutant cells. Hence, they proposed to employ 
pharmacological inhibition of such pathway to treat cancers harboring Ras mutations 
(Luo et al., 2009). 
To reveal new transcriptional regulators that govern the self-renewal capacity and 
regenerative potential of stem cells, Fuchs and co-workers performed an RNA-
interference-based loss-of-function screening on hair follicle stem cells (HF-SCs) 
purified from their native niche in-vivo (Chen et al., 2012). Primary HF-SCs were 
transfected with a lentiviral pool encoding about 2000 candidate shRNAs (400 genes 
in total) that were found to be enriched in stem cells compared to progenitors. Cells 
were cultured for different passages and shRNAs were amplified and sequenced at 
each passage to reveal shRNAs depleted or enriched as a consequence of their ability 
to influence long-term proliferative potentials. They focused on the strongest shRNAs 
able to suppress long-term self-renewal and selected TBX1 gene for in-vivo analyses. 
TBX1-null stem cells, indeed, failed to replenish the niche during tissue regeneration, 
thus uncovering a new key regulator of skin stemness (Chen et al., 2012).  
Similarly, in the work of Ali et al., a pooled lentiviral shRNA library was used to 
infect primary human hematopoietic stem cells (HSCs) searching for modifiers of 
HSC self-renewal (Ali et al., 2009). HSCs isolated from umbilical cord blood were 
transfected with a pooled library targeting 1300 human genes and passaged in liquid 
cultures for 10 weeks followed by colony-forming-cell assays to select for clones that 
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acquired enhanced self-renewal potential. DNA was extracted from each colony and 
sequenced. Three hit candidates were pointed out and further validated, demonstrating 
the potential of RNAi screening on human primary stem cell populations (Ali et al., 
2009).  
In the elegant work by Gupta and co-workers, an RNAi screen was performed to 
uncover agents that specifically kill breast epithelial cancer stem cells (CSCS) (Gupta 
et al., 2009). About 16000 compounds were screened for their effects on a normal 
breast cell line that was previously induced to an epithelial-to-menchymal transition 
in order to favor the acquisition of stem cell traits (HMLEshEcad). Cells were 
individually tested for viability 3 days upon treatment with chemicals by a 
luminescence assay. 32 compounds were found to specifically reduce the viability of 
HMLEshEcad as compared to control HMLE. Eight candidates were chosen and four of 
them were individually validated. Of note, the strongest compound, Salinomycin, was 
also tested on the breast cancer cell line HMLER and found to inhibit cancer stem 
cells, as i) it specifically decreased the cancer stem cell content by FACS (CD44high 
CD24low); ii) it reduced the number of tumorspheres by 10-fold; 3) it decreased the 
tumor-seeding efficiency by 100 fold and tumor volume and metastasis in-vivo (Gupta 
et al., 2009). 
 
1.5.1 Functional microRNA screenings 
A new emerging challenge is elucidating the biological processes in which miRNAs 
play a role. As for protein coding genes, the function of a miRNA might be also 
revealed by knocking it down or out from the genome of interest. However, this 
method requires prior knowledge where a miRNA is expressed and sufficient 
knockdown to demonstrate an observable effect is not always guaranteed. Adding to 
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this challenge is the possibility that many miRNAs may elicit only subtle changes or 
are redundant with other family members.  
A more convenient approach, which overcomes these problems, is to overexpress a 
given miRNA in the system of interest. As miRNAs closely resemble 
siRNAs/shRNAs, it is possible to exploit the same kind of approaches, such as i) 
siRNA oligos with the sequence of miRNAs (miRNA mimics); ii) viral vectors 
expressing miRNA precurosors. 
MicroRNA mimics are chemically synthesized miRNA duplexes, which express 
miRNAs in their mature form, so that the canonical miRNA biogenesis pathway is not 
required. Bypassing this physiological processing step has several implications. For 
instance, it is possible that transfection of miRNA mimic achieves cellular 
concentrations beyond physiological relevance. Conversely, the lenti- or retro-viruses 
are integrated in to the host genome and swiftly and stably express miRNA genes, 
allowing long term assays or the use of primary cells hard to transfect, such as adult 
stem cells. 
To identify specific miRNAs that promote the G1/S transition in embryonic stem (ES) 
cells, a screening using 266 mouse microRNA mimics individually transfected into 
the Dgcr8 knockout embryonic stem cells was performed (Wang et al., 2008). As 
Dgcr8-mutant ES cells lack endogenous miRNAs and display a proliferation defect, 
transfected cells were evaluated for changes in their rate of cell proliferation.  
MiRNAs that rescued the proliferation defect of Dgcr8-/- cells were identified, 
including members of the miR-290 cluster (miR-291a-3p, miR-291b-3p, miR-294, 
and mir-295) and the miR-302a-d.  Authors revealed that these miRNAs control the 
expression of key regulators of the G1/S transition such as Cdkn1a (Wang et al., 
2008) and could promote the induction of pluripotency (iPS) when introduced into 
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mouse embryonic fibroblasts along with reprogramming transcriptional factors (Oct4, 
Sox2 and Klf4 (Judson et al., 2009).  
By combining miRNA expression pattern and phenotype screening, Yu and 
collaborators identified key miRNAs that promote ES cells differentiation (Ma et al., 
2014). In particular, they focused on 40 miRNA individually transfected as mimics in 
Dgcr8 knockout embryonic stem cells to search for those responsible of ES 
differentiation. They pointed out miR-27a and miR-24, able to directly target 
pluripotency factors and signal transducers of ESC self-renewal networks such us 
Foxo1, Oct4 and Smad4 (Ma et al., 2014).  
By performing a high-throughput functional screening, the group of Giacca uncovered 
a set of microRNAs that stimulates cardiomyocytes (CM) proliferation and promotes 
cardiac repair (Eulalio et al., 2012). A library of 875 miRNA mimics was used to 
infect neonatal rat cardiomyocytes and two microRNAs in particular (miR-590 and 
miR-199a) significantly induced proliferation of CM. By injecting these synthetic 
microRNAs in-vivo into the heart of neonatal rats, they further prove that these 
molecules not only are able to control CM proliferation but also they boost the 
normally ineffective myocardial repair that takes place after myocardial infarction 
(Eulalio et al., 2012). Notably, the findings that exogenously administered miRNAs 
have the potential to restore cardiac function to almost normal levels after myocardial 
infarction have evident translational value.  
 
1.5.2 Functional screening assays to reveal cancer-associated miRNAs 
Given the great biological impact of miRNAs on cancer and considering that the 
number of miRNAs is considerably lower than the total human genes, it is not 
surprising that a lot of effort is now being directed to finding new strategies to study 
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miRNAs involved in cancer. Currently, two main approaches are used: expression 
profiling studies and functional screenings. The first approach is mainly based on the 
frequently observed differences in miRNA expression profiles between tumoral and 
not-tumoral tissues, due to aberrant expression of miRNA genes in cancer. This 
approach is a good strategy for identifying novel miRNA tumor biomarkers; however, 
it does not usually allow the detection of “driver” tumor miRNAs. In contrast, 
functional screenings allow the identification of miRNAs with cancer-associated 
phenotypes, without considering their level of expression. This type of screening 
involves two steps: 1) a systematic introduction of miRNAs into cells; 2) detection of 
miRNAs with a cancer-associated phenotype by microarray analysis or next 
generation sequencing. 
Recently, vector-based (either retroviral or lentiviral) miRNA libraries have been 
exploited for this purpose. Such pooled libraries are used to stably express precursor 
miRNAs that are challenged in phenotype competition assays. As example, in their 
work Agami and co-workers (Voorhoeve et al., 2006) introduced a homemade 
miRNA pooled library of 197 miRNAs into immortalized human foreskin fibroblasts 
(BJ|ET) and subsequently transduced the cells with RASV12. The difference in 
abundance of all miR-vectors was then detected by a homemade miR-microarray after 
3 weeks by growing cells in 2D adherent conditions. They found that miR-372 and 
miR-373 were positively selected in three independent experiments, capable of 
conferring growing advantage. They further demonstrated that cells overexpressing 
this cluster were capable of growth in soft agar conditions, and demonstrated that 
miR-372 and miR-373 collaborate with RAS in the transformation process in a 
manner that resembles p53 inactivation. Finally, they found that these miRNAs were 
overexpressed in 4 out of 7 testicular germ cell tumors tested, all of which were WT 
  Introduction 
 
 38 
for p53 and presented chemotherapy resistance (Voorhoeve et al., 2006). This study is 
an example of a positive screening assay in which a cell population with a phenotype 
of interest increases during the selection process.  
To examine the potential of miRNAs for treatment of head and neck squamous cell 
carcinomas (HNSCC), a retroviral human miRNA expression library containing 370 
miRNAs was used to infect the cancer cell line population VU-SCC-120 and the 
normal oropharyngeal keratinocytes ciOKCs as control (Lindenbergh-van der Plas et 
al., 2013). The majority of the clones were not able to influence the survival of either 
the tumor cell or the control, or the lethal effect was similar in both models. 
Conversely, 19 microRNA candidates specifically affected the head and cancer cell 
line VU-SCC-120. By individual transfection, they validated 6 out of 19 microRNA 
candidates, as they were able to decrease proliferation specifically in HNSCC cells. 
Moreover, they demonstrated that 3 of these microRNAs target the nuclear protein 
kinase ATM, that activates DNA damage through several downstream pathways 
(Lindenbergh-van der Plas et al., 2013).  
In the work of Nakagama et al. (Izumiya et al., 2010), authors performed a high-
throughput functional screening using a pooled miRNA library containing about 450 
miRNA clones. The pancreatic cancer cell line MIA PaCa-2 was infected with this 
library to detect miRNAs able to suppress cell proliferation in adherent 2D condition. 
They deconvoluted miRNA clones by the use of a custom-made microarray and 
determined changes in the relative abundance of a miRNA, by comparing its 
depletion or increase over time relative to the initial population. They thus identified 5 
negatively-selected miRNAs, putatively acting as anti-proliferative miRNAs. By 
single validation, they showed that 4 out of 5 miRNAs were able to cause a cell cycle 
block, confirming the feasibility of the drop-out screening in which a microRNA is 
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negatively-selected and thus decreases from the initial population (drop-out). 
The analogous group then applied the same library to detect tumor suppressor 
miRNAs in colon carcinogenesis (Tsuchiya et al., 2011). They infected the HCT116 
cell line and identified 24 putative anti-proliferative miRNAs by microarray analysis. 
To narrow the selection, they integrated the functional analysis to expression profiling 
and identified miR-22 as miRNA candidate for tumor suppressor. They then moved 
on to study the mechanism of action of miR-22 and identified p21 as its direct target. 
In turn, miR-22 is a transcriptional target of p53. Briefly, they propose the p53–miR-
22–p21 axis is a crucial regulatory component involved in the determination of p53-
dependent apoptosis. 
Overall, genome-wide screening approaches for identifying miRNAs involved in 
particular phenotypes appear to be a successful strategy.  
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2 MATERIAL AND METHODS 
2.1  Cellular biology 
2.1.1 Cell lines 
MCF10A (human normal mammary gland cell line) cell line was provided by ATCC 
and cultured in DMEM/F12 (1:1) + Glutamax, 5% horse serum, EGF (20 ng/mL), 
Cholera Toxin (100 ng/ml), Human insulin (10 µg/ ml), Hydrocortisone (500 ng/ml), 
Pen/strep 1%. [CO2 ] = 5% 
MCF7 (luminal human primary breast cancer cell lines) cell line was provided by 
ATCC and was cultured in DMEM supplemented with 10% fetal bovine North 
American serum (Hyclone, TermoScientific), 2mM Glutammine under an atmosphere 
of 5% CO2 at 37°C. 
SUM159PT (triple negative human primary breast cancer cell lines) cells were 
commercially available (Asterand, Detroit, MI) and were cultured in Ham’s F12 
medium (Invitrogen Life Technologies) supplemented with 5% fetal bovine North 
American serum (Hyclone, TermoScientific), 2mM Glutammine, 5ug/mL insulin, 1 
µg/mL hydrocortisone and 10mM HEPES and were cultured under an atmosphere of 
10% CO2 at 37°C. 
 
2.1.2 Lentiviral infections 
293T packaging cells were cultured in a humid atmosphere containing 5% CO2 in 
DMEM supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin and 100 
µg/ml streptomycin. For third- generation lentiviral production 293T cells were 
transfected with the calcium-phosphate procedure with a mixture of: 10 µg of pRSV-
Rev, 10 µg of pMDLg/pRRE (gag&pol), 10 µg of pMD2.G (VSV-G), and 20 µg of 
  Material and methods 
 
 41 
the lentiviral vector per plate, 250 µl of 2M CaCl2 , in a final volume of 2 ml TE 0.1X. 
This mix was added drop wise to 2 ml of 2X HBS, by bubbling, and then the calcium-
phosphate precipitates were added to the cells at 70% of confluence. The medium of 
293T cells was replaced after 12-16 hs post-transfection; the viral supernatant was 
collected at 36h post transfection and filtered with a 0.45 µm syringe-filter. To 
concentrate the viral stock, we ultra-centrifuged the viral supernatant for 2h at 19800 
rpm at 4°C and the viral pellet obtained was resuspended in MEBM medium at 100X 
concentration. 
 
2.1.3 microRNA lentiviral vectors 
MicroRNA overexpression and non-targeting controls (SCR and PCDH) was obtained 
by lentiviral infection with commercially available vectors from System Biosciences 
(SBI).  List of clones: Scramble control CD511B-1; PCDH control CD511B-1 pCDH-
CMV-MCS-EF1; Lenti-miR-34a MI0000268; Lenti-miR-191 MI0000465; Lenti-
miR-483 MI0002467; Lenti-miR-96 + miR-183 MI0000273, MI0000098; Lenti-miR-
200c MI0000650; Lenti-miR-146a MI0000477; Lenti-miR-342 MI0000805; Lenti-
miR-24-1 MI0000080; let-7a-2 MI0000061; Lenti-miR-125a MI0000469; Lenti-miR-
124a-1 MI0000443; Lenti-miR-1-1, MI0000651; Lenti-miR-153-2 MI0000464; 
Lenti-miR-379 MI0000787; Lenti-miR-204 MI0000284; Lenti-miR-889 MI0005540; 
Lenti-miR-664 MI0006442; Lenti-miR-657 MI0003681; Lenti-miR-144+miR-
451a+miR-4732 MI0001729, MI0017369, MI0000460. 
microRNA lentiviral vectors enabled to set up stable and heritable microRNA 
overexpression. microRNAs were all expressed as precursor transcripts (pre-
miRNAs) in their native sequence context to ensure a natural interaction with 
endogenous processing machinery and  leading to authentic mature microRNAs. 
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Transduced cells were monitored thanks to the co-expression of copGFP fluorescent 
marker by FACS analysis. 
 
2.1.4 Colony assay 
5000 transduced MCF10A cells, (overexpressing one of the following constructs: 
PCDH, miR-34, miR-483, miR-200c, miR-191) were plated in 2D adherent 
conditions onto three different cell culture dishes and incubated for 10 days before 
visualizing colonies by crystal violet staining. Crystal violet staining solution was 
prepared by dissolving 1g of crystal violet powder in 100 mL of 20% EtOH and 
filtered at 0.45 micron. For the staining procedure, plates were initially washed with 
1X DPBS and after, the staining crystal violet solution was gently and 
homogeneously distributed with a sufficient volume to cover the surface along the 
plates. The staining solution was left in contact with cells for few minutes and then 
removed. Plates were finally washed with water at least twice and were left to dry 
inverted before visualizing colonies. 
 
2.1.5 Calculation of integration number (IN) 
We needed to control the number of integration upon infection, thus we introduced 
two parameters:  
- Molteplicity of infection (MOI)  
 
- Integration number (IN)  
  
N° of virus particles 
N° of total cells 
N° of integrated particles 
genome 
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The MOI can be calculated prior to the infection, since it depends on the virus titer 
and on the number of cells to be infected. On the contrary, IN must be determined 
upon infection. 
To measure the IN, a calibration curve was generated by means of q-PCR using the 
Global UltraRapid Lentiviral Titer Kit containing six DNA samples with known 
integration numbers (INs) as it is here describred: 
The q-PCR was performed using two primers for each standard sample 1) the 
Upstream conserved region 1 (UCR1), a common region of the human genome, and 
2) the woodchuck hepatitis post-transcriptional regulatory element (WPRE), a 
specific region for the integrated viral cassette. 
UCR1 Forward: CAGGCTTTGCTGAGCAGTTT 
UCR1 Reverse: CCTCTCCCAGTCAGGGATTT 
WPRE Forward: TCCTTCTGCTACGTCCCTTC 
WPRE Reverse: GAGATCCGACTCGTCTGAGG 
 




where X is 2-[Ct (WPRE) – Ct (UCR1)] and can be calculated experimentally for any new 
condition, 0.3095 is the slope value and Y is the IN. We used this linear equation to 
determine the number of integration of any unknown sample infected at different 
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MOI. In particular low MOI (1-2) corresponded to IN=1 and higher MOI  (>3) 
corresponded to multiple number of integrations. To keep IN number equal to one, we 
used a low MOI in every experiments discussed throughout this text. 
Moreover we determined a correlation between the MOI and the GFP% upon 
infection, so that the IN could be easily deduced from the GFP content evaluated by 
FACS analysis. 






2.1.6 Library infection 
Human miRNAs lentiviral library was provided by System Bioscience. SUM 159 
cells (650000) were seeded in a 15 ∅ plate one day prior to infection. We infected at 
low multiplicity of infection (MOI = 2) with a viral titer of 7,2 x 108 (IFU/mL). At 
72h post transduction, infection efficiency was checked with fluorescence 
microscopy. GFP expressing cells were selected by flow cytometry using the Influx 
cell sorter (BD with a 488 nm laser). 
Sorting gates were maintained constant for all the experiments throughout this thesis: 
only cells with a bright GFP intensity (>102) were isolated. The gate for negative cells 
was selected according to the basal fluorescence of not infected cells. 
Selected cells (GFP+) were challenged in the 3D and 2D competition assays. The 
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2.1.7 In-vitro 3D-assay – Mammosphere assay 
SUM159 cells transduced with the lentiviral library (GFP+ cells) were cultured in 
non-adherent conditions using free serum MEMB (Lonza) basal medium 
supplemented with glutamine (1%), penicillin-streptomycin antibiotics (1%), insulin 
(5 ug/mL), hydrocortisone (0,5 ug/mL) and (eparine 1 U/mL) with fresh growing 
factors EGF (40 ng/mL), FGF (40 ng/mL) and B27 (Gibco, 2X). A total of 3 x 105 
GFP+ sorted cells were plated for the competition assay in non-adherent condition at 
2000 cells/mL final concentration  (15 ∅ cm plate) in stem medium + methylcellulose 
(ratio 1:1). 10 days after, mammospheres were nicely formed and dissociated (both 
enzymatically and mechanically using trypsin-EDTA diluted 1:10 in to PBS, 50mg/L 
trypsin final concentration). Single cells were then re-seed in non-adherent conditions 
for a new round of the assay. At each passage ≈ 3 x 105 cells were kept for gDNA 
extraction. This procedure was repeated for six passages, keeping GFP+ cells by 
FACS-sorting every two passages. Cells were cultured for a total of 6 passages (F1-
F6). 
In parallel the sphere forming efficiency was checked plating cells at 1000 cells/mL in 
a 12-well plus methylcellulose (2% w/v, Sigma Aldrich) in triplicates (diluted 1:1 
with stem medium with 2x of growth factors).  
Each generation of mammosphere, that expressed the miRNA along with a 
fluorescent reporter marker (GFP or RFP), was counted with an automated macro-
based system generated in house with Java and run on Fiji software (ImageJ). Briefly, 
we collected the images of each generation of all the12-well plate and the macro 
counted only the rounded (≥ 0.8) fluorescent spheres with a diameter > 70 µm.  
The sphere forming efficiency was calculated using the formula: 
%SFE = [n° of spheres/n° of plated cells] X100) 
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All the data (as number of spheres, diameter in micron, circularity and mean 
dimension area) were collected in an excel file for further analysis.  
 
2.1.8 In-vitro 2D-assay – Proliferation assay 
SUM159 cells transduced with the lentiviral library (P0 = 90000 GFP+ cells) were 
cultured onto 2D adherent condition as growing in cell culture plates (at least 250k 
cells). Cells were regularly split every two days in growing condition. Each week, 
GFP+ cells were selected by sorting to avoid transgene silencing and keeping ≈ 3 x 
105 cells for gDNA isolation. Cells were cultured for a total of 6 weeks (P1-P6). 
 
2.1.9 Validation Step 
SUM159 were individually infected using 10 microRNA candidates (miR-1, miR-
124, miR-889, miR-664, miR-657, miR-125a, miR-144, miR-204, miR-379 and miR-
153-3 plus a scramble vector as control). All lentiviral vectors were purchased by 
System Biosciences.  
At first, 293T cells were transfected using 20000 ng of lentiviral DNA vector per 
plate with the protocol previous reported (see section “lentiviral infections”) to 
produce lentiviruses expressing each specific microRNA. Viruses were concentrated 
at 100X final concentration. Finally, SUM159 were infected at high MOI using 30 uL 
or 70 uL of concentrated virus and monitored for their viability. Cells infected with 30 
uL of virus were vital and their GFP expression was evaluated by FACS sorting 48h 
post infection. Cells expressed high levels of GFP (>75%) and were all sorted to 
generate the first round of mammospheres in 15 ∅ cm plate for propagation (2000 
cells/mL final concentration, for a total of 200k cells for each condition) and at 1000 
cells/mL in a 12-well to evaluate SFE%. After 10 days cells were dissociated to single 
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cells and plated for the second round of mammospheres (F2). Cells were not sorted, 
but GFP expression was evaluated by FACS analysis. Dissociation was performed 
again after 10 days and cells were sorted to avoid clone counterselection and plated 
for the last round of mammosphere (F3). SFE% was calculated as previously 
indicated (see section “in-vitro 3D assay”) soon after the sorting procedure (F1 and 
F3). 
 
2.1.10 Oligo-mimic transfection 
SUM159 cells were plated in 60 mm dishes and transfected according to fast-forward 
protocol with miRNA Mimic (for hsa-miR-124-3p OE we used the mimic 
MSY0000422, for hsa-miR-657 OE we used the mimic MSY0003335 and for control 
the all star negative control siRNA SI03650318; Qiagen, stock concentration: 20 µM) 
at a final concentration of 50 nM. The transfection mix was prepared using Hiperfect 
transfection reagent (Qiagen) as following:   
MIX 1X (60 mm dish) 
N. cells plated 450.000 
Volume  3 ml 
miRNA Mimic 20 µM 7. 5 µl 
HiPerfect 20 µl 
Optimem       Up to 100 µl 
 
Mix was incubated for 5-10 minutes at room temperature to allow the formation of 
transfection complexes, and then added drop-wise on cells. Cells were collected at 16 
and 24 hours post transfection for gene expression analysis. 
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2.1.11 In-vivo experiments and animal manipulation 
The sample material to be injected (SUM159 cells) was collected into sterile 
Eppendorf tubes and gently pelleted in microfuge. Cell pellets (50k cells) were 
resuspended in a mix composed of: 14 µl of PBS and 6µl of Matrigel® (injection 
volume = 20 µl). Immunocompromised female mice (NOD scid gamma) of 6-7 weeks 
old were anaesthetized by intraperitoneal injections of 2.5% Avertin in PBS (stock 
solution Avertin: 10 g of tribromoethanol, Sigma, in 10 ml of tertamyl alcohol, 
Sigma) and were injected intra-nipple.  
Animals injected with tumorigenic cells were euthanized after 4/6 weeks (depending 
on tumor latency), when the tumors were approximately 0.5-1 cm in the largest 
diameter, in compliance with regulation for use of vertebrate animal in research.  
 
2.2  Molecular biology technique 
 
2.2.1 gDNA extraction and transgene selection by PCR  
Starting from ≈ 3 x 105 cells, gDNA was extracted using the “ Puregene Core Kit B” 
provided by Qiagen according to manufacturer’s protocol. The DNA quality and 
quantity was assessed by spectrophotometry using a Nanodrop 2000 (Thermo 
Scientific). The gDNA was used to select and amplify transgenes (precursor 
miRNAs) by PCR (Hot Star Taq PCR - Qiagen) using two primers specific for the 
viral transgene and common for all the precursor clones.  
 LVL Forward: GCCTGGAGACGCCATCCACGCTG 
 LVL Reverse: GATGTGCGCTCTGCCCACTGAC 
Here is reported the PCR conditions for a 50 µL reaction: 200ng of gDNA, 0,25 µL 
enzyme, dNTPs 10 mM 1µL, primers 2uM 5 uL, buffer 10X 5 µL, H20. PCR was 
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performed using the following thermo profile: 5I 95°, 30II 94°, 1I 67°, 1I 72°, 10I 72°, 30 
cycles. 
PCR products were run in a 2% agarose gel, extracted and purified (NucleoSpin Gel 
and PCR Clean-up, Macherey-Nagel). The PCR amplicon size was ≈ 500 to 700 bp. 
and used to prepare a library for high-throughput sequencing by NGS. 
 
2.2.2 Clones deconvolution – Next generation sequencing gDNA  
PCR products were used to prepare standard libraries for DNA sequencing. 
Amplicons were shared by sonication and adapters were added to the fragmented 
sequences. Tagged PCR products were then sequenced at 50 base pair, single-read 
mode with the HiSeq 2000 (Illumina). Sequencing was performed by the Genomic 
Unit at the Center for Genomic Science of IIT@SEMM. 
Raw reads were mapped on the human genome hg19 and, then, aligned over the 
reference genome consisting of all the miRNA precursor clones. For each condition, 
the number of matching reads were normalized over the total reads number per 
million (RPM) and imported into an excel worksheet for further analysis.  
RPM = (number of reads miR-(X) /number of total reads) X 1*10^6 
Since reads consisted of some repeated microRNA within clusters, we filtered 
according to redundant sequences in order not to introduce biases by counting the 
same microRNA twice.  
We, first, analyzed the distribution of the clone of the initial population (F0) before 
the competition assay. Thus, we could select the clones that were represented in the 
initial population by more than 100 independent cells/CSCs (Coverage>100). This 
parameter depends on the number of transduced cells and the number of different 
constructs in the library and is also influenced by the phenotype of interest, since it 
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depends on the percentage of cells capable of displaying a phenotypic response. 
 
A coverage mean value was calculated with the following formula: 
 
where SFE = [n° of spheres/n° of plated cells] and is considered only in the 3D 
experiments.  
Than, the specific coverage value of each construct was calculated: 
C (miR-X) = ϖ * miR-ratio 
where, 
miR-ratio = Numb. of reads miR-X (RPM) ⁄ Average numb. of reads all detected 
microRNAs (RPM) 
Next, we evaluated if microRNA precursor clones were increased or depleted over 
passage as consequence of the phenotype competition. We calculated a ratio score 
comparing the RPM (expressed in log2) of the late passage (F6 in the 3D assay; P8 in 
the 2D assay) against the original population (F0) for each of the microRNA 
constructs.  
3D score = log2 (RPMF6/ RPMF0) 
2D score = log2 (RPMP6/ RPMP0) 
We measured the 3D scores for both the biological replica experiments and generated 
the 3D bubble plot. Similarly, the 2D scores of the biological replica experiments 
were used to create the 2D bubble plot. A 3D vs. 2D bubble plot was finally generated 
by plotting the 3D scores (average of the two experiments) in the y-axis against the 
2D scores in the x-axis (average of the two experiments) to select for microRNA 
modifiers. 
ϖ = Coverage mean 
N. of detected miRNAs  
Total sorted cells at P0 (* SFE)  = 
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2.2.3 Total RNA extraction  
Cells were washed with PBS 1X and then TRIzol® reagent (Invitrogen) was added 
(for less than 1*106 cells add 500 µl, otherwise 1 ml of TRIzol). 
The homogenized sample was incubated for 5’ at RT, then was added 0,2 ml of 
chloroform per 1 ml of TRIzol reagent. Shake tubes for 15’’ and incubate sample for 
2-3’ at RT then centrifuge samples at 11.800 x g for 15’ at 4° C. 
Collect aqueous phase and transfer it in a clean tube, then add 1.5 volumes of pure 
ethanol and mix. Supernatant was transferred into miRNeasy Mini columns and total 
RNAs was purified according to manufacturers ‘instructions. 
Accurate total RNA concentration was measured with a NanoDrop spectrophotometer 
at at λ= 260 nm. 260/280 ratios were above 2 for all samples used in this study. 
 
2.2.4 Reverse transcription 
We used miScript II reverse transcription kit (Qiagen) that allows to reverse 
transcribe miRNAs and mRNAs in a single step process. The kit comprises a poly (A) 
polymerase, which adds a poly (A) tail to miRNAs, a reverse transcriptase that 
converts RNA in cDNA, and a buffer that contains Mg2+, dNTPs, oligo-dT primers 
and random primers. The reverse transcription mix was prepared as following: 
miScript Hispec buffer 5X 4 µl 
miScript Nucleics mix 10X 2 µl 
Template RNA 250-1000 ng 
RNasin® Ribonuclease Inhibitor 0,5 µl 
miSript Reverse Transcriptase Mix 2 µl 
RNase-free water Up to 20 µl 
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Sample was incubated for 60’ at 37° C, then 5’ at 95 ° C to inactivate miScript reverse 
transcriptase mix, cDNA was diluted at a final concentration of 1 ng/µl for the 
following Real-Time PCR. 
The kit Superscript VILO (QIAGEN) was used to reverse transcribe mRNA. The mix 
was prepared as following: 
 
Enzyme mix 10X 4 µl 
Vilo reaction mix 5X 2 µl 
Template RNA 500 ng 
RNase-free water Up to 20 uL 
 
Sample was incubated for 60’ at 42° C, then 5’ at 85 ° C. cDNA was diluted at a final 
concentration of 1 ng/µl for Real-Time PCR. 
 
 
2.2.5 Quantitave RT-qPCR  
After the RT, for microRNA expression we routinely used Qiagen miScript Sybr 
Green PCR kit. We prepared a qPCR reaction master mix as indicated in the scheme 
(a 10% excess was always added to consider pipetting errors; all reaction were 
performed in duplicate or triplicate): 
 
Reagent Volume/ reaction 
2x miScript SYBR Green PCR 
master mix 
10 µl 
10x miscript Universal Primer 2 µl 
10x miscript Primer assay 2 µl 
Template cDNA 5 ng 
RNase-free water Up to 20 µl 
 
qPCR detection of mature microRNAs was assayed with the following assays 
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(Qiagen):  miR-124 (MS00006622) miR-657 (MS00010479), as controls we used 
SNORD61 (MS00033705) or SNORD72 (MS00033719). 
For mRNA expression, we used the QuantiFast SYBR Green PCR (Qiagen)  
Reagent Volume/ reaction 
2x quantifast SYBR Green PCR 
master mix 
7,5 µl 
10uM primer (F+R)  1,5 µl 
Template cDNA 5 ng 
RNase-free water Up to 10 uL 
 
qPCR detection of mature microRNAs was assayed with the following home-
designed primers: 
Primer sequences miR-124 targets 
ATGCTCTGTGGCCTTTCTTG FZD4 Forward 
TCTGAAAGTCCCCCAGATTG FZD4 Reverse 
ACGAATTTGGTCAGGCTCTC CLDN1 Forward 
AGGTTTTGGATAGGGCCTTG CLDN1 Reverse 
ATGGTTGGGAGGGAAAAGAC SOS1 Forward 
TCATGTTTGGCTCCTACACG SOS1 Reverse 
TTCTCCAGAAGGTGGTTTCG ITGB1 Forward 
ACATTCCTCCAGCCAATCAG ITGB1 Reverse 
TGCAGAAGACCTTGTGCTTG LAMC1 Forward 
TGGATAGGAATTGCCCTGAG LAMC1 Reverse 
AGGGGTGAATGGCTCTTTTC VAMP3 Forward 
GTTTCTGCTTCCAGCATTCC VAMP3 Reverse 
AGCAACCAAAGTGGGACTTC RAB27A Forward 
TCCCTGACCCTTCAATCAAC RAB27A Reverse 
TCCAGCTTTCCACACAGTTG RHOG Forward 
ATTCTGTGGCTCCCTCATTG RHOG Reverse 
CCCACACGGGACATGTGAAT MAGT1 Forward 
TCCATGTCAGAGGTAGCAGC MAGT1 Reverse 
 
Primer sequences miR-657 targets 
AGGCTTCCAGGGAGAAAAAG COL13A1 Forward 
TGGAACTCCAATTGGTCCTG COL13A1 Reverse 
TGATTTGGCCAGGCTCTATG CDKN2C Forward 
CCTCCCCACGTTTATTGAAG CDKN2C Reverse 
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TGGACCCACAGAATTCCTTC PDCD1LG2 Forward 
TCCACACACCTCTGCTTTTG PDCD1LG2 Reverse 
GGTTGTTTTGCTACCTGCCG TSPAN6 Forward 
CGGTGACACCACAACAATGC TSPAN6 Reverse 
GCGATTTCAAACCTGGAGAC PSIP1 Forward 
TGGCTTTACAGCTCCATCAG PSIP1 Reverse 
TGTGTGGAAGAGCTGAATGC EIF4G3 Forward 
GTAATTGGCCCATGTGATCC EIF4G3 Reverse 
CAAAAGCCTGGGTGAGAATC SHC1 Forward 
ATCAGGTTGGCACAGGAAAG SHC1 Reverse 
CTGCAACTCGGGGACATACA CD83 Forward  
TGTAGCCGTGCAAAACAAGTG CD83 Reverse  
TGTAGCTCCGAGAGGCATGA CDH8 Forward 
CAGCTCTGCCACGTGTCTAT CDH8 Reverse  
GAAGCTGTCTCTGATCCGCA CCND2 Forward  
TGCTCCCACACTTCCAGTTG CCND2 Reverse  
GGAACTCACCCAACACCTCG KCNMA1 Forward  
AGGTCCCAGATACGGCATCC KCNMA1 Reverse  
GAGTCAGAGGGGTGACCAGA FRMD6 Forward  
GGCAATTCCTCAGGTTCCCA FRMD6 Reverse  
GCGCTTGAAGAGGCTCAGAA VPS53 Forward 
CCGTATTGTCTTCGCCTGGT VPS53 Reverse 
 
For normalization, we used the housekeeping genes GAPDH (QT00079247) provided 
by Qiagen. 
 
2.2.6 RNA-SEQ  
RNA extracted from cells transfected with miR-124 and miR-657 at 24h was used to 
create libraries for RNA-sequencing. According to the manufacture’s manual, 
libraries were prepared with the use of  “TruSeq RNA Sample Preparation LS (low 
sample)” protocol provided by Illumina.  
Biefly, poly-A containing mRNAs molecules were purified using poly-T magnetic 
beads and fragmented. After cDNA synthesis, adpaters were ligated and fragments 
were amplified by PCR. A quality control analysis on the library was performed with 
the use of Bioanalyzer instrument. Finally libraries were run  (3X plexity, 9 samples 
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in total) and sequenced at 50bp length and single read mode with a depth of 80 
million reads.  
Reads were analyzed by Benedetta Cerruti using an in-house pipeline, available in our 
campus IFOM-IEO The latter operates by i) filtering reads on the base of their quality 
ii) removing adapters and duplicate reads due to PCR amplification iii) aligning reads 
on the human reference genome. 
At the end of the procedure, final data consisted in about 30 millions aligned reads for 
sample.  Reads were mapped on the reference genome, which included 23368 genes, 
and normalized in FPKM  (fragment per kilobase of exon per million reads mapped) 
in order to measure homogeneously all the genes within the libraries.  
 
FPKM = numbers of reads ⁄ (genes dimension (kilobase)* number of total reads) 
*10^9 
Genes with FPKM >2 were selected to get rid of the low expressed ones and 
eliminate genes not distinguishable from technical noise; FPKM > 2 = 10950 genes. 
We obtained a total of 10950 expressed transcripts that were further analyzed. 
 
2.2.7 mRNA gene expression and data analysis  
We analyzed the mRNA gene expression of SUM159 OE miR-124, SUM159 OE 
miR-657 and SUM159 control SCR. 
Principal Component Analysis was used to evaluate the variability among the 
different samples and performed on the 10950 gene list (with FPKM > 2) using 
JMP® software (SAS). 
Seed enrichment analysis was performed by Sylarray software 
(http://www.ebi.ac.uk/enright-srv/sylarray/). All the ≈10000 genes were ordered from 
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the most down-regulated to the most up-regulated upon overexpression of miR-124 
OR Mir-657 in SUM159 cells. This list was uploaded in Sylarray (Bartonicek and 
Enright, 2010) to compute word enrichment. The analysis was performed searching 
7mers sequences within the 3’ UTR, which usually contains the MREs. For SUM159 
OE mir-124 dataset, the highest enrichment was observed in 3’ UTR sequences within 
the “down-regulated” genes, and the most represented words (7mers) exactly matched 
with the canonical seed of the overexpressed miR-124. For SUM159 OE mir-657 
dataset, the highest enrichment was observed in 3’ UTR sequences within the “down-
regulated” genes, and the most represented words (7mers) exactly matched with the 
canonical seed of the overexpressed miR-657. 
We identified miRNA-regulated transcripts by comparing the expression regulation 
between groups (SCR vs. 124 and SCR vs. 657) with a statistical tool (DeSEQ2, 
(Anders and Huber, 2010)). We selected only genes that showed either up-regulation 
or down-regulation greater than |0.2| log2fold change with a false discovery rate 
(FDR) < 0.01. We identified a list of 769 genes regulated upon miR-124 
overexpression (455 down-regulated genes and 314 up-regulated genes) and a set of 
182 genes (130 down-regulated genes, 52 up-regulated genes) regulated upon miR-
657 overexpression. 
Ingenuity system pathway analysis was performed using IPA software (Qiagen).  The 
769 genes list of miR-124 OE regulated genes was analyzed running a core analysis, 
and we selected all the upstream regulators with a z-score > |2| and with a  
p-value> 10-3.  
Gene Set Enrichment Analysis (GSEA, http://www.broadinstitute.org/gsea/index.jsp) 
was performed using the ≈10000 original gene list of miR-124 OE regulated genes. 
As gene set to calculate the normalized enrichment scores (NES), we used four stem 
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cells signatures    (Polyak, Stingl, Pece and Visvader) subdivided in STEM UP genes 
and STEM DOWN genes. P-values were calculated by performing 1,000 random 
permutations of genes labels to create ES null distribution. 
The lists of miR-124 and miR-657 putative targets were downloaded from Targetscan 
Human database (release 6.2, http://www.targetscan.org) and from MiRanda database 
(http://www.microrna.org/microrna/home.do, release Agust 2010). 
 
2.2.8 Clustering analysis 
Heat map was generated by Java TreeView software for Mac OS X. Statistical 
analyses were performed within the statistical software JMP9. Significance of the 
differences was calculated using Welch’s t test. Categorical data were analyzed with a 
contingency analysis within JMP (SAS). P-values were calculated with a Fisher’s 
exact test. 




3.1 General strategy for whole-genome phenotype screening 
The aim of the present study was to identify miRNA “modifiers” of mammary stem 
cell self-renewal by performing an unbiased genetic screening. A miRNA lentiviral 
library expressing the most comprehensive set of human miRNAs was used for this 
purpose. The library, Lenti-miR virus precursor library (System Biosciences), consists 
of a pool of 632 lentiviral human miRNA constructs (representative of approx. 80% 
of the breast miRNome) expressed in their native genomic context (pre-miRNA). This 
latter point is important as it preserves putative miRNA hairpin structures involved in 
biologically relevant interactions with the endogenous processing machinery and with 
regulatory partners. Each library construct is able to induce stable expression of a 
single miRNA upon lentiviral infection. Moreover, the constructs contain a human 
EF1α promoter that drives the expression of a GFP reporter transgene, which acts as 
fluorescent marker and helps in isolating miRNA expressing clones, as GFP-positive 
cells, by flow cytometry (Figure 9). 
 
Figure 9 - Map of the HIV-based lentiviral plasmid expressing miRNA precursors from the 
System Biosciences (SBI) collection. The plasmid map shows the elements in the lentiviral vector 
pMIRNA1 that are required for different functions, including propagation in mammalian cells (SV40 
Origin), selection (ampicillin resistance gene for selection in E.Coli), packaging and stable integration 
  Results 
 
 59 
(cPPT,  GAG, LTRs). In particular, the CMV promoter guarantees high level of expression of the 
integrated miRNAs, while expression of the fluorescent reporter, copGFP, is driven by the Human 
EF1α promoter (image from www.systembio.com). 
Our experimental plan consisted of expressing the miRNA lentiviral library in 
mammary epithelial cells (SUM 159 PT) that are able to self-renew in vitro (see Figure 
10). 
Upon infection, cells transduced with miRNAs were selected as GFP-positive (GFP+) 
cells by fluorescence-activated cell sorting (FACS), and then challenged to the self-
renewal phenotype by performing a 3D in vitro mammosphere assay. Through the 
serial propagation of mammosphere cultures, we selected for or against miRNAs that 
positively or negatively affect the self-renewal capability of mammary stem cells, 
respectively. In parallel, the same initial transduced cell population was subjected to a 
2D proliferation assay, in order to identify miRNAs that could also affect the 
proliferation of mammary epithelial cells over several passages. 
To identify miRNAs that were positively or negatively selected during serial 
propagation of mammosphere or 2D-proliferation cultures, genomic DNA (gDNA) 
was extracted from a small amount of GFP+ cells at each passage and integrated viral 
regions were amplified by PCR. The PCR products were then analyzed by DNA 
sequencing (Figure 10). Using this approach, it was possible to determine the frequency 
of each miRNA transgene in the total cell population, at each passage. Positively or 
negatively selected miRNAs were then identified by comparing the frequency of 
miRNAs in transduced cells (GFP+) at the baseline (P0, after transduction) and at 
different passages (Pn). These positively or negatively selected miRNAs represent 
candidate “modifier” miRNAs of the biological phenotypes being examined (i.e., 
stem cell self-renewal and survival/proliferation). 





Figure 10 – Schematic diagram of experimental design. The figure summarizes the strategy used for 
the identification of miRNA modifiers of mammary stem cell self-renewal by phenotype competition 
screening. Mammary epithelial cells were transduced with miRNA-expressing viruses and replated for 
serial propagation of mammospheres. By isolating and sequencing the integrons, we physically counted 
how many times each miRNA was present in the initial mammosphere culture (passage 0, P0) and in 
successive passages (Pn). This enabled us to determine whether a particular miRNA was positively or 
negatively selected during the assay and, thus, represent a candidate modifier of self-renewal. 
 
3.2 Competition assay 
The approach used for selection of candidate miRNA “modifiers” of mammary stem 
cell self-renewal is based on a competition assay, in which different cell populations, 
each expressing a specific pre-miRNA, compete for a selected phenotype. In other 
words, each cell population is influenced by the miRNA that has been transduced, so 
that its ability to display the selected phenotype (i.e. self-renewal or 
survival/proliferation) is altered. In principle, there are three ways in which the 
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transduced miRNAs could affect the phenotype (summarized in Figure 11): 1) the 
miRNA could enhance the phenotype and, thus, the cells expressing that miRNA will 
be positively selected during the assay (positive effect, red line); 2) the miRNA could 
have little or no effect on the phenotype and, thus, cells expressing this type of 
miRNA will not be selected for or against during the assay (neutral effect, green line); 
3) the miRNA could inhibit the phenotype; in this case the cells expressing this 
miRNA will be negatively selected or even lost over successive passages (negative 
effect, blue line). 
 
 
Figure 11 - Candidate selection.  Diverse cell populations are generated upon miRNA library 
infection of the parental mammary epithelial cell culture. Each population expresses a miRNA that 
could influence the selected phenotype in different ways. We assumed that the vast majority of 
miRNAs would not influence, or only slightly influence, the phenotype (green line “b”), thus, this 
population will be neutral during the competition assay. Conversely, miRNAs able to enhance or 
inhibit the phenotype will be positively (red line “a”) or negatively (blue line “c”) selected over 
successive passages. In the case of the stem cell self-renewal phenotype, positively and negatively 
selected miRNAs might represent candidate oncogenic and tumor-suppressor miRNAs, respectively. 
An enhancement or reduction in an individual miRNA representation would indicate a 
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selective advantage or disadvantage during the screening process. Thus, under 
selective pressure, resistant cells increase in the population and sensitized cells 
decrease. In our screening strategy, the selective pressure in the 3D mammosphere 
assay was represented by the ability of cells to survive in anchorage-independent 
conditions, so that only cells that have such ability, that is to say the stem cell 
population, could survive and generate spheres. Nevertheless, some confounding 
factors still exist and could impact on the screening influencing final results.  
For instance, since we are using viral vectors to express miRNA precursors, which are 
integrated into the genome, there is the possibility that functional outcomes are 
associated with insertional mutagenesis events (activation of proto-oncogenes or 
silencing of a tumor suppressor) rather than the expression of the miRNA precursors. 
Therefore, we worked at low integration number, thus preventing multiple integration 
events, and considered only those miRNA precursors with high coverage, which are 
represented by multiple independent insertions. Under these conditions, we could 
associate a precise role to a specific microRNA avoiding data misinterpretation. 
Keeping low the integration number has also other advantages. For instance, if two or 
more miRNAs are integrated within a single cell, synergistic effects could take place, 
so that the observed phenotype depends on the combination of different miRNA 
molecules rather than a single one. All together these effects would lead to the 
impossibility to recognize i) miRNAs that do have an effect from those that are 
ineffective ii) miRNAs that act together, possibly amplifying the effect. 
Besides, we reasoned that keeping high the coverage decreases the possibility to score 
false negative results, which typically occurs for transgenes that are a miRNA poorly 
represented in the initial population (P0). In a preliminary setting performed using in-
vivo serial transplantation of tumor as cancer stem cell assay, we noticed that the 
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selection process was so fast that even at the first passage (formation of tumors after 
first round of injection) just few clones were found, while the vast majority was lost. 
However, the experiment was not reproduced when repeated, suggesting that the 
functional outcome was not dependent on the transgene but on the specific clones that 
were able to grow in the recipient mice. Likely with a very high number of 
independent experiments (injections), the sensitivity and specificity of the in-vivo 
condition could be enough to obtain reliable results. However, it would have required 
a number of initial cells and recipient mice so high to make the whole experiment 
unfeasible (too much expensive, too much cumbersome). Therefore, we decided to 
focus on the mammosphere assay for screening and use the in-vivo transplantation 
assay only for validation purposes. 
However, keeping high the coverage has some drawbacks. Indeed, we discarded 
miRNA constructs that are toxic or not tolerated, including those which strongly 
affect cell proliferation or induce apoptosis. Indeed, in few days (3 days) necessary 
for infecting and stabilizing the initial population (P0), these miRNAs are already 
depleted and thus are not included in the competition screening. Besides, we 
discarded those constructs that had an insufficient number of virus particles within the 
library and could not be efficiently transduced. This event reflects the possible not-
homogenous library production, so that some virus particles could be more 
represented than others. 
Moreover, we aimed to control microRNAs representation also during the whole 
screening. Indeed, a decrease in library complexity, resulting in a reduction of 
miRNA clones, could be due to the loss of GFP. To overcome this bias, we 
introduced a sorting step throughout the screening to minimize loss of clones. With 
this approach, we selected only GFP+ expressing miRNA cells that could compete in 
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the assay and could be able to affect the self-renewal of the mammosphere (3D 
screening) or influence cancer cell proliferation (2D screening). 
Finally, we also aimed to distinguish between proliferation effects and self-renewal 
ones. Since our main aim was to identify miRNAs that specifically regulate self-
renewal, we had to monitor those that simply interfere with proliferation.  
Considering that the self-renewal mechanism is the way through stem cell proliferates 
and thus, the mammosphere contains both the stem cell and the early progenitors, 
which constitute the bulk of the sphere, we expect that if a microRNA impacts only 
on cell proliferation the sphere size should be reduced compared to the average sphere 
size of the specific cell line.  
Based on this statement, we measured the sphere dimensions for our best candidates, 
so that if i) the miRNA candidate negatively acts only on the self-renewal the sphere 
forming efficiency should be reduced compared to the control, but the sphere size 
should remain equal; ii) the miRNA candidate acts on self-renewal and on the 
proliferation of progenitors within the sphere, we should observe both a decrease in 
sphere size as well as in the sphere number; iii) the miRNA candidate affects only the 
proliferation, we expect the same sphere forming efficiency but smaller spheres. 
Obviously, when performing the whole screening, it is impossible for us to 
discriminate between the two phenotypes: in this case, the gDNA will contain both 
smaller and larger spheres as well as all cells that are not stem cells and thus are not 
resistant to anoikis. Indeed, to better evaluate whether the microRNA is influencing 
specifically self-renewal rather than proliferation, we performed a validation step on 
our top hit candidates. All microRNA candidates were individually tested in the 
mammosphere assay and for each of them, we calculated the sphere forming 
efficiency as well as the sphere dimension of the validated clones. 
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3.3 Set-up of experimental conditions for the whole-genome 
phenotype screening 
To perform the whole-genome phenotype screening, we first had to develop and 
optimize the different steps of the competition assay, from the lentiviral infection to 
the DNA sequencing. A detailed description of all the steps followed to carry out the 
screening is reported here. 
 
3.3.1 Lentiviral infection and competition assay 
When setting up the conditions for the lentiviral infection, we aimed to have a 
transduction efficiency that would yield approximately one viral integration per cell. 
This was desirable in order to avoid multiple integrations per genome, which would 
increase the likelihood of random insertion of transgenes into critical genomic regions 
that could alter per se the phenotype under selection (such as, by insertion into a 
tumor suppressor gene). Furthermore, having multiple miRNAs within each 
population would increase the noise in the system, making it more difficult to 
associate a precise effect to a specific miRNA.  
We set-up a quantitative method to count the number of viral cassettes integrated into 
the genome by means of q-PCR analysis of two genomic regions: i) the Upstream 
Conserved Region 1 (UCR1) that is a common region of the human genome; ii) the 
woodchuck hepatitis post-transcriptional regulatory element (WPRE), a region that is 
specific for the integrated viral cassette (see Figure 9). Both regions were amplified by 
q-PCR using the same gDNA as template. To obtain an absolute quantitative 
measurement, we built a calibration curve using DNA samples with known numbers 
of integration sites (see “Materials and Methods”, Section 2.1.4 for details). We also 
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derived a formula to measure the number of integrations [i.e., the integration number 
(IN)] in each experiment, based on the fact that IN is proportional to 2-[Ct (WPRE) – Ct 
(UCR1)]. Following this approach, we measured the number of integration events 
following infection of the normal breast epithelial cell line MCFF10A with the PCDH 
lentiviral construct at different multiplicities of infection (MOI; Figure 12A). 
Specifically, at a MOI of 1 (low) we observed approximately one integration per 
genome (Figure 12A, blue diamond), while at a MOI of 5 (high) we observed 5 
integration per genome (Figure 12A, red diamond). 
We, then, verified that we could observe biological effects induced by the transduced 
miRNAs even when the IN was low. We infected normal human breast epithelial 
MCF10A cells with a miRNA, miR-34a, which is known to have an anti-proliferative 
effect on these cells, using MOI 1 and MOI 5, corresponding to IN=1 and IN = 5 
respectively. We, then, checked if miR-34a still induced growth arrest in 2D adherent 
conditions at low IN as compared to the control vector (PCDH) and to high IN 
conditions by means of a colony assay. Results show that colonies expressing miR-
34a both at high and low IN were smaller in size and reduced in number compared to 
the negative control, indicating that even with a low number of integrations (1), 
miRNA phenotypes are maintained (Figure 12B). 
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Figure 12 – Set-up of the experimental conditions for the lentiviral infection.  A) Calibration curve 
for the determination of the number of transgene integrations. The calibration curve was constructed by 
performing a qPCR analysis [using specific PCR primers designed for a common human 
ultraconserved region (UCR1) and for a lentiviral-specific integrated region (WPRE)] of different 
gDNA samples with known INs (standard samples, grey diamonds). Since the integration number (IN) 
is linearly correlated to q-PCR results [2^(-ΔCt), where ΔCt = Ct (WPRE) – Ct (UCR1)], we obtained 
a linear equation by which it is possible to measure the IN at different multiplicity of infections 
(MOIs). We next infected MCF10A cells with the PCDH lentiviral construct at high (5) and low (1) 
MOI (red and blue diamonds, respectively) and determined the IN using the standard curve. B) The 
effect of a known anti-proliferative miRNA (miR-34a) on normal human breast epithelial MCF10A 
cells was evaluated in the colony forming assay at different MOIs, 5 and 1, equivalent to an IN of 5 and 
1, respectively. The PCDH control vector (Crtl) was used as a negative control. 5000 transduced 
MCF10A cells were plated in 2D adherent conditions onto three different cell culture dishes and 
incubated for 10 days before visualizing colonies.    
 
Finally, we investigated whether we could decipher the effect of multiple miRNAs, 
infected at the same time, on a particular biological phenotype by analyzing the 
gDNA of the total cell population. For this purpose, we infected MCF10A cells with a 
“mini-pool” of four different miRNAs, namely miR-191, miR-34a, miR-483 and 
miR-200c, together with the control construct PCDH, and tested the ability of the 
miRNAs to regulate cell proliferation. Each construct had previously been assessed 
for their individual effects on MCF10A cell proliferation in the colony-forming assay 
in 2D adherent conditions; only miR-191 and miR-34a were shown to have an anti-
proliferative effect (Figure 13A). In the “mini-pool” experiment, cells were initially 
infected with different amounts of the viral pool to select the condition corresponding 
to approx. one integration per genome. Infected cells were then grown for up to 4 
passages. gDNA was collected at each passage for qPCR analysis to evaluate how 
each miRNA-expressing cassette varied over successive passages, using primers 
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specific for each of the miRNA constructs. We observed that the viral cassettes 
expressing miR-34a and miR-191 were promptly depleted over consecutive passages, 
while the other miRNAs were maintained (Figure 13B), in agreement with the results 
from the individual colony forming assays. Therefore, we concluded that, albeit in a 
preliminary setting with a limited number of miRNAs, the competition assay is 
feasible and that the genomic analysis is sensitive, since it allows us to score also 




Figure 13 – Evaluation of the feasibility of the competition assay in the mini-pool experiment. A) 
The colony forming assay was performed on MCF10A cells separately infected with the indicated 
miRNAs and the control vector (Crtl PCDH) to evaluate their ability to inhibit proliferation. miR-34a 
and miR-191 (displayed in orange) showed an anti-proliferative effect on MCF10A cells, producing no 
or small colonies. B) The same miRNAs were used in a pooled experiment (mini-pool), mixing the 
different viruses together and infecting MCF10A cells at a low MOI. (IN=1).  Cells were then sorted 
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for GFP expression and grown in 2D for 4 passages. At each passage, transduced cells were collected 
and gDNA was extracted and subjected to qPCR to measure how the different miRNAs were 
maintained in the cell population over time. The results are expressed as the enrichment of each 
miRNA in the population relative to P0 (as log2fold-change). The mean ± ssdev of thee technical 
replicas are shown. 
 
3.3.2 Evaluation of the advantages and disadvantages of selecting GFP+ cells 
throughout the competition assay 
 
 We were aware of the fact that using a low MOI to prevent multiple integrations has 
the drawback that most cells of the initial population do not express any miRNA 
precursor. Furthermore, the transgene could lose expression during the assay due to 
an unfavorable integration event or heterochromatin formation induced by viral 
regions. Indeed, even few cells that fail to express the transgene will outcompete 
those in which expression is effective, thus altering the sensitivity of the assay. We 
reasoned that for the accomplishment of the phenotype competition screening, we 
should keep to a minimum the number of cells that do not express or that silence the 
transgene. To this aim, we could exploit the presence of the GFP marker within each 
miRNA construct, and preserve transduced cells that express the transgene by means 
of FACS-sorting. However, adding another step to the screening protocol would 
increase the complexity of the assay, and FACS-sorting could negatively influence 
the recovery and viability of cells at each passage. We, therefore, wanted to verify 
whether the selection of GFP+ cells at each passage increases the sensitivity of the 
competition assay. 
To this end, we performed another “mini-pool” experiment, which mimics the 
competition of different miRNA-expressing cell populations, using a pool of seven 
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viral constructs expressing miR-34a, miR-200c, miR-96, miR-146a, miR-342, miR-24 
and let-7. MCF10A cells were infected with the mini-pool at a low MOI (IN = 1) and 
transduced cells were selected on the basis of GFP expression to generate the starting 
population (P0). The P0 populations were then divided into two groups and cultured 
in parallel in 2D using two different procedures: i) one group of cells was FACS-
sorted for GFP expression at each passage, ii) the other group was simply replated 
without sorting. We extracted the gDNA from each of the samples (sorted and non-
sorted) at every passage and evaluated the enrichment of miRNAs by qPCR analysis. 
This analysis revealed that the depletion of the anti-proliferative miRNAs, miR-34a 
and miR-96, was more evident in samples that were sorted for GFP expression at each 
passage compared to the non-sorted samples (Figure 14). Consequently, we decided to 
include FACS-sorting of GFP+ cells in our competition screening protocol to increase 
the sensitivity of the assay. However, considering the requirements to perform the 
mammosphere assay, we decided to sort cells positive for GFP every two passages to 





Figure 14 - Comparison of sorting vs. non-sorting procedure in the competition assay. A mini-
pool of seven miRNAs (34a, -200c, -96, -146a, -342, -24 and -let-7) was used to infect MCFA10A 
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cells at low MOI. Upon infection, GFP+ cells were selected by FACS-sorting, subdivided into two 
groups and cultured in 2D; in one group, cells were sorted for GFP expression at every passage (up to 
three, x-axis), in the other group, cells were not sorted. Q-PCR analysis was performed on extracted 
gDNA using specific primers for each of the miRNAs and fold-change of miRNA enrichment relative 
to the P0 population was calculated. 
 
 
3.3.3 Deconvolution of miRNA integrons by deep sequencing 
 
 
When using the entire miRNA library (approx. 650 clones) in the competition assay, 
it was not feasible to perform qPCR analysis on gDNA to measure all the miRNA 
integrons in the cell population at each passage. Instead, we decided to exploit high-
throughput DNA sequencing that allows the identification of miRNA integrons in 
gDNA directly by sequencing. This approach has several advantages: it is quantitative 
(the number of sequences obtained for each miRNA cassette is proportional to its 
representation in the total cell population); it is unbiased (there is no need for specific 
PCR primers); it is cost-effective (a single sequencing lane is sufficient to analyze up 
to 12 samples at the same time, saving money and time). Thus, we needed to develop 
and optimize a protocol for the high-throughput sequencing of integrated regions 
using the Illumina HiSeq 2000 workstation, available in the lab. Briefly, this approach 
involves amplifying integrons from gDNA by PCR using primers that recognize a 
common sequence in the library constructs and then sequencing the PCR product by 
next-generation sequencing.  
We reasoned that the most critical step in the detection of miRNA integrons is the 
selection and amplification of the integrons from the gDNA by PCR. Indeed, this 
PCR step is required to select from gDNA only lentiviral cassettes to be sequenced 
and, at the same time, to increase the amount of sequencing template. For this step, 
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we took advantage of the presence of specific primers (LVL) in the miRNA 
expressing constructs that flank the miRNA sequence.  
A potential disadvantage of this amplification step is that it could alter the frequency 
with which miRNA integrons are detected. To test for this this possibility, we 
compared two different protocols for measuring miRNA integrons: i) the first method 
involved measuring integrons by qPCR analysis directly on gDNA using miRNA-
specific primers; ii) the second approach involved first selecting and amplifying by 
PCR the integrons from gDNA using the LVL primers and then measuring the 
integrons by qPCR analysis. For this experiment, we used MCF10A cells infected 
with miR-191 and miR-34a viral constructs (Figure 15). We generated three samples: 
sample A, in which the quantity of gDNA of miR-34 was greater than that of miR-
191; sample B, in which the quantity of gDNA of miR-191 was greater than that of 
miR-34; sample C, with equal quantity of gDNA of miR-191 and miR-34, to use as 
reference for normalization. We were able to score almost the same fold-change in the 
number of miRNA enrichment when performing the qPCR analysis directly on the 
gDNA or following the PCR selection step (Figure 15). This result indicates that 
selection and amplification of miRNA integrons from gDNA by PCR prior to their 
detection does not affect the original frequency of miRNA cassettes (Figure 15). 
 




Figure 15 – Selection of viral integrons by PCR does not alter the quantification. Fold-change in 
miRNA enrichment (over the reference, which consisted in the mixture of miR-34 and miR-191 gDNA 
with a ratio 1:1) was calculated by q-PCR. MCF10A cells were infected with both miR-191 and miR-
34 at varying the quantity of gDNA: sample A, gDNA of miR-34 > miR-191; sample B, gDNA of 
miR-191 > miR-34a. We measured miR-191 and miR-34 enrichment by performing a q-PCR analysis 
directly on gDNA (blue columns, gDNA). Alternatively, we selected the viral integrons by PCR and 
used the diluted PCR product, instead of the gDNA, to measure miR-191 and miR-34 abundance (red 
columns, PCR 1:50000).  
 
3.4 Proof-of-principle experiment using MCF7 breast cancer cells: 
library detection and deconvolution of clones  
Having defined the experimental strategy and optimized assay conditions (MOI, IN, 
gDNA purification, PCR selection and sequencing), we performed a proof-of-
principle experiment using the entire miRNA library and the breast cancer cell line, 
MCF7. The aim of this experiment was: 1) to assess whether the experimental 
conditions defined in the assay set-up work well when using the whole miRNA 
library; 2) to determine whether we could detect integrons in gDNA by PCR 
amplification and next generation sequencing; 3) to verify whether we could detect a 
high percentage of miRNA clones with respect to the entire library.  
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MCF7 cells were infected with the lentiviral miRNA library at a low MOI (= 2), 
corresponding to an IN equal to one, and ~300,000 GFP+ cells were recovered by 
FACS-sorting (equivalent to the P0 population). gDNA was extracted from these cells 
and used as a template for PCR amplification of the precursor miRNA transgenes 
using the LVL primers (Figure 16A). As the distribution of miRNA precursor lengths is 
centered on ≈ 600 bp (Figure 16A), we expected to generate PCR products of this size. 
Different protocols were used in the PCR selection step, varying the amount of gDNA 
template, enzyme type and annealing temperature to optimize the yield of the PCR, 
while keeping the number of cycles to a minimum (Figure 16B) to avoid biases in the 
amplification. The resulting PCR products were of the expected size and the sample 
with the highest yield was selected and sequenced at a 50 bp single-read mode with 
the HiSeq 2000 (Illumina) by the Genomic Unit of IIT@SEMM. 
Raw sequencing reads were processed, filtered and aligned over the reference 
genome, which consisted of all the miRNA precursor clones (see “Material and 
Methods” Section 2.2.2 for details). Of note, we retrieved a total of 509 miRNAs 
precursors after sequencing. About 75% of the clones (381) were significantly 
represented (>10 reads) and the majority clones (342, 67%) had high-abundance reads 
(>10,000 reads, Figure 16C). We previously retrieved miRNA expression data from 466 
human primary breast tumors generated by “The Cancer Genome Atlas (TCGA)” 
consortium (TGCA, 2012) Of the 421 miRNAs found to be expressed in breast cancer 
(> 10 RPM) in the TGCA dataset, approx. 80% (338) were represented in the miRNA 
library (Figure 16C). 
Together, the results of the proof-of-principle experiment indicated that the assay 
conditions and the next generation sequencing approach for integrons detection 
worked successfully; we achieved a good level of detection of clones within the 
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library (509 out of 637 clones; 80%). Moreover, the breast cancer associated miRNAs 
were well represented in the library (80%), meaning that its use was a good starting 
point for the identification of miRNA modifiers of mammary stem cell self-renewal. 
 
 
Figure 16 – Proof-of-principle experiment of miRNA library infection and integron detection in 
MCF7 breast cancer cells. A) Top: schematic diagram showing the position of PCR primers (LVL 
FW and LVL REV) used to select and amplify viral integrated regions (integrons) from gDNA. These 
primers were common to all miRNA precursors generated from the library. Bottom: histogram showing 
the distribution of the lengths (in bp) of miRNA precursors in the library. Lengths are centered on ≈ 
600 bp. B) The entire miRNA library (approx. 650 constructs) was used to infect MCF7 cells at a low 
MOI (=2), corresponding to an IN = 1. After 72 h, GFP+ cells were isolated by FACS-sorting and 
gDNA was extracted. Integrons were selected and amplified by PCR using the primers shown in A. 
The PCR protocol was optimized to maximize specificity and yield. The gel shows PCR products 
generated with two different enzymes (Qiagen and Applied Biosystems) and with two concentrations 
of template gDNA or with different numbers of PCR cycles. The most abundant PCR product (boxed 
in red) was purified from the agarose gel and used for DNA sequencing (Illumina). C) Left: sequencing 
results of the proof-of-principle experiment described in ‘B’. miRNA precursors were identified by 
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mapping the sequencing data over the reference genome (UCSC database) using BLAT ( BLAST Like 
Alignment Tool). A total of 509 precursor clones were identified, of which 75% were consistently 
identified in more than 10 reads, and 67% in > 10,000 reads. Right: to understand how many miRNAs 
related to human breast cancer are present in the library, we retrieved expression data from The Cancer 
Genome Atlas Consortium (TGCA). Of the 421 miRNAs expressed in breast cancer in the TGCA 
dataset (>10 reads per million, RPM), 338 (80%) miRNAs are present in the library. 
 
3.5 Choice of cell line for the competition screening assay 
A potential problem associated with genome-wide competition screening assays is the 
misinterpretation of the data due to stochastic events. To avoid such misinterpretation, 
a general rule that is applied in these kinds of assays is that only clones that are 
significantly represented in the initial population (P0), with at least 100 independent 
transduction events, can be considered to really compete each other during the assay. 
Hence, we defined a new parameter, Coverage (C), which indicates the number of 
cells in the initial population (P0) that bear the same transgene (precursor miRNA in 
our case), and which could effectively compete in the assay. Coverage is dependent 
on the number of transduced cells and the number of different constructs in the 
library. This parameter is also influenced by the phenotype of interest, since it 
depends on the percentage of cells capable of displaying the phenotypic response. In 
the case of the proliferation phenotype, all viable cells in the initial population (P0) 
have the potential to proliferate. However, in the case of the self-renewal phenotype, 
only a minor fraction of cells in the initial population (P0) possess stem cell traits and 
can therefore form mammospheres in 3D conditions. Hence, only this minor stem cell 
population can compete for the phenotype. 
Considering this information, we screened different breast cell lines with the aim of 
identifying cells that can form mammospheres in vitro with a high SFE and thus 
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potentially achieve an optimal coverage value (100), which is needed for reliable 
results. Moreover, we tested the ability of the screened cell lines to be serially 
propagated as mammospheres, a prerequisite of the self-renewal phenotype 
competition screening. Many efforts were made to accomplish this goal, as the 
optimal mammosphere assay conditions varied from one cell line to another (cell 
concentration, medium, dissociation protocol) and were not always compatible with 
the sorting procedure. Indeed, the efficiency of FACS-sorting depends on the intrinsic 
cell shape and on cell vitality, which in this case depends on the conditions used for 
growth and dissociation of mammospheres.  
The human breast cancer cell lines, MDA-MB-231, MDA-MB-361, MFC7, SUM 
149PT, SUM 159PT, and the normal MCF10A breast cell line along with its 
malignant RAS-transformed derivatives (MII and MIV), were tested for their ability 
to form mammospheres. The cell lines MDA-MB 231, MII, MIV, and SUM 149PT 
were not able to form clonal mammospheres under the conditions used (Figure 17A). In 
contrast, MCF7, MCF10A and MDA-MB-361 cells were able to form 
mammospheres, albeit with a low sphere forming efficiency [SFE] (~0.1-0.15% at the 
first generation, F1), which dropped steadily upon serial propagation (i.e., they 
displayed a self-extinguishing “mortal” behavior; Figure 17A and B). The low SFE of 
these cell lines means that the number of cells needed to reach a good coverage in the 
competition screening assay is too high to be feasible. Instead, SUM 159PT cells 
(hereafter referred to as SUM159), a basal-like and claudin-low breast cancer cell 
line, displayed a very high SFE of ~10% at the first generation, which increased over 
successive generations (i.e., they displayed an “immortal” behavior, Figure 17A and B). 
Based on these results, the number of initial SUM159 cells needed to perform the 
phenotype competition assay (300,000) is feasible.  
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Next, we assessed whether SUM159 cells have the potential to generate solid tumors 
in vivo, a feature that could be useful in the future validation experiments. We 
injected 5 x 104 SUM159 cells into the mammary fat pads of recipient NOD/SCID 
mice. We observed that SUM159 are highly tumorigenic in vivo with 9 out 10 mice 
developing a visible and palpable tumor after a short latency period (4 – 6 weeks; 
Figure 17B and C). Moreover, it has been described in the literature that upon limiting 
dilution transplantation in mice, SUM159 cells are able to form solid tumors at 1000 
cells⁄mL in 3 out of 8 mice (Fillmore and Kuperwasser, 2008). 
Based on these in vitro and in vivo data, we chose the SUM159 cell line as the cell 




Figure 17 – Self-renewal capacity of different breast cell lines assessed by the mammosphere 
assay. A) Breast cell lines belonging to different histological subtypes were tested for their ability to 
form mammospheres in vitro in conditions compatible with the phenotype competition screening assay. 
MCF7 and 231 were plated at 5000 cells⁄mL; 361 and SUM 149 were plated at 20000 cells⁄mL 
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SUM159 cells were plated at 2000 cells⁄mL.Cells were cultured for eight days and colonies were 
visualized at light microscopy. Top panels: representative images of cells not able to form clonal 
mammospheres; MDA-MB-231 cells formed large clumps of cell while SUM149 PT cell line was not 
able to form spheres. Bottom panels: representative images of mammospheres formed by the MCF7, 
MDA-MB-361 and SUM159 cell lines. B) Table reporting: type (normal vs. tumor); breast cancer 
subtype; in vivo tumorigenicity (data taken from our laboratory and from the biological resource center 
ATCC); SFE at first generation of mammospheres (SFE%, F1); behavior (mortal vs. immortal) upon 
serial propagation of mammospheres under conditions compatible with the screening assay. C) Ability 
of SUM159 cells to form tumors upon xenograft transplantation in vivo. Cells (5 x 104) were injected 
into the mammary fat pads of 10 NOD/SCID mice and tumor growth was monitored 4 – 6 weeks after 
injection. Image of representative tumors (indicated by arrows) and table summarizing results is 
shown. 
  
3.6 Verification of the clonal origin of SUM159 mammospheres 
 
Our screening strategy for miRNA modifiers of self-renewal is based on the in vitro 
mammosphere assay. In this assay, cells with stem cell-like properties are able to 
grow in non-adherent conditions as clonally-derived cell spheroids composed of one 
(or a few) putative stem cells and a bulk of differentiating progenitor cells (Dontu et 
al., 2003). Hence, it was important to verify that, in the condition used for our 
screening assay, SUM159 cells give rise to spheroids that are clonally-derived rather 
than resulting from cell aggregation; a condition that would lead to misinterpretation 
of the screening results.  
To assess the clonal origin of mammospheres generated by SUM159 cells, we used 
two different lentiviral vectors: one expressing a GFP reporter gene and the other 
carrying an RFP reporter gene. Since our phenotype competition screening assay 
involves the serial propagation of mammospheres, we decided to verify the clonal 
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origin of SUM159 mammospheres over several generations. Thus, we serially 
propagated FACS-sorted RFP-or GFP-expressing SUM159 cells as mammospheres, 
and at every generation we assessed the clonality of mammospheres (see Figure 18A 
for experimental design). To this end, we mixed together an equal number of FACS-
sorted RFP- and GFP-SUM159 cells, derived from the starting population (F1) or 
dissociated mammospheres (Fn), and cultured cells as mammospheres (Figure 18A). 
With this approach, we could easily distinguish clonal spheroids, which are composed 
entirely of either red or green cells, from aggregates that contain both red and green 
cells. We observed that, at every generation (F1 – F3), the vast majority of SUM159 
cell spheroids appeared either green or red, with just a few (<5%) appearing as mixed 
red and green aggregates (Figure 18B). This result confirms the clonal origin of the 
majority of SUM159 cell spheres, confirming their suitability as the model system for 
the screening assay.  
In the same experiment, we also verified our previous observation that SUM159 cells 
display an “immortal” behavior in the mammosphere serial propagation assay (see 
Figure 17B). We assessed the SFE of RFP- and GFP-SUM159 cells over serial passages 
of mammosphere cultures (Figure 18A), and observed an increase in SFE over 
sequential passages: GFP-SUM159 cells, SFE at F1 ~10%, SFE at F3 ~20%; RFP-
SUM159 cells, SFE at F1 ~4%, SFE at F3 ~28% (Figure 18C). This result confirms that 
SUM159 cells display an “immortal” behavior in the mammosphere serial 
propagation assay similar to that of high-grade breast tumors (Pece et al., 2010). 
 




Figure 18 – Analysis of the ability of SUM159 cells to form mammospheres. A) Schematic diagram 
of experimental design. SUM159 cells were separately infected with lentiviral vectors carrying either a 
GFP or RFP reporter gene. Cells were sorted for reporter gene expression by FACS to obtain purified 
red and green cell populations. These cells were then analyzed separately for their ability to be serially 
propagated as mammospheres. In parallel, for every generation of mammospheres (i.e., F1, F2, F3) red 
and green cells were mixed together in a 1:1 ratio and cultured as mammospheres to check the clonal 
derivation of spheres vs. the formation of cell aggregates. B) Representative images of F1, F2 and F3 
mammospheres visualized with an EVOS fluorescent microscope at 4X magnification. C) The 
efficiency of mammosphere formation (SFE) for the RFP and GFP expressing SUM159 cells over 
three different generations (F1, F2 and F3). 
3.7 Identification of candidate miRNA “modifiers” of self-renewal 
using the SUM159 cell model system 
3.7.1  In-vitro screening: 3D mammosphere assay and 2D proliferation assay  
We performed an in-vitro phenotype competition assay with the miRNA library and 
SUM159 cells to identify candidate miRNA modifiers of self-renewal using serial 
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propagation of mammosphere as the phenotype read-out. To better evaluate effects 
that influence self-renewal or cell proliferation and survival, we used the same initial 
cell population transduced with the library (P0) into two parallel assays: a 2D 
proliferation assay and a 3D mammosphere assay (Figure 19A). 
Cells were infected at MOI = 2, and those expressing the transgene were selected by 
FACS-sorting on the basis of GFP positivity to obtain the initial population (P0). This 
P0 population was divided into two groups that were challenged in parallel for the 
self-renewal (3D mammosphere serial propagation assay – 300,000 cells) and 
proliferation (2D proliferation assay – 90,000 cells) phenotypes (Figure 19A). Every 
second passage cells in from the 2D and 3D assays were sorted to ensure maintenance 
of transgene expression in the majority of cells during the screening (Figure 19B). In 
the 3D assay, the mammospheres were collected, dissociated and replated for a total 
of six generations (F1, F2 …F6). In parallel, the proliferation screen was carried out 
untill the 8th passage (P1, P2 …P8). The entire procedure was repeated twice, with 
independent batches of cells and rounds of infection, thus generating two complete 










Figure 19 – Summary of the in vitro phenotype competition screening assay performed on 
SUM159 cells. A) SUM159 cells were infected with the lentiviral library at a MOI = 2 GFP+ cells were 
FACS-sorted and the resulting P0 population was divided into two groups and assessed in two parallel 
competition assays based on the 3D serial propagation mammosphere assay (self-renewal) or a 2D 
serial proliferation assay. gDNA was extracted from each passage and integrons were identified by 
PCR and next generation DNA sequencing analysis. B) To enrich for transduced cells, samples were 
sorted for GFP+ cells every second passage. The bar graph shows the fraction of GFP+ cells in the 
starting population (F0) and in second (F2), fourth (F4) and sixth (F6) generations of the 3D 
mammosphere experiment. 
 
3.7.2 Next generation sequencing for clone deconvolution and candidate 
identification 
We collected gDNA from each passage of the 2D and 3D assays, and identified 
integrons by PCR amplification and next generation sequencing (Figure 20). Reads 
were mapped on the human genome hg19 and, then, aligned over the reference 
genome, which consisted of the entire human miRNA lentiviral library. Raw reads 
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obtained were then normalized by library size (RPM). At the end of this analysis (see 




Figure 20 – miRNA screening in SUM159 cells: intergron selection by PCR. The phenotype 
competition experiment as described in Figure 11 was performed in SUM159 cells. gDNA was 
extracted at the indicated passages of the parallel 3D (Fn) and 2D (Pn) assays, and integrons were 
amplified by PCR. The PCR products were resolved on 2% agarose gels along with positive and 
negative controls (CTR+ and CTR-, respectively) and size markers (M). Shown are the results of the 
two independent biological replicas (1st and 2nd experiment). 
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The PCR amplification and sequencing step was repeated twice to generate a 
technical replicate for each sequenced sample. A bivariate analysis was used to test 
the reproducibility of the sequencing results among technical replicates (Figure 21). 
The sequencing results were extremely reproducible (R >0.95), in particular, for 
samples that were significantly represented (>100 reads). As the entire screening was 
performed twice, we also assessed the reproducibility of the two independent 
biological experiments; we compared the mean number of reads (derived from the 
two technical replicates) from the two independent experiments for the initial P0 cell 
population. This P0 population is composed of transduced GFP+ FACS-sorted cells 
that have not yet undergone phenotype competition; hence, an analysis of this 
population will give an indication of the reproducibility of the library infection. Once 
again, we obtained a linear correlation (R= 0.76), which indicates good 
reproducibility of the two infections (Figure 22). 
Similarly, we performed a bivariate analysis to evaluate the biological reproducibility 
at different passages (F2, F4, F6). As shown in Figure 22, the F2 reproducibility is 
almost identical to that of the initial population (0.75), indicating that at the early 
passages the vast majority of clones are still high represented and that the rate through 
which clones are lost, because of the selective pressure, is low.   
Conversely, in the final passages (F4, F6) the biological replicas showed quite 
different behavior (Figure 22; R=0.1 at F4; R=0.01 at F6). This could be interpreted as 
poor consistence in the results or as the mere consequence of the variability in the 
speed and in the extent of loss/gain of clones between independent experiments. 
When we compared the final (F6) with the initial population (F0) in each of the two 
experiments, most clones were concordant in their trend of behavior (see Bubble Plot 
in Figure 25), suggesting similar biological effects. 




Figure 21 – Technical reproducibility of DNA sequencing analysis. Two independent PCR 
reactions were performed on each gDNA sample derived from different generations (P0, F2, F4, F6) of 
mammospheres in the 3D assay. The resulting PCR products were analyzed by next generation DNA 
sequencing. The graph shows a bivariate analysis of the number of reads obtained in the two technical 
replicates for each miRNA precursor (represented by each black dot), along with the linear correlation 
coefficient (R). 





Figure 22 – Reproducibility of DNA sequencing data from the two biological replicates of the 
screening. Reproducibility of the DNA sequencing data across the biological replicates was assessed. 
The same human miRNA lentiviral library was used in two independent experiments on SUM159. 
gDNA samples from the initial P0 cell populations were sequenced twice (technical replicates) in each 
independent experiment and the mean number of reads calculated. The means from the two biological 
replicates at different passages (P0, F2, F4, F6) were then compared by bivariate analysis as shown in 
the graph where each dot represents a specific miRNA. The value of the linear correlation coefficient 
(R) is also shown. 
 
We, then, focused on the initial population (P0) to select clones that were significantly 
represented and could therefore compete in the 2D and 3D assays. For this purpose, 
we calculated the coverage (C) of each construct in the 2D and 3D assays (Figure 23, 
see “Material and Methods” for details on the coverage calculation). Of note, all 
(100%) transduced SUM159 cells were able to compete for the proliferation 
phenotype, while only a minor fraction (about 10%) was able to grow as clonal 
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mammospheres in 3D conditions. Hence, the calculation of coverage had to take into 
account this difference. In particular, considering the clones that were represented by 
at least 100 independent transduction events (C>100), we found, in the first 
experiment, 375 and 179 different miRNA precursor clones in the 2D and 3D assays, 
respectively (Figure 23¸1st experiment). The same analysis was repeated with the 
second biological replica, yielding very similar numbers of miRNA precursor clones 
above the C>100 cut-off: 379 and 195 in the 2D and 3D assays, respectively (Figure 
23, 2nd experiment).  
Biologically the P0 coverage selection is determined by all those clones that are 
enough represented as virus particles within the commercial library and possess also a 
good and reproducible efficiency of transfection. Of course, with the coverage cut-off 
at the initial population, we excluded miRNAs that: i) were toxic or poorly tolerated 
by the cells and, thus were depleted immediately after infection, even before the 
competition started; ii) had an insufficient number of virus particles because of 
intrinsic library heterogeneity; iii) had a low transduction efficiency (see section 3.2 
for details).  
Since our first aim was to reveal microRNA modifiers of self-renewal, we selected 
the hits from the 3D experiments, irrespectively of their result in 2D. Conversely, we 
did not select those miRNAs that had an effect just on the proliferation screen. 
For this reason, we filtered for the common miRNA clones from the 3D assays of the 
two biological repeats, considering only those with a coverage value ≥100 in both 
experiments. In total, 152 common miRNAs were identified (Figure 24) and selected 
for further analysis to establish whether they were positively or negatively selected 
(see below). Note that these 152 miRNAs were also in common with the 2D assay. 




Figure 23 – Analysis of clone coverage. Based on the sequencing results, the coverage at P0 of 
miRNA precursor clones was calculated for the 2D and 3D assays. The coverage in the 3D assay was 
lower than in the 2D assay since only 10% of SUM159 cells are able to form mammospheres at the 
first passage. The bar graphs show the number of miRNA precursor clones (y-axis) above different 
coverage cut-off values (x-axis) for the 2D proliferation screening (red) and the 3D mammosphere 
assay (blue) in the two independent biological repeats. A high coverage value indicates a more robust 





Figure 24 – Identification of common miRNA clones in the two biological repeats. Venn diagram 
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3D screening results 
To reveal how each miRNA clone behaved in the mammosphere competition assay, 
we calculated the “3D enrichment scores” for the 152 common miRNAs using the 
equation:  
3D enrichment score = log2 (RPMF6/ RPMP0) 
where RPMF6 is measure of clone abundance based on the number of reads, 
normalized by library size at the last passage (F6), and RPMF0 is the clonal abundance 
in the starting population (P0). 
The 3D enrichment scores were calculated for both experiments and used to generate 
a graphical representation (the “bubble plot”) of the screening results (Figure 25). Each 
bubble corresponds to a specific miRNA, with the size of the bubble being 
proportional to the miRNA coverage: the bigger the bubble, the higher the coverage. 
The coordinates of each bubble are relative to the 3D enrichment scores, with the 
values relating to the first experiment on the y-axis and those relating to the second 
experiment on the x-axis (Figure 25).  
The bubble plot is divided into four regions: the top right and bottom left quadrants 
contain clones that are reproducibly enriched or depleted in the two experiments, 
respectively; the top left and bottom right quadrants contain clones with disjointed 
results, being enriched in one experiment and depleted in the other. Of note, most of 
the bubbles (miRNAs) were located in the bottom left quadrant close to the middle 
axes, suggesting that the vast majority of clones were not neutral (they should be 
located around zero), but tended to be depleted.  
We claimed that this behavior of clone depletion could be mainly due to independent 
reasons. For instance, the stringent selective pressure of the mammosphere assay 
allows only stem cells to survive and generate spheres. Indeed, loss of clones is 
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generally observed when performing competition assays and the more severe is the 
selective pressure which is applied in the screening, the most rapidly the clones are 
depleted from the population. There is also the possibility that global loss is the result 
of the intrinsic ability of miRNA molecules to behave like tumor suppressor genes 
rather than oncogenes (Kumar et al., 2007). Accordingly, miRNAs that function by 
inhibiting self-renewal of CSCs are considered to have tumor suppressor potential. 
Finally, we still have to comment on the model used in the screening, which is a very 
aggressive cell line, with extremely high rate of sphere formation. Hence, using this 
cell line we could have a bias in identifying miRNAs that decrease rather than 
increase the efficiency of mammosphere formation. In these circumstances, miRNAs 
that decrease mammosphere formation tend to be depleted from the population over 
passages, so that the system ensures the propagation of the spheres. Even so, our first 
aim was to search for miRNA that potentially inhibit cancer stem cells, so this bias 
should have not marred the screening results. 
To identify the most negatively selected clones from the bubble plot, we selected 
those with a ratio value of ≤ -4 (pink bubbles in Figure 25).  Conversely, only two 
positively-selected clones were pinpointed (green bubbles in Figure 25). 
In conclusion, from the 3D experiments, which consisted of growing cells in non-
adherent conditions as mammospheres, 18 depleted and 2 enriched miRNAs were 
selected as top candidates for negative and positive regulators of self-renewal, 
respectively.  
 




Figure 25 – Identification of candidate miRNA modifiers of stem cell self-renewal with C>100. 
The “Bubble-Plot” shows the behavior of the 152 common miRNAs (C > 100) during the 
mammosphere assay (3D) in the two independent experiments. Each bubble represents a different 
miRNA, where the size of the bubble is proportional to its coverage value. Based on sequencing 
results, an enrichment 3D score for each miRNA was calculated as the number of reads in the last 
passage (F6) divided by the number of reads in the starting population (P0), in log2 scale. The 
enrichment scores of the first experiment are plotted on the y-axis and those of the second experiment 
are plotted on the x-axis. The most downregulated (negatively-selected) and upregulated (positively-
selected) miRNAs were selected for validation studies (shown as pink and green bubbles, respectively). 
The value of the linear correlation coefficient (R) is also shown. 
 
To possibly broaden the selection of miRNA candidates and include known self-
renewal inhibitor miRNAs (like miR-200 family), we reduced the coverage cut-off to 
50 cells, which means starting with 269 miRNA clones present in the P0 in both 
biological replicas. Same as previous, we generated a bubble plot for those 269 
regulated miRNAs with C>50.  
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Notably, we observed a similar plot, with most clones slightly decreased and with 22 
additional miRNAs, in the negatively-selection area (Figure 26, blue bubbles). Among 
these clones, we found a member of the miR-200 (miR-200a), which has been 
previously described by several groups as inhibitor of breast Cancer Stem Cells 
(Shimono et al., 2009) (Wellner et al., 2009). No additional positively-selected clones 
were found. It could be interesting to test, some of the new candidates to i) reveal new 
other inhibitors of stem cell self-renewal, and ii) to understand whether the validation 
rate drops under this coverage, claiming for stochastic rather than functional effects in 
clone behavior.  
 
 
Figure 26 Identification of candidate miRNA modifiers of stem cell self-renewal with C>50. The 
“Bubble-Plot” shows the behavior of the 269 common miRNAs (C > 50) during the mammosphere 
assay (3D) in the two independent experiments. Each bubble represents a different miRNA, where the 
size of the bubble is proportional to its coverage value. Based on sequencing results, an enrichment 3D 
score for each miRNA was calculated as the number of reads in the last passage (F6) divided by the 
number of reads in the starting population (P0), in log2 scale. The enrichment scores of the first 
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experiment are plotted on the y-axis and those of the second experiment are plotted on the x-axis. The 
downregulated (negatively-selected) clones, that were not included in the previous analysis with 
C>100, are depicted in blue. The pink bubbles in the background represent the negatively-selected 
miRNAs regulated in the 3D experiment with C>100. The value of the linear correlation coefficient (R) 
is also shown. 
 
2D screening results 
We next assessed whether the 152 common miRNAs from the 3D assay were 
negatively or positively selected in the proliferation assay (2D). This approach would 
highlight if a microRNA might have a possible double role both in the self-renewal as 
well as in the proliferation of tumor cells. To this end, we calculated the 2D 
enrichment scores for the 152 miRNAs using the equation: 
2D enrichment score = log2 (RPMP6/ RPMP0) 
where RPMP6 is the clone abundance (number of reads, normalized by library size – 
RPM) at the last passage (P6, corresponding to F6 in the 3D screen) and RPMP0 is the 
clone abundance in the initial population (P0).  
As with the 3D assay, the 2D enrichment scores were calculated for both experiments 
and used to generate a “bubble plot” representative of the 2D screening (Figure 27). In 
this case, most of the clones had a neutral effect and were located around the center of 
the graph (around zero) with a tail in the bottom left quadrant, meaning that they have 
a slight negative effect on cell proliferation. We identified the location in the bubble 
plot of the 20 most depleted (in pink, Figure 27) and the most enriched miRNA clones 
(in green, Figure 27) from the 3D analysis (Figure 25) to determine how these clones 
were selected in the proliferation assay. 





Figure 27 - Identification of candidate miRNA modifiers of proliferation and survival.  The 
“Bubble-Plot” shows the behavior of the 152 miRNAs in the proliferation assay (2D) in the two 
independent experiments. Based on sequencing results, a 2D enrichment score was calculated as the 
number of reads in the last passage (F6) divided by the number of reads in the starting population (P0), 
in log2 scale. The enrichment scores of the first experiment are plotted on the y-axis and those of the 
second experiment are plotted on the x-axis. Each bubble represents a different miRNA with a size 
proportional to its coverage value. The pink and green bubbles represent most negatively and positively 
selected miRNAs regulated in the 3D experiment, respectively (see previous graph). 
 
Next, we generated a 3D vs. 2D “bubble plot”, in which we plotted the 3D enrichment 
score (average of the two experiments) on the y-axis against the 2D enrichment score 
on the x-axis (average of the two experiments), in order to identify hits that were 
unique to the 3D assay or might have also an effect on proliferation (Figure 28).  
In general, we observed the tendency of clones to be neutral or slightly negatively-
selected in the 2D screening and strongly depleted in the 3D assay, highlighting the 
fact that the selective pressure acting on the 3D assay is more severe compared to that 
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of the proliferation screening. This suggests that most of the miRNAs behaved as 
weak inhibitor of self-renewal of CSCs or more likely that the overexpression of any 
given miRNAs is less tolerated when cells are grown under 3D condition than in 2D 
conditions.  
Self-renewal is, indeed, a particular mechanism of proliferation and, hence, the two 
mechanisms could share some kind of regulation. In other cases, proliferation and 
self-renewal could behave as distinct mechanisms. Indeed, we could distinguished 
these different behaviors in the 3D assay. We expect that the proliferation effect 
mainly impacts on the bulk population, thus determining a reduction of the sphere 
size, while acting on self-renewal mechanism means decreasing just the 
mammosphere number, whereas a combination of the two would indicated an effect 
on both stem cell and bulk sphere proliferation. 
Accordingly, we distinguished three different categories of miRNAs within the 
bubble plot (Figure 28): i) 2 positively-selected miRNAs specific for the 3D assay 
(Figure 28 green bubbles); ii) 15 miRNAs stronger regulated in the 3D assay compared 
to the 2D one, suggesting that their effects could be specific for the self-renewal 
phenotype; iii) 3 miRNAs (Figure 28 red bubbles: miR-1-1, miR-124-1 and miR-889) 
strongly depleted in both 2D and 3D assays, suggesting that they might have a strong 
effect on both self-renewal and proliferation. 
Based on these results, we selected the most promising candidates (based on the 
strongest regulation) for further analysis. Specifically, we selected as the “top hit 
candidates”: miR-1-1, miR-124-1 and miR-889 as negatively selected clones, and 
miR-664 and miR-657 as positively selected clones. These 5 “top hit candidate” 
miRNAs together with some other selected clones (miR-153-2, miR-144, mir-204, 
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miR-125a, miR-379 plus the scramble control) were individually validated for their 
effects on stem cell self-renewal. 
 
 
Figure 28 – Comparison of the enrichments scores in the 3D vs. 2D screening for the 152 miRNA. 
The bubble plot shows the enrichment scores (average of the two independent experiments, log2 scale) 
of the 152 miRNAs with C>100 in the 3D screening (y-axis) vs. their scores in the proliferation 2D 
screening (x-axis). Each bubble represents a different miRNA with a size proportional to its coverage 
value. Three miRNAs (red bubbles) were found to be depleted in both assays (2D and 3D) and thus are 
putative anti-proliferative and anti-self-renewal miRNAs. Fifteen miRNAs (pink bubbles) were found 
to be more markedly depleted in the 3D experiment compared with the 2D experiment, and thus 
represent candidate negative regulators of self-renewal. Two miRNAs (green bubbles) were found to 
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3.8 Validation of microRNA modifiers 
3.8.1 Single infection and sphere forming efficiency evaluation: looking for “real 
miRNA modifiers”   
Through a genome-wide screening of the human miRNA lentiviral library, we 
identified 20 miRNA candidates that could potentially be involved in the regulation of 
mammary stem cell self-renewal. Three of these hits (miR-1, miR-124, miR-889) 
were also identified as putative negative regulators of breast cancer cell proliferation. 
To validate these potential miRNA “modifiers” of stem cell self-renewal, we 
evaluated their effects individually on the SUM159 breast cancer cell line. We first 
focused on the 5 “top hits”, as these miRNAs showed the strongest effects on self-
renewal and on cell proliferation, compared to the other hits. In this validation step, 
we also examined 5 other candidate miRNAs (miR-153-2, miR-144, mIr-204, miR-
125a, miR-379), which appeared to be more markedly depleted in the mammosphere 
assay compared to the 2D proliferation screening.  
We infected SUM159 cells with single lentiviral constructs (SBI) with high 
integration number (IN) to have a population that homogenously expresses the 
miRNAs with high transduction efficiency. As previously demonstrated (Figure 12), 
there is no difference in phenotype outcome using low or high MOI with single 
lentiviral constructs. Conversely, with low MOI the transduction efficiency is also 
very low (<10% GFP), which makes unfeasible the individual validation of miRNAs 
by serial propagation of mammosphere. 
We optimized the virus titer to use to avoid toxicity and maximizing efficiency (see 
section 2.1.9 for details). Typically, we infected cells with different amount of 
concentrated virus (30uL and 70uL) and monitored cells for their viability and 
transduction efficiency (% of GFP+) up to 48h-72h post infection. We selected the 
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sample that showed a good efficiency (>50% GFP+) with the lowest amount of virus 
(30uL), nicely growing and with no signs of suffering. The samples were used to 
isolate the GFP+ fraction by FACS-sorting. 
With high MOI (MOI=10), we obtained more than 80% of GFP + cells at P0, 
meaning that we could easily perform a serial propagation of mammosphere 
experiments as assay to measure directly the effect of miRNAs on self-renewal 
(number of spheres at the first and in the next passages) and on proliferation (size of 
spheres and number of cells grown in 3D).  
For the validation step, we performed a serial propagation of mammospheres over 
three generations. A control construct (SCR), which expresses a non-targeting 
sequence, was used in parallel to evaluate the background effects of lentiviral 
infection and transgene expression. As a control for the maintenance of transduced 
cells during the assay, we measured the percentage of GFP+ positive cells at each 
generation and observed a general decrease in GFP levels over the passages, 
indicating that miRNA-expressing cells were being lost (Figure 29). This effect did not 
appear to be an effect of the lentiviral vector per se, since the SCR control construct 
did not show this behavior, but was common for all the miRNA expressing vector. 
We, thus, claimed that the decrease in GFP expression is the due to the fact the forced 
expression of any miRNA is poorly tolerated in 3D conditions. To limit the loss of 
GFP+ cells, we FACS-sorted cells from the second passage (F2), in addition to the 
original FACS-sorting of the initial transduced population (P0), to enrich for GFP+ 
clones and to allow the evaluation of SFE on a cell population that homogenously 
expresses the miRNA (SFE% calculated at F1 and F3). The GFP expression of cells 
from the F1 generation, that were not sorted, was simply monitored by FACS 
analysis. 
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Since the measure of SFE relies on the precise count of clonal spheroids, we further 
optimized the assay to increase its sensitivity and robustness by: i) seeding cells at a 
limited concentration (1000 cells\mL, in triplicate) in methylcellulose to avoid the 
formation of cell aggregates; ii) automatically counting spheres using a technique 
based on image processing (see “Material and Methods” for details); iii) 
discriminating between “green” (GFP+) and “not-green” (GFP-) spheres, to associate 
the phenotype only to miRNA-expressing cells (spheres that presented a 




Figure 29 – Analysis of the maintenance of transduced cells upon serial propagation of 
mammospheres. SUM159 cells (250000 cells) were infected at high integration number with the 
System Bioscieneces lentiviral construct expressing the indicated miRNA hits or a scramble control 
sequence (CTRL SCR). Transduced cells were selected by FACS-sorting for GFP+ cells and then 
plated in non-adherant conditions to allow mammosphere formation for 3 generations. The % of GFP+ 
cells was assessed by FACS analysis of the initial, infected, FACS-sorted cell population (P0) or of 
dissociated first and second generation mammospheres (F1, F2).  





Figure 30 – Optimization of the mammosphere assay. To obtain a precise mammosphere count we: 
i) plated cells at a low concentration (1000 cells\mL) on methylcellulose, to avoid cell aggregation and 
preserve the clonality of mammospheres; ii) set-up the automatic counting of mammospheres based on 
a number of strict criteria that were established through a series of optimization experiments. The 
criteria included only counting spheres that were > 70 micron (top image), which is the average sphere 
size of SUM159,  and that displayed a homogenous expression of GFP (bottom image of an excluded 
sphere displaying heterogeneous GFP expression). 
 
Using the optimized assay, we measured the SFE of SUM159 cells transduced with 
the 10 selected miRNA hits, at the first (F1) and third generation (F3) of spheres, and 
evaluated the effects miRNA overexpression on SFE. Among the five “top candidate 
hits”, Figure 31, two miRNAs (miR-124 and miR-657) markedly affected the SFE. In 
particular, miR-124, which was negatively selected in both the 2D and 3D 
competition screenings, significantly inhibited the SFE at F1 and F3 (p<0.001; Figure 
31) In contrast, miR-657 expressing cells displayed an increase in SFE, which was 
particularly evident at the third passage (p<0.001 at F3; Figure 31). In addition, miR-1-
1, another negatively selected miRNA in the 2D and 3D screening assays, also 
significantly decreased the SFE at the first and third passage (p<0.05 at F1 and 
p<0.001 at F3) compared to the control, although not to the same extent as miR-124 
(Figure 31). 
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Regarding the other 5 candidate miRNA modifiers of self-renewal (miR-153-2, miR-
144, mIr-204, miR-125a, miR-379) all of them were predicted by the screening to 
decrease self-renewal of SUM159 cells, while having a minimal effect on 
proliferation. They all decreased the SFE at the first generation, albeit not 
significantly (F1; Figure 32). However, at F3, most of the inhibitory effects were lost, 
with miR-144, miR-153 and miR-204 showing a significant albeit limited effect 
(Figure 32). We can conclude that out of 10 tested miRNAs, 6 of them had an effect on 
mammosphere formation, with two miRNAs, miR-124 and miR-657, having a 
particularly marked effect.  
For these six validated miRNAs, we measured the sphere dimension over the control 
(SCR) to reveal whether a miRNA impacts exclusively on the self-renewal ability of 
stem cells, which is reflected by the decrease of the number of spheres, or may act 
also on the proliferation of the bulk of the sphere, determining a reduction on the 
sphere size. 
As shown in Figure 33, most of clones formed spheres with a similar dimension to the 
control, whereas miR-124 formed less and smaller sphere (25%), possibly suggesting 
that this miRNA is able to act by negatively modulating both self-renewal, decreasing 
the sphere number, and tumor cell proliferation, diminishing the sizeof the sphere. 
Natably, miR-124-1 and miR-657, which showed the strongest effect on self-renewal, 
were both in the “top five hit candidates”. These validation results indicate that our 
screening strategy is a robust and effective approach for identifying regulators of self-
renewal. In addition, the results suggest that miR-124-1 and miR-657 could be 
important molecular tools for exploring the mechanisms regulating mammary stem 
cell properties, as well as potential molecular targets to control the self-renewal of 
breast cancer stem cells. Both possibilities are addressed in the next chapter. 







Figure 31 – Hit validation by the mammosphere assay. Evaluation of the individual effects of the 
top 5 miRNA hits on the sphere forming efficiency (SFE) of SUM159 cells. Cells were infected with 
lentiviral vectors expressing the indicated miRNA precursors or with a control vector (CTRL SCR). 
After 72 h, transduced GFP+ cells were selected by FACS-sorting and plated in methylcellulose at 1000 
cells\mL to allow mammosphere formation. Mammosphere cultures were then serially propagated for 3 
generations. To preserve the expression of the transgene, cells were sorted after the 2nd generation of 
spheres (F2>F3). The figure shows the SFE calculated for the first (F1, upper panel) and third (F3, 
lower panel) generations of spheres. Spheres were counted in triplicate per sample and the mean SFE ± 
sdev is shown. For each sample, the percentage of spheres expressing the GFP marker (GREEN), or 










Figure 32 - Hit validation by mammosphere assay. Evaluation of the effects of the 5 additional 
selected hits on sphere forming efficiency (SFE) of SUM159 cells. Cells were infected with lentiviral 
vectors expressing the indicated miRNA precursors or with a control vector (CTRL SCR). After 72 h, 
transduced GFP+ cells were selected by FACS-sorting and plated in methylcellulose at 1000 cells\mL 
to allow mammosphere formation. Mammosphere cultures were then serially propagated for 3 
generations. To preserve the expression of the transgene, cells were sorted after the 2nd generation of 
spheres (F2>F3). The figure shows the SFE calculated for the first (F1, upper panel) and third (F3, 
lower panel) generations of spheres. Spheres were counted in triplicate per sample and the mean SFE ± 
sdev is shown. For each sample, the percentage of spheres expressing the GFP marker (GREEN), or 










Figure 33 – Sphere dimension evaluation. Sphere size data were calculated using the automated 
macro-based in-house system (see section 2.1.7) and collected in an excel file. For each miRNA, the 
average sphere size between the triplicates was measured. The histograms shows, for each validated 
miRNA, its average sphere dimension over the average size of CTR spheres.  
 
3.8.2 Transcriptional changes induced by miR-124 and miR-657 
Since miR-124 and miR-657 were capable of influencing mammosphere formation in 
SUM159 cells, we decided to investigate the effects of these miRNAs at the 
molecular level. In particular, our aim was to identify their target genes, as well as to 
gain insights into the pathways involved in the control of self-renewal of breast cancer 
stem cells. 
To this end, we transiently overexpressed miR-124 and miR-657 in SUM159 cells 
using miRNA oligo mimics and performed an in-depth analysis of the transcriptome 
by RNA-sequencing. As a negative control, we used an unrelated oligo (SCR) 
transfected at the same concentration [50 nM] in SUM159 cells. As we were mainly 
interested in early targets of the miRNAs, we collected RNA at 16 h and 24 h after 
transfection from three independent biological replicas. Initially, we verified the 
transfection efficiency of the two miRNAs by RT-PCR and observed a significant 
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increase in miR-124 and miR-657 levels over the control, comparable to that observed 
using lentiviral miRNA vectors (Figure 34). 
 
 
Figure 34 - Efficacy of miRNA oligo transfection. Left panels, SUM159 cells were transiently 
transfected with oligos (50 nM) mimicking either miR-124 (upper part) or miR-657 (lower part). A 
control oligo (scrambled, SCR) was used as a negative control. Shown, the qRT-PCR analysis 
performed to assess the efficacy of transfection in three independent biological replicas. miRNA 
expression was calculated as Log2fold change over SCR. Results are expressed as the mean ± sdev. 
The right panels report the quantification of miRNA expression from the lentiviral vectors used in the 
screening and in the validation experiments. 
 
Before performing the “unbiased” analysis of the transcriptional changes by RNA-
seq, we performed a “biased” approach, selecting the top predicted target genes of 
miR-124 and miR-657, and looking by RT-qPCR at their transcriptional changes 
upon miRNA overexpression. This analysis also served to establish whether there was 
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a significant transcriptional response under the experimental conditions used. For 
each miRNA, we selected the top 200 predicted target genes using the TargetScan6.2 
algorithm (www.targetscan.org). This algorithm identifies potential miRNA targets 
based on the presence of conserved miRNA Responsive Elements (MREs), 
complementarity to the “seed” region of miRNAs, in the 3’UTR of messenger RNAs 
(mRNASs). Putative target genes are ranked according to a context-score (CS), which 
takes into account the type of complementarity (7mer), the location of the MRE 
within the 3’UTR, and potential secondary structures: the lower the CS value the 
stronger the predicted interaction between miRNA and its target. We, thus, restricted 
the “biased” analysis to potential targets with a CS < -0.4, selecting those with the 
lowest value. As a further filter, we considered only those targets that were expressed 
in our model system (namely SUM159 cells), using an in-house expression dataset. 
We obtained a final list of 10 predicted target genes of miR-124 and 13 predicted 
targets of miR-657 (listed in Figure 35).  
 
 





Figure 35 – A “biased” approach for identification of miR-124 or miR-657 target genes. The 
upper diagram summarizes the strategy used to select putative targets of miR-124 and miR-657. 
Starting from predicted targets (according to the Targetscan 6.2 algorithm), the first 200 ranked targets 
(with a context-score < -0.4) were chosen and further selected by checking their expression levels in 
the SUM159 cell line (only targets expressed in the model system were considered). The top predicted 
genes for each miRNA (10 for miR-124 and 13 for miR-657) are listed with the Gene Symbol (Target 
gene), full gene name, expression value (according to an in-house microarray dataset of SUM159 
cells), and context-score (by TargetScan 6.2). 
 
These target genes were then analyzed by qRT-PCR in SUM159 cells transfected 
with the miRNA oligo mimics. We observed that the majority of miR-124 predicted 
target genes (7 out of 10) were effectively downregulated upon miR-124 
overexpression (Figure 36). Of note, these validated target genes include known 
regulators of the epithelial-to-mesenchymal transition (EMT) program, SNAI2 and 
the integrin ITGB1, which have been previously associated with stem cell traits in 
breast cancer cells. Regarding the miR-657 predicted target genes, 3 out of 13 were 
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highly regulated and 4 other genes showed a mild transcriptional effect (Figure 37). 
Thus, the “biased” approach indicated that a significant transcriptional response 
occurred upon miR-124 and miR-657 mimics transfection. In particular, miR-124 was 
able to induce the repression of many genes.  
 
 
Figure 36 – Expression of putative miR-124 target genes upon miR-124 overexpression in 
SUM159 cells. A qRT-PCR analysis was performed to evaluate the change in expression of 10 putative 
miR-124 target genes 24 h post-transfection with miR-124 oligos in SUM159 cells. Expression levels 
are shown as log2fold change regulation over the control oligo (SCR) in three independent 
experiments. Black and red bars represent SCR and miR-124 overexpressing samples, respectively. 
Seven out of the 10 analyzed target genes were consistently downregulated by miR-124 (Regulated 
Targets), while the remaining 3 were not regulated (Not Regulated Targets). 
 
 





Figure 37 - Expression of putative miR-657 target genes upon miR-657 overexpression in 
SUM159 cells. A qRT-PCR analysis was performed to evaluate the change in expression of 13 putative 
miR-657 targets upon miR-657 overexpression in SUM159 cells. Expression levels are shown as 
log2fold change in regulation over the control oligo (SCR) in three independent experiments. Black 
and red bars represent SCR and miR-657 overexpressing samples, respectively. Three out of the 13 
analyzed target genes were consistently downregulated by miR-657 (Regulated Targets), while 4 
targets displayed a mild downregulation (Mild Regulated Targets). The remaining 6 targets were not 
regulated (Not Regulated Targets). 
 
3.8.3  RNA- sequencing: data analysis and quality control of samples   
We, next, implemented an “unbiased” analysis of transcriptional changes induced by 
miR-124 and miR-657 by means of RNA-sequencing, performed at 50 bp length and 
single read mode with a depth of 80 million reads (for details on library preparation 
see “Materials and Methods”). We obtained about 90 million reads from each sample, 
which were analyzed by a bioinformatician of our group (Benedetta Cerruti) using an 
in-house pipeline. This pipeline consists of standard processing and filtering steps 
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including: i) sequencing quality controls, ii) removal of adapters and duplicated reads, 
and iii) alignment on the reference (human) genome. At the end of the procedure, the 
final data consisted of ~ 30 million aligned reads per sample, making a total of > 270 
million reads. Expression data were also normalized to library size and transcript 
length, and were expressed as fragment per kb of exon per million reads mapped 
[FPKM = no of reads ⁄ (gene dimension {kb}*no of total reads)*109]. The reference 
genome includes 23,368 transcripts, most of which are poorly expressed or not 
expressed at all and barely distinguishable from technical noise. We, thus, eliminated 
transcripts that were not significantly represented, using a standard cut-off for this 
type of experiment (FPKM >2; meaning that there are at least 2 reads per kb of gene, 
every million of mapped reads in all nine samples). Using this approach, we obtained 
a total of 10,950 expressed transcripts, which is in line with similar analyses 
performed by our and other groups. 
Initially, we performed a principal component analysis (PCA) to examine the global 
transcriptional differences between all samples, without any a priori definition of 
groups. According to the PCA, the samples are visualized in multidimensional data 
sets (typically 2D or 3D graphs) according to the main sources of variability 
(components; Figure 38). In particular, in our case, this analysis helped us in assessing 
whether the experimental conditions (i.e. miRNA overexpression) influence the 
transcriptome of each sample more than the technical and biological variability. We 
observed that all the biological triplicates were clustered together, meaning that their 
transcriptional profiles are similar (Figure 38). Moreover, the different treatments 
(transfections) were far away each other, indicating that we are dealing with different 
expression profiles as a consequence of a profound change in the gene expression 
upon miRNA overexpression (Figure 38).  





Figure 38 - RNA-sequencing analysis of transcriptional effects induced by either miR-124 or 
miR-657 overexpression: Principal component analysis (PCA). SUM159 cells were transiently 
transfected with miR-124 or miR-657 in three independent experiments. A control oligo (scrambled, 
SCR) was also used as a negative control. The transcriptional effects induced by miRNA 
overexpression were evaluated by RNA-sequencing. A PCA was performed on approx. 10,000 genes 
that were expressed in SUM159 (FPKM>2) revealing similarities and differences between individual 
samples. As shown in the graph, samples treated with the same way grouped together, suggesting that 
the biological differences between samples were far greater than technical noise observed between 
replicates. 
 
Based on the evidence that mammalian miRNAs predominantly act to decrease target 
mRNA levels (Guo et al., 2010), we reasoned that the transcriptional changes 
observed could be primarily due to mRNA silencing mechanisms. Indeed, preliminary 
analysis of selected putative target genes for miR-124 and miR-657 by RT-qPCR 
revealed that both miRNAs were able to induce downregulation of their target genes 
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(see Figure 36 and Figure 37). We exploited a computational tool, available on the web, 
known as SylArray (Bartonicek and Enright, 2010), which searches for 
overrepresented MREs in the 3′UTR sequences of transcripts coming from a given 
dataset. The algorithm returns the distribution of the MREs for any miRNA within the 
selected gene expression dataset. If the distribution of the MREs is asymmetric, then 
the corresponding miRNA is affecting gene expression.  
Figure 39 shows the SylArray analysis of the SUM159-miR-124 dataset. As expected, 
there was a significant enrichment (red line in plot) of the sequence matching the 
miR-124 seed, with a remarkable enrichment score (MAX P-value 10-95) 
asymmetrically distributed towards the downregulated genes (Figure 39). This means 
that the miR-124 target genes are frequently downregulated, and almost completely 
depleted from the “not regulated” or “upregulated” part of the dataset. Similarly, 
SylArray analysis of the SUM159-miR-657 dataset indicated that the miR-657 seed 
was enriched among the downregulated genes, although the enrichment was less 
pronounced than that of the miR-124 seed in the SUM-miR-124 dataset (MAX P-
value 10-13; Figure 40). Curiously, SylArray analysis of the mi-124 and miR-657 
datasets revealed a mild (MAX P-value 10-10; Figure 39) or strong enrichment (MAX 
P-value 10-37; Figure 40) of the miR-2054 MRE among upregulated genes, 
respectively. These results could indicate that these genes are upregulated as the result 
of downregulation of miR-2054 upon miR-124 or miR-657 overexpression; a 










Figure 39 - RNA-sequencing analysis of transcriptional effects induced by miR-124: Sylarray 
analysis of the SUM159 miR-124 dataset. Seed enrichment analysis was performed using the 
Sylarray algorithm, which performs an unbiased search for miRNA binding sites (MREs) in the 3’-
UTR of the sequenced genes. The graph reports the distribution of MREs in the RNA-seq dataset 
generated from SUM159 cells transfected with the miR-124 oligo, 24 h post-transfection. On the x-
axis, the sequenced genes are ordered from the most downregulated to the most upregulated genes; on 
the y-axis, corresponding enrichment score of the 7mer MREs for each sequenced gene, expressed as a 
P-value. The three miRNAs with the most significantly enriched MREs among: 1) the upregulated 
genes, indicative of downregulated miRNAs, are shown in shades of blue (below x-axis); 2) the 
downregulated genes, indicative of upregulated miRNAs, are highlighted in shades of red.  






Figure 40 - RNA-sequencing analysis of transcriptional effects induced by miR-657. Sylarray 
analysis of the SUM159 miR-657 dataset. Seed enrichment analysis was performed using the 
Sylarray algorithm, which performs an unbiased search for miRNA binding sites (MREs) in the 3’-
UTR of the sequenced genes. The graph reports the distribution of MREs in the RNA-seq dataset 
generated from SUM159 cells transfected with the miR-657 oligo, 24 h post-transfection. On the x-
axis, the sequenced genes are ordered from the most downregulated to the most upregulated genes; on 
the y-axis, corresponding enrichment score of the 7mer MREs for each sequenced gene, expressed as a 
P-value. The three miRNAs with the most significantly enriched MREs among: 1) the upregulated 
genes, indicative of downregulated miRNAs, are shown in shades of blue (below x-axis); 2) the 
downregulated genes, indicative of upregulated miRNAs, are highlighted in shades of red. 
 
3.8.4 Identification of miR-124 regulated genes and pathways involved in the 
control of mammary stem cell self-renewal 
Next, we identified the miRNA-regulated transcripts by comparing the gene 
expression regulation between miRNA-transfected samples and controls (i.e., SCR vs. 
miR-124 and SCR vs. miR-657) using a statistical tool (DeSEQ2, (Anders and Huber, 
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2010)). We selected only genes that showed an upregulation or downregulation 
greater than |0.2| log2fold change with a false discovery rate (FDR) < 0.01. We 
identified a list of 769 genes regulated upon miR-124 overexpression (455 
downregulated and 314 upregulated), and a set of 182 genes regulated upon miR-657 
overexpression (130 downregulated, 52 upregulated), as shown in the heatmap 
reported in Figure 41A. To reveal the function of the miR-124 down-regulated genes, 
we also performed a functional analysis on those genes (Figure 41B) and found out that 
a great number of them are involved in eight different cellular functions: self-renewal, 
cellular homeostasis, proliferation of cells, expression of DNA, cell movement, 
migration of tumor cells, cell movement of tumor cells and migration of cells. 
Notably, these different functions can be classified in three main categories: i) self-
renewal; ii) proliferation/apoptosis; iii) migration, suggesting that miR-124 could 
directly act on these mechanisms to exert its anti-tumoral function.  
 





Figure 41 – Identification of miR-124 and miR-657 target genes regulated upon overexpression of 
these miRNAs in SUM159 cells. A) Gene expression data were analysed using the DeSEQ2 statistical 
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tool. Genes DISPLAYING an upregulation or downregulation greater than |0.2| log2fold change, with a 
false discovery rate (FDR) < 0.01 were considered.  The heatmap shows the target genes regulated 
upon miR-124 overexpression (middle), miR-657 overexpression (lower part) and common to both 
miR-124 and miR-657 overexpression (upper part). The colour intensity reflects the log2fold regulation 
vs. SCR oligos: red indicates maximum upregulation, blue maximum downregulation. B) Functional 
analysis of miR-124 downregulated genes. For each function, a p-value annotation enrichment is 
reported in brackets.   
 
To reveal critical hubs affected by the two miRNAs and the signaling pathways to 
which they belong, we performed an upstream Ingenuity Pathways Analysis (IPA) in 
collaboration with Dr. Matteo Marzi in our lab. We focused initially on miR-124, 
since it showed the most consistent transcriptional effects in the RNA-seq analysis. 
We performed a “Core Analysis” by IPA using the 769 regulated genes above-
mentioned as the query gene list (for details see “Material and Methods”). We 
searched for all the possible gene sets that significantly overlap with the query 
dataset, including gene sets associated with gene ontology (molecular functions or 
biological processes), molecular pathways, upstream regulators, and disease-
associated signatures (such as cancer). The analysis also implements a series of 
statistical calculations to measure the significance of the overlap identified. For 
significantly associated pathways, IPA analysis assigns a Z-score, which reflects the 
type and the strength of regulation. If the pathway is activated the Z-score is positive, 
if it is inhibited the Z-score is negative. The higher the value of the Z-score (absolute 
value), the higher the level of regulation of the pathway (activated or inhibited). 
Results from the IPA analysis revealed that several pathways are significantly 
associated with miR-124 transcriptional changes (Figure 42). These pathways can be 
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grouped into three main effects: inhibition of stem cell self-renewal, inhibition of cell 





Figure 42 – Analysis of the transcriptional effects induced by miR-124 overexpression by IPA. 
We used the list of 769 regulated genes upon miR-124 overexpression as the input for the IPA-based 
core analysis. The most significantly affected pathways (z-score> |2| and with a p-value> 10-3) upon 
miR-124 overexpression are reported in the graph: a negative Z-score indicates downregulation, while 
a positive Z-score indicates upregulation. Three main functional categories were distinguished, related 
to self-renewal (self-renewal of cells), migration (migration of cells, cell movement of tumor cells, cell 
movement) and cell cycle/apoptosis regulation (growth failure, organismal death, G1 phase of tumor 
cell lines, S phase of tumor cell lines).  
 
We next focused on the “self-renewal of cells” pathway, which fits with our original 
aim, and generated a network comprising 13 stem cell genes found in the miR-124 
overexpression signature (Figure 43). This analysis revealed that the majority of the 
genes that induce self-renewal, such as JAG1, STAT3, SMAD5, GLI3, are 
downregulated by miR-124. Indeed these genes are associated to relevant stem cell 
self-renewal pathway such us Notch (through Jag1), Hedgehog (through GLI3), non-
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canonical TGF-β (through SMAD5) or inflammation pathways that converge to 
STAT3. 
Overall, the effect of miR-124 is to largely inhibit self-renewal through the repression 
of several hubs of stem cell self-renewal. 
 
 
Figure 43 – Analysis of miR-124 regulated genes belonging to the “self-renewal of cells” pathway. 
The image shows a network of 13 miR-124 regulated genes belonging to the IPA “self-renewal of 
cells” pathway (see Figure 32). The transcriptional effect induced by miR-124 is indicated by a color 
code (red, induction of expression; green, repression. Higher is the intensity of color, higher is its 
regulation) and a value which corresponds to the log2fold regulation. The arrows in the network are 
also colored to indicate whether the effect on gene expression was “consistent” (blue) or “inconsistent” 
(yellow) with the overall effect of self-renewal inhibition. 
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We reasoned that the transcriptional changes induced by miR-124 treatment might be 
related to stem cell-associated gene expression programs. Thus, we retrieved from the 
literature, gene expression signatures related to breast stem cell enriched populations 
(Stem cell-signatures) isolated with different approaches. These included: 1) a 
signature derived from human normal and breast cancer stem cells isolated as lin-
CD44+/CD24- cells, hereafter referred to as the “Polyak” signature (Shipitsin et al., 
2007); 2) a signature derived from mammary repopulating units (MRU) isolated from 
murine normal mammary tissue as CD49fhigh /CD24med cells, hereafter referred to as 
the “Stingl” signature (Stingl et al., 2006); 3) a signature derived from mammary stem 
cells (MaSCs) isolated from murine normal mammary tissues as Sca1-
/CD49fhi/CD29hi/CD24+ cells, hereafter called the “Visvader” signature (Lim et al., 
2010); 4) a signature derived from quiescent PKH26 label-retaining cells isolated 
from human normal primary mammospheres, hereafter referred to as the “Pece” 
signature (Pece et al., 2010). Since two signatures were derived from murine tissues 
(Stingl and Visvader), we considered only those genes conserved between human and 
mouse for our analysis. 
We used a computational tool known as Gene Set Enrichment Analysis (GSEA) 
(Subramanian et al., 2005) to analyze the correlation of each stem cell-signature (gene 
set) with the gene expression changes that occurred upon miR-124 overexpression. 
Briefly, each gene set is ordered according to the regulation of a query dataset (in our 
case, the miR-124 or miR-657 dataset) from the most upregulated to the most 
downregulated genes. The negative hypothesis (non correlation) implies that genes 
are distributed randomly in the query dataset. However, if two datasets are correlated 
(positively or negatively), the distribution will be asymmetric. The overlap between 
the gene sets is expressed by the normalized enrichment score (NES) with a FDR (q-
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value) as a measure of the statistical significance of the correlation. Of note, a positive 
NES indicates gene set enrichment at the top of the ranked list; a negative NES 
indicates gene set enrichment at the bottom of the ranked list. The GSEA analysis 
protocol suggests that an enrichment is significant when the FDR is at least less than 
0.25 (cut-off value), meaning that the result is likely to be valid 3 out of 4 times.  
We performed the GSEA analysis on the miR-124 dataset, splitting each stem cell-
signature in two, according to their regulation in the original dataset:  i) UP, gene 
induced in stem cells; and ii) DOWN, gene repressed in stem cells. We observed that 
two of the stem cell-signatures were significantly correlated with the miR-124 dataset, 
in particular, the “Polyak UP” (NES = -1.51, FDR = 0.03) and the “Visvader UP” 
(NES = -1.26, FDR = 0.18) signatures (Figure 44). This result suggests that the 
expression of miR-124 could inhibit the expression of genes specifically involved in 
sustaining and maintaining stem cell functions (“UP” signatures). No significant 
enrichment (FDR > 0.25) was observed for other two SC signatures, Stingl and Pece 
(Figure 45). 
Taken together, these analyses confirmed that miR-124 negatively regulates a 
transcriptional program associated with the acquisition of stem cell traits and self-
renewal.  
 





Figure 44 - GSEA analysis of the miR-124 dataset against the Visader and Polyak mammary 
stem cell signatures. GSEA was used to correlate stem cell signatures with the gene expression 
changes observed upon miR-124 overexpression in SUM159 cells. The enrichment plot together with 
the normalized enrichment score (NES) and significance (FDR q-value) are shown for the Visvader 
(UP and DOWN) and the Polyak (UP and DOWN) signatures used as gene sets. The enrichment was 
considered significant when the FDR was < 0.25.  
 






Figure 45 - GSEA analysis of the miR-124 dataset against the Stingl and Pece mammary stem cell 
signatures. GSEA was used to correlate stem cell signatures with the gene expression changes 
observed upon miR-124 overexpression in SUM159 cells. The enrichment plot together with the 
normalized enrichment score (NES) and significance (FDR q-value) are shown for the Stingl (UP and 
DOWN) and the Pece (UP and DOWN) signatures used as gene sets.  The enrichment was considered 
significant when the FDR was < 0.25. 
 
We, next, set out to identify those genes belonging to stem cell pathways that are 
directly targeted by miR-124. Hence, we retrieved the complete list of predicted miR-
124 targets using the two most widely used prediction algorithms, namely 
Targetscan6.2 and miRanda. These two algorithms use quite different metrics to 
calculate the candidate targets, such as the presence of conserved seed sequences that 
bind with perfect complementarity to the 3’UTR of mRNAs (TargetScan) or free 
energy binding contribution to non-perfect complementary binding (miRanda). We 
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obtained 3482 miR-124 targets by Targetscan and 3156 miR-124 targets by miRanda; 
these targets were largely overlapping. We filtered these target predictions using the 
genes regulated upon miR-124 overexpression, and obtained 279 genes predicted by 
both Targetscan and miRanda that were also transcriptionally downregulated by miR-




Figure 46 - Identification of miR-124 putative target genes. The Venn diagram shows the strategy 
used to identify miR-124 putative target genes by combining predictive algorithms (TargetScan6.2 and 
miRanda) with the transcriptional effects observed upon miR-124 overexpression in SUM159 cells by 
RNA-seq. A group of putative common target genes (279) was identified, which comprised more than 
50% of all downregulated genes following miR-124 overexpression. 
 
Among these 279 “common” genes, we searched for those that could be related to 
stem cells functions, such as: i) genes belonging to any of the four stem cell 
signatures; ii) genes belonging to a home-made signature obtained by comparing 
SUM159 grown in non-adherent conditions (3D vs. adherent conditions (2D). iii) 
genes belonging to the “self-renewal of cells” function by IPA. We obtained a list of 
35 genes associated with mammary stem cells and self-renewal function that could 
explain the phenotype induced by miR-124 overexpression (Figure 47). Among them, a 
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top candidate is JAG1, a gene concomitantly regulated in all the above-mentioned 
analysis, which has already been identified as a validated miR-124 target in 
neurogenesis (Baud et al., 2011; Cheng et al., 2009).  
Of course, further experiments are needed to establish whether the activity of miR-
124 is effectively mediated by JAG1 regulation or also involves other stem cell-
related targets. Moreover, an extensive validation of the tumor-suppressive effects of 
miR-124 on primary cancer stem cell (CSC)-rich human tumors is also required. 
 
Figure 47 - Identification of miR-124 stem cell target genes: the “35-gene list”. The list shows the 
35 putative direct miR-124 target genes related to mammary stem cells or self-renewal. The list was 
obtained by combining the 279 common regulated genes (Miranda + Targetscan+ RNA seq) with the 
stem cell signatures (Polyak, Visader, Stingl, Pece UP) and IPA “self-renewal of cell” pathway. The 
table shows the list of 35 genes (gene symbol) and the signatures which they belong to (indicated by 
‘YES’). A fifth in-house list was also included (3D vs. 2D), which was obtained by analyzing the 
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transcriptional changes measured in 3D wild type (WT) SUM159 mammospheres vs. 2D WT SUM159 
cells. The master regulators identified by IPA were included. 




4.1  Phenotype screening to unravel miRNA functions in complex phenotypes 
 
Emerging evidence indicates that, in the breast cancer, a rare subpopulation of cells 
within the tumor bearing stem cell (SC)-like properties, named CSCs, is responsible 
for the degree of aggressiveness of the tumor (Pece et al., 2010), as well as the 
emergence of therapeutic resistance and disease relapse (Liu and Wicha, 2010; 
Visvader and Lindeman, 2008). Therefore, we reasoned that the identification of key 
molecules able to regulate the properties of CSCs is of primary importance to our 
understanding of the underlying mechanisms of “stemness” and to the development of 
novel therapeutic approaches to fight even the most aggressive and resistant forms of 
cancer. miRNAs are extremely attractive candidates for molecules that could have a 
key role in the regulation of “stemness” properties. They are critical hubs in gene 
expression networks that control cell fate specification and stem cell properties. 
Indeed, a growing body of evidence supports a role for miRNAs as critical regulators 
of self-renewal for many stem cell types, including adult tissue stem cells and CSCs 
(Greene et al., 2010b) (Xu et al., 2009). Nevertheless, research on miRNAs and their 
relationship to MaSCs is still in its infancy. In particular, the identity of miRNAs that 
regulate “stemness” and differentiation in the breast, and their related cellular 
pathways are still largely unknown. Equally importantly, we do not know whether it 
is possible to harness miRNA biological action to control CSC expansion and, 
therefore, neutralize the most aggressive forms of breast cancer. 
To improve our knowledge on miRNAs that are able to specifically act on BCSCs, we 
decided to quantitatively and systematically characterize individual miRNAs of the 
human genome by performing an unbiased genetic screening. Our approach was 
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based on the assumption that individual miRNAs could alter the “stemness” 
properties of breast cancer cells and, hence, be selected (either positively or 
negatively) in a stem cell phenotype screening assay.  
Compared to other approaches, phenotype screenings have several advantages. 
Firstly, they are unbiased and no prior knowledge on the function of specific miRNAs 
is required. The selection is based on the “pure” ability of miRNAs to alter the 
transcriptome in such a way that cells acquire a new property, or improve an existing 
property, and are therefore positively selected. Conversely, miRNAs could inhibit an 
existing property and confer a disadvantage to cells, thereby resulting in their negative 
selection. Of course, the stronger the effect of the miRNA, the more rapid and 
powerful the selection will be. 
Another advantage of the screening approach is that it is possible to screen almost all 
of the human miRNAs in one experiment due to the relatively low complexity of the 
miRNA genome. Moreover, since miRNAs are enriched for critical regulators of cell 
fate and stem cell properties, the probability of scoring key regulators of these 
properties is relatively high. Furthermore, miRNAs are themselves appealing 
therapeutic molecules. Indeed, the potential usefulness of a microRNA-based therapy 
in cancer is now being exploited, with the attempt to modulate their expression, 
reintroducing microRNAs lost in cancer or inhibiting oncogenic microRNAs by using 
anti-microRNA oligonucleotides (Li and Rana, 2014) (Chen et al., 2010) (Esposito et 
al., 2014). Hence, in addition to providing information on the mechanisms that control 
“stemness” properties in tumors, our screening could also highlight microRNA-
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4.2  A stem cell self-renewal phenotype screening strategy to target BCSCs 
 
A major restrain when studying cancer stem cells is their rareness and their hard 
manipulation, so that a critical issue in setting up our phenotype screening strategy 
was to employ a suitable biological assay.  
To date, the only approach to enrich breast cancer stem cells in-vitro is culturing cells 
as mammospheres. Indeed, it was shown that rare, single-founder stem cells can form 
multicellular sphere structures under serum-free suspension conditions that are 
enriched for stem and early progenitors cells (Dontu et al., 2003). 
 As demonstrated by our lab and others, this assay reproduces the behavior of normal 
and cancer stem cells in-vitro: i) it selectively measures the clonogenic ability of cells 
with stem cell-like properties, i.e., those able to withstand anoikis and to generate 
actively proliferating and differentiating progenitors that constitute the bulk of the 
sphere; ii) it measures the self-renewal potential of such cells upon the serial 
propagation of sphere cultures (Dontu et al., 2003) (Pece et al., 2010). We, therefore, 
reasoned that miRNA selected with this assay might influence either the ability of 
stem cells to survive or the ability of stem cells to self-renew.  
For samples derived from human breast cancers, the mammosphere forming ability 
correlates with the CSC content of the tumor, established by in-vivo transplantation 
assay (Pece et al., 2010). Moreover, the ability of breast cancer cells to be serially 
propagated as mammospheres in-vitro correlates with their self-renewal potential 
determined in-vivo. This result suggests that the serial propagation of mammospheres 
can be considered as an in-vitro proxy for the content and self-renewal ability of 
CSCs ((Pece et al., 2010) and Pece personal communication). For these reasons, we 
strongly believe that the identification of key molecules able to regulate self-renewal 
mechanisms of CSCs will provide fundamental insights into tumorigenesis, in turn 
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leading to efficient methods to control stem cell self-renewal for cancer therapy. 
Here, we exploited the enrichement of CSCs in mammospheres to establish a high-
throughput unbiased pooled screening system suitable to identify microRNAs that are 
specifically involved in the regulation of those rare cells CSCs.  
Indeed, by combining the extremely powerful genome-wide screening with the 
challenging and sensitive next-generation sequencing methods, we could uncover 
microRNAs capable of affecting the self-renewal ability of breast cancer stem cells.  
As far as we know, this is the first whole-genome screening approach specifically 
performed on a stem cell population, enriched by exploiting the arduous 
mammosphere assay, which lead to the identification of possible microRNA 
therapeutic molecules that could specifically target breast cancer stem cells.  
Taken together, our findings confirm the utility of the presented screening strategy to 
identify processes with specific relevance to CSCs and also, our results gave an 
insight into the molecular mechanisms that govern CSC properties through the control 
of microRNA molecules. 
 
4.3 Set-up of the screening system 
 
The main drawback of phenotype screenings is that they are technically challenging, 
in the sense that a number of steps have to be improved and optimized to obtain a 
high enough reproducibility, robustness and reliability of results. As described in 
detail in the results section of this thesis, we performed an extensive optimization of 
almost all the steps of the screening, trying to keep to a minimum, confounding 
factors (such as those due to multiple integration events or transgene silencing). 
Whenever possible, we performed pilot experiments to establish the feasibility of the 
procedure or to assess the effect of modifications of the protocol (e.g. selection of 
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GFP+ cells in the assay). Indeed, one of the main aims in this optimization was to 
avoid the selection of stochastic events. This means that the driver of the positive or 
negative selection of the miRNA is not the miRNA function, but a random event 
already present in the initial cell population (cancer cells are heterogeneous) or 
generated by the procedure (e.g. by transgene integration events). 
To circumvent this problem, we devised two strategies: i) the screening was 
duplicated and only results obtained in the two independent experiments were 
considered meaningful; ii) we included in the analysis only those miRNAs that were 
significantly represented in the initial population, so that their positive or negative 
selection is the result of miRNA-driven effects, rather than random effects. Regarding 
this latter point, for each miRNA we calculated its “Coverage” (C), i.e., number of 
cells in the initial population that, as a result of independent integration events, 
express the particular miRNA. In our analysis, we included only those miRNAs with 
a coverage above a certain threshold. 
The choice of the threshold was absolutely arbitrary, although it was immediately 
clear that the higher the coverage the more robust the effect of the miRNA in the 
screening assay. However, a high coverage has the disadvantage that fewer miRNAs 
will be considered in the screening. We therefore decided for a coverage threshold of 
C>100, which allowed the analysis of 150 different miRNAs from the pool of 650 
constructs present in the library. As we mapped about 500 miRNA precursors in our 
initial population, this means that overall we discarded results for almost 350 
miRNAs that were poorly represented in the initial transfected population. However, 
the distribution of results in the two replicas was quite reproducible for the 150 clones 
with C>100, while it was much more variable for the pool of 350 clones with C<100 
(data not shown), suggesting that stochastic events were taking place when coverage 
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was below our threshold. Nonetheless, it could be interesting to select a few of the 
350 discarded miRNAs to see if any of them are positively and negatively selected, 
and eventually compare their validation efficiency with that of the hit candidates 
selected from the C>100 pool. 
Another limitation of the screening assay is that its results are very much dependent 
on the cell model used. Cancer cell lines bear specific mutations/genetic alterations 
that reproduce only some of all the possible alterations occurring in the breast cancer; 
hence, screening results likely reflect the modifiers related to those specific genetic 
alterations. To circumvent this limitation, we also considered further alternative breast 
cancer cell lines (i.e., luminal MCF7 and metastatic MDA-MB-231), thus 
encompassing multiple genetic backgrounds. However, the screening assay was not 
feasible with these alternative models, mainly due to a low efficiency of 
mammosphere formation (which negatively impinges on the coverage) and to the 
requirement of cell type-specific optimizations. For these reasons, the screening was 
performed on SUM159 cells, which have the desired qualities needed to ensure the 
feasibility of the screening assay. Firstly, SUM159 cells display a remarkably high 
efficiency of mammosphere formation (SFE > 10%), meaning that the frequency of 
cells with stem cell properties is high, in line with previous findings from other labs 
(Fillmore and Kuperwasser, 2008). Secondly, SUM159 cell reproduce one of the most 
adverse subtypes of breast cancer, the claudin-low subtype harboring mutant p53 and 
lacking the ER, PR and HER2 receptors; this breast cancer subtype typically has a 
high number of CSCs with immortal behavior (Visvader and Stingl, 2014). Thirdly, 
SUM159 cells are one of the few cell lines in which conversion from CSCs to non-
CSCs (and vice versa) has been observed and shown to rely on a specific 
transcriptional program (Gupta et al., 2011) (Scheel et al., 2011) (Chaffer et al., 
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2013). Thus, in our screening assay it is possible that a miRNA could influence this 
transcriptional program directly.   
Another technical issue of the screening assay relates to the analysis of gDNA and 
clone deconvolution. Two approaches could be used to count miRNA clones in the 
initial transfected cell population and over the different passages, in order to reveal 
those that were positively or negatively selected during the assay: i.e., microarray 
analysis or NGS. Microarrays are widely used for genome-wide experiments, in 
particular, for transcriptome analysis or the identification of genetic 
alterations/variants; but these kind of arrays cannot be used for clone deconvolution, 
which requires custom-made arrays as described by other groups (Izumiya et al., 
2010) (Tsuchiya et al., 2011). Moreover, microarrays have a limited specificity and 
sensitivity, and a poor dynamic range in quantification experiments. In contrast, NGS 
could be easily applied to clone deconvolution, as it generates qualitative and 
quantitative information with an incredibly high throughput. Furthermore, due to the 
possibility of combining multiple samples in just one sequencing experiment 
(multiplexing), costs would be massively reduced and technical variability would be 
minimized with NGS. 
 
4.4 Positive and negative miRNA modifiers of CSCs 
The screening provided reliable results for 152 miRNAs, which were significantly 
represented (C>100) in the initial population (P0) in the two biological replicas. This 
pool of miRNAs was further analyzed in the parallel 2D and 3D assays to establish 
which miRNAs may influence the behavior of cancer cells in respect to proliferation 
of cells in adherent condition (2D) and self-renewal of cells in non-adherent condition 
(3D). Overall we noticed that most miRNAs had a strong negative effect in the 3D 
assay, while being neutral or have a slightly negative effect in the 2D assay. The 
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simplest (and more likely) interpretation is that cells grown in condition selective for 
CSCs (3D) are more sensitive to even the slightest transcriptional interference 
(produced by the expression of any miRNA) than cells simply grown in adherent 
condition. Nevertheless, we were able to identify some clones that were significantly 
enriched or depleted in both 3D replicas, potentially inhibiting or increasing CSC self-
renewal, respectively. We identified up to 20 candidate miRNAs, most of which (18 
miRNA) depleted plus a couple of miRNAs that were enriched. This uneven 
distribution of miRNA candidates (depleted miRNA clones > increased miRNA 
clones) likely reflects specific biological properties of miRNAs. Indeed, multiple 
experimental evidences suggest that most miRNAs tend to have a tumour suppressor 
function (Kumar et al., 2007). Accordingly, miRNAs that could inhibit the growth 
and/or self-renewal of CSCscould be considered with tumour-suppressive function. 
An alternative possibility is that, given the high CSC content of SUM159 cells, it is 
easier to find modifiers that decrease rather than increase the efficiency of 
mammosphere formation.  
A number of so-called “stem-inhibitor” miRNAs have been already identified, and 
some even in the breast. For instance, let-7 and miR-200c, whose levels are typically 
low in CSCs with respect to non-CSC cells, could both inhibit CSC growth and self-
renewal by targeting critical cell fate determinants, such as BMI (Shimono et al., 
2009) or HMGA2 (Yu et al., 2007). Notably, our screening was able to confirm these 
data: both let-7a-1 and miR-200a were found to be consistently depleted in the 3D 
mammosphere assay. In particular, let-7 is among the 20 candidates, as it possesses a 
coverage value>100 (see bubble plot 3D vs 2D with C>100), miR-200a is not present 
within the 20 candidate list, but is included in the negative-selected clones when we 
consider a lower coverage cut-off (see bubble plot 3D vs 2D with C>50).   
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Combining the results of the 3D with the 2D experiments, we could stratify the 20 
candidate miRNA modifiers into three groups: i) a group of 3 common miRNAs, 
miR-1-1, miR-124-1 and miR-889, which were negatively selected in both assays; ii) 
a group of 15 miRNAs which had a stronger effect in the non-adherent (3D) 
conditions compared to the 2D ones; iii) 2 enriched miRNAs specific for the 3D 
assay. These results suggested that proliferation and CSC growth/self-renewal likely 
rely on distinct mechanisms, targeted by different miRNAs. The few miRNAs that 
were in common (miR-1; miR-124 and miR-889) could either have independent 
functions on both processes or could impact on self-renewal through proliferation. Of 
course, it is not possible to discriminate between these two possibilities without 
analyzing the effect induced by such miRNAs in individual assays. Indeed, we 
performed a proof-of-principle validation by analyzing candidate miRNAs in 
SUM159 directly. We selected 10 out of 20 miRNAs in the validation steps, of which 
half (5 miRNAs) displaying the strongest effects in the 3D screening (the “ top hit 
candidates”: miR-1, miR-124, miR-889, miR-657, miR-664). Overall 6 clones 
confirmed to have an effect on the formation and propagation of SUM159 
mammospheres, suggesting that the screening had a 60% validation rate. Of note, 
most of the clones (3/5) of the “top hit” list confirmed a very strong effects even in 
this individual validation step. In particular, miR-1 and miR-124 profoundly and 
significantly decreased the SFE capability of SUM159 throughout the generations, 
with miR-124 showing an almost complete block in sphere formation capability. 
Micro-RNA-1 is a muscle-enriched miRNA that inhibits proliferation of progenitor 
cells and promotes myogenesis. In lung and prostate cancers, miR-1 has been reported 
as a tumor suppressor miRNA, being downregulated in tumor cells and able to inhibit 
cancer cell growth when overexpressed (Hudson et al., 2012; Nasser et al., 2008). 
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Indeed, miR-1 could target many cell cycle genes plus (Zhao et al., 2007) the 
oncogene MET, a receptor tyrosine kinase, which is frequently upregulated in tumors 
and associated to migration, metastasis and epithelial-to-mesenchymal transition 
(EMT) (Nasser et al., 2008).  
miR-124 is an important regulator of neuronal differentiation during neurogenesis, 
where it controls the expression of the self-renewal marker Sox9 (Cheng et al., 2009). 
In cancer, miR-124 appears to be a potential tumor suppressor miRNA, because it is 
downregulated in multiple cancer types, such as hepatocellular, endometrial, 
colorectal and prostate carcinomas, and glioma (Lu et al., 2013) (Lang, 2012)(Li et 
al., 2014) (Wang et al., 2013) (Shi et al., 2013) (Xia et al., 2012) (Liang et al., 2013). 
In some cancer cells, the expression of miR-124 inhibited tumor growth both in vitro 
and in vivo (Lu et al., 2013). In hepatocellular carcinoma, miR-124 was found to 
target important oncogenic pathways, such as the signal transducer and activator of 
transcription 3 (STAT3) pathway (Lu et al., 2013) and the PI3K/Akt pathway through 
the phosphoinositide 3-kinase catalytic subunit alpha (PIK3CA) (Lang, 2012 #1173). 
miR-124 also targets the androgen receptor (AR) in prostate cancer, which in turn 
induces an upregulation of the tumor suppressor p53 (Shi et al., 2013), whereas in 
glioma, miR-124 targets SNAI2, thereby impairing tumorigenicity and neurosphere 
formation (Xia et al., 2012). In breast cancer, miR-124 expression is inversely 
correlated with histological grade, and has been described to inhibit EMT by targeting 
SLUG in the aggressive breast cancer cell lines, MDA-MB-231 and BT-549 (Liang, 
2013). These data suggest an important role for miR-124 as a strong tumor suppressor 
molecule with anti-metastatic potential and as a possible biomarker for diagnosis.  
In contrast to miR-1 and miR-124, miR-657 enhanced the sphere forming capability 
of SUM159 cells over several passages suggesting that it could act as an oncogenic 
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molecule. Intriguingly, miR-657 is a poorly characterized miRNA, reported to have 
altered expression in cancers of the cervix (Ding, 2014 #1180) and a potential 
oncogenic function in liver cancer (Zhang et al., 2013a). 
Three other miRNAs (miR-144, miR-153 and miR-204) were also validated, showing 
a significant albeit limited effect. The expression of miR-144 has been found to be 
downregulated in thyroid cancer and its restoration is able to suppress invasion and 
migration in vitro by targeting the E-cadherin suppressors, ZEB1 and ZEB2 (Guan et 
al., 2014). Moreover, in nasopharyngeal carcinoma, miR-144 was found to promote 
cell proliferation, migration and invasion, and to repress the tumor suppressor PTEN 
(Zhang et al., 2013b). miR-153 has been shown to be significantly downregulated in 
lung cancer, and its overexpression in these cancer cells inhibited their proliferation, 
migration and growth as xenograft tumors in vivo (Yuan et al., 2014). Finally, miR-
204 was found to be downregulated in gastrointestinal tumor tissues and its 
overexpression in these tumor cells inhibited cell proliferation in vitro (Zhang et al., 
2014).  
It is worth mentioning that even the clones that were not confirmed in the validation, 
displayed effects on SUM159 cells that could explain why they were positively or 
negatively selected in our screening assay. For instance, miR-664, a miRNA 
positively selected in the screening, did not increase the SFE of SUM159 cells, but 
did increase the proliferation of cells in the 3D mammosphere assay over multiple 
generations, as evidenced by an increase in mean sphere size (data not shown). This 
observation can be explained by an effect of miR-664 on progenitor proliferation in 
3D condition. Hence, during the 3D competition screen, the number of cells that bears 
miR-664 increases over time. Conversely, other miRNAs affected SFE only in the 
first generation of spheres (F1), but not in the following generations. Hence, these 
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miRNAs likely inhibit the ability of SUM159 cells to adapt to non-adherent growth 
conditions rather than CSC growth and self-renewal.  
Taken together, our findings strongly support the use of miRNA-based phenotype 
competition screenings to identify potential regulators of complex biological 
functions. To our knowledge, this is one of the few miRNA-based screening 
approaches able to select both positive and negative regulators of a specific 
phenotype. We speculate that this kind of approach could be extended to other 
phenotypes, or even, to other classes of molecules, including long non-coding RNAs 
(lncRNAs), whose functions have still to be elucidated.  
 
4.5 miR-124 targets multiple pathways involved in CSC maintenance  
Our screening highlighted some miRNAs as promising regulators of stemness 
properties in breast cancer and, therefore, as potential therapeutic targets. In 
particular, miR-124 and miR-657, the miRNAs that most markedly inhibited or 
enhanced the sphere-forming ability of SUM159 cells, respectively, were the most 
interesting candidates.  
We were interested in characterizing the mechanism through which these miRNAs 
influence CSC self-renewal, as observed in the SUM159 model system. Therefore, we 
analyzed the transcriptional changes induced upon miRNA overexpression by RNA-
seq, based on the assumption that miRNA effects occur predominantly at the 
transcriptional level (Guo et al., 2010). A comparison of the effects of the two 
miRNAs on the transcriptomes of SUM159 cells revealed that they had largely 
independent effects, with different sets of genes being regulated by them miRNAs. As 
a whole, the miR-124 transcriptional effects were far larger than those of miR-657 
(769 vs. 182 regulated genes, respectively). The observed transcriptional changes are 
likely the consequence of direct effects of the miRNAs, as shown by the remarkable 
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enrichment of genes containing the corresponding MREs, identified by Sylamer 
analysis. Intriguingly, the set of downregulated genes following miR-124 
overexpression appeared to be enriched in miR-124 target genes. With the use of 
Bioinformatics tools to predict miRNA targets (miRanda and Targetscan), we 
identified 279 predicted miR-124 target genes among the set of 455 downregulated 
genes upon miR-124 overexpression. In contrast, miR-657 induced fewer 
transcriptional changes, involving fewer putative direct target genes than miR-124. 
This difference in the magnitude of the transcriptional effects of miR-124 and miR-
657 might reflect the different evolutionary histories of these two miRNAs. miR-657 
is a recently evolved miRNA that exists only in humans, whereas, miR-124 is highly 
conserved across many species and could have thus evolved many miRNA:target 
interactions to affect multiple genes and/or multiple pathways at the same time, as 
underlined by our experiments.  
Functional analysis by IPA revealed at least three main biological effects associated 
with miR-124 transcriptional changes: inhibition of self-renewal, inhibition of 
migration and cell-cycle/apoptosis regulation. Each effect was associated with largely 
different gene sets indicating that miR-124 can inhibit multiple pathways 
simultaneously. This peculiar property of miR-124 might explain why it was selected 
both in the 3D screen (where it regulates self-renewal) and in the 2D screen (where it 
regulates the cell proliferation). 
Regarding the self-renewal inhibition exerted by miR-124 overexpression, 13 stem-
related genes were found to be under the control of this miRNA, belonging to 
different pathways associated with CSCs: EMT signaling, NOTCH pathway, 
Hedgehog, STAT3 and TGFbeta/Wnt signaling. Of note, 8 out of 13 stem cell genes 
were downregulated by miR-124 (such as JAG1, STAT3, SMAD5, and GLI3), in line 
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with the observed effect of this miRNA on self-renewal. We, thus, searched for the 
possible miR-124 direct targets related to stem cells and self-renewal functions and 
generated a list of 35 candidate genes (the “35-gene list”) that could explain the self-
renewal phenotype regulated by miR-124. Among these, JAG1 appears to be one of 
the top candidates. This gene has been shown to be a direct target of miR-124 (Baud 
et al., 2011) and is involved in the Notch pathway (JAG1 is a NOTCH receptor 
ligand), which is one of the pathways activated by the stem cell to tightly control self-
renewal and the balance between asymmetric/symmetric cell division in human 
MaSCs (Dontu et al., 2004). 
Given the fact that the MaSC is a complex system in which individual pathways 
interact extensively to maintain the delicate balance between self-renewal, 
proliferation and differentiation (Izrailit and Reedijk, 2012; Liu et al., 2005), and that 
miR-124 targets a great number of genes, it is reasonable to suggest that the miR-124 
might coordinate multiple signaling pathways. Therefore, miR-124 might act as key 
controller by operating at multiple levels on gene regulation, impinging on genes that 
are tightly interconnected to modulate CSC self-renewal. Indeed, the IPA analysis 
also revealed a possible role for miR-124 as negative regulator of cell migration. This 
function was not directly assayed in our screening, but is indeed relevant to CSCs. 
Together, our results suggest that miR-124 could be a multifunctional tumor 
suppressor, with the ability to act on the tumor bulk, reducing cell proliferation and 
inducing apoptosis, and also on CSCs, limiting their self-renewal potential, and 
inhibiting migration ability and invasion potential, thus reducing metastasis.  
 
4.6 Future plans 
In order to develop target CSC therapies, it is essential to understand the molecular 
mechanisms of CSC properties. To study those mechanisms, we developed a high-
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throughput unbiased screening system and provided evidences that it is suitable to 
identify microRNAs involved in the regulation of CSCs. 
Our results mainly identified miR-124 to act as putative tumor suppressor gene, 
specifically targeting breast cancer stem cells. 
Further evidences are now needed to corroborate the biological role of this miRNA as 
regulator of BCSC properties.  
Firstly, in-vivo experiments must be carried out to reveal whether this miRNA is able 
to counteract tumor formation. To this aim, we are exploiting patient-derived 
xenografts (PDXs) models, where surgically resected tumor samples are engrafted 
directly into immune-compromised mice. Numerous tumor-specific PDX models 
have been established in our laboratory and, importantly, they are all biologically 
stable as they maintain the molecular, genetic and histological heterogeneity typical 
of tumors of origin through serial passaging in mice. 
Moreover, PDXs provide an excellent in-vivo platform to study cancer stem-cell 
biology and to assess novel cancer therapeutics. 
For our goals, in-vivo experiments support a more relevant system to clinically test 
our hypotheses that miR-124 should impair human tumor development by employing 
PDX models rather than cell lines. In-vivo experiments using one of the triple 
negative breast cancers PDX available in our lab are now ongoing. We expect that 
PDXs overexpressing miR-124, upon lentiviral infection, should not be longer able to 
sustain tumor growth and propagation through serial passaging in mice compared to 
control treated PDX. We claim that miR-124 treatment in-vivo should 1) block stem-
cell self-renewal, thus directly targeting BCSCs 2) impede tumor cell proliferation by 
targeting the tumor bulk population 3) prevent metastasis.  
Secondly, the mechanisms through which this miRNA exerts its function must be 
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clarified. The “35 gene-list” could represent an interesting starting point to uncover 
new pathways related to the self-renewal of breast cancer stem cells. We are currently 
developing a genetic screening strategy, based on RNA interference, using a pooled 
library constituted of shRNA targeting the possible 35 direct target genes of miR-124, 
which are related to its self-renewal mechanism. 
In parallel, the recognition and the study of the genes associated to the proliferation 
mechanisms as well as those having an anti-migratory function must be elucidated.  
Thirdly, the physiological role of miR-124 needs to be illustrated. To this aim, miR-
124 sensor that specifically measures miR-124 levels could be used to reveal the 
endogenous expression of this microRNA in-vivo using “friend virus B type (FVB)” 
mice, which possess a normal genetic background. Moreover, miR-124 inhibitors, 
based on anti-sense oligonucleotide sequences, could be used to knock down this 
microRNA in-vivo in FVB mice and the mammosphere assay could then be exploited 
to reveal whether miR-124 absence promotes mammosphere formation by enhancing 
self-renewal mechanisms in normal conditions.   
Lastly, we have planned to measure miR-124 levels on different primary tumor 
samples from patients through the use of specific probes and take advantage of the in-
situ hybridization technique. This would indicate us whether miR-124 expression 
could be exploited to stratify breast cancers for their grade of aggressiveness and thus 
be used not only as a therapeutic molecule, but also as a diagnostic marker. 
For all these reasons, we strongly believe that miR-124 could represent an “ideal 
drug” acting on different pathways and involving several mechanisms and thus, its 
role in the context of breast cancers obviously requires further investigations.
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